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A B S T R A C T
Background
This review is one of six looking at the primary medical management options for patients with chronic rhinosinusitis.
Chronic rhinosinusitis is common and is characterised by inflammation of the lining of the nose and paranasal sinuses leading to
nasal blockage, rhinorrhoea, facial pressure/pain and loss of sense of smell. The condition can occur with or without nasal polyps. The
use of topical (intranasal) corticosteroids has been widely advocated for the treatment of chronic rhinosinusitis given the belief that
inflammation is a major component of this condition.
Objectives
To assess the effects of intranasal corticosteroids in people with chronic rhinosinusitis.
Search methods
The Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; Central Register of Controlled Trials (CEN-
TRAL 2015, Issue 8); MEDLINE; EMBASE; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials.
The date of the search was 11 August 2015.
Selection criteria
Randomised controlled trials (RCTs) with a follow-up period of at least three months comparing intranasal corticosteroids (e.g.
beclomethasone dipropionate, triamcinolone acetonide, flunisolide, budesonide) against placebo or no treatment in patients with
chronic rhinosinusitis.
Data collection and analysis
We used the standard methodological procedures expected by Cochrane. Our primary outcomes were disease-specific health-related
quality of life (HRQL), patient-reported disease severity and the commonest adverse event - epistaxis. Secondary outcomes included
general HRQL, endoscopic nasal polyp score, computerised tomography (CT) scan score and the adverse events of local irritation or
other systemic adverse events. We used GRADE to assess the quality of the evidence for each outcome; this is indicated in italics.
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Main results
We included 18 RCTs with a total of 2738 participants. Fourteen studies had participants with nasal polyps and four studies had
participants without nasal polyps. Only one study was conducted in children.
Intranasal corticosteroids versus placebo or no intervention
Only one study (20 adult participants without polyps) measured our primary outcome disease-specific HRQL using the Rhinosinusitis
Outcome Measures-31 (RSOM-31). They reported no significant difference (numerical data not available) (very low quality evidence).
Our second primary outcome, disease severity , was measured using the Chronic Sinusitis Survey in a second study (134 participants
without polyps), which found no important difference (mean difference (MD) 2.84, 95% confidence interval (CI) -5.02 to 10.70;
scale 0 to 100). Another study (chronic rhinosinusitis with nasal polyps) reported an increased chance of improvement in the intranasal
corticosteroids group (RR 2.78, 95% CI 1.76 to 4.40; 109 participants). The quality of the evidence was low.
Six studies provided data on at least two of the individualsymptoms used in the EPOS 2012 criteria to define chronic rhinosinusitis
(nasal blockage, rhinorrhoea, loss of sense of smell and facial pain/pressure). When all four symptoms in the EPOS criteria were available
on a scale of 0 to 3 (higher = more severe symptoms), the average MD in change from baseline was -0.26 (95% CI -0.37 to -0.15;
243 participants; two studies; low quality evidence). Although there were more studies and participants when only nasal blockage and
rhinorrhoea were considered (MD -0.31, 95% CI -0.38 to -0.24; 1702 participants; six studies), the MD was almost identical to when
loss of sense of smell was also considered (1345 participants, four studies; moderate quality evidence).
When considering the results for the individual symptoms, benefit was shown in the intranasal corticosteroids group. The effect size
was larger for nasal blockage (MD -0.40, 95% CI -0.52 to -0.29; 1702 participants; six studies) than for rhinorrhoea (MD -0.25,
95% CI -0.33 to -0.17; 1702 participants; six studies) or loss of sense of smell (MD -0.19, 95% CI -0.28 to -0.11; 1345 participants;
four studies). There was heterogeneity in the analysis for facial pain/pressure (MD -0.27, 95% CI -0.56 to 0.02; 243 participants; two
studies). The quality of the evidence was moderate for nasal blockage, rhinorrhoea and loss of sense of smell, but low for facial pain/
pressure.
There was an increased risk of epistaxis with intranasal corticosteroids (risk ratio (RR) 2.74, 95% CI 1.88 to 4.00; 2508 participants;
13 studies; high quality evidence).
Considering our secondary outcome, general HRQL, one study (134 participants without polyps) measured this using the SF-36 and
reported a statistically significant benefit only on the general health subscale. The quality of the evidence was very low.
It is unclear whether there is a difference in the risk of local irritation (RR 0.94, 95% CI 0.53 to 1.64; 2124 participants; 11 studies)
(low quality evidence).
None of the studies treated or followed up patients long enough to provide meaningful data on the risk of osteoporosis or stunted
growth (children).
Other comparisons
We identified no other studies that compared intranasal corticosteroids plus co-intervention A versus placebo plus co-intervention A.
Authors’ conclusions
Most of the evidence available was from studies in patients with chronic rhinosinusitis with nasal polyps. There is little information
about quality of life (very low quality evidence). For disease severity, there seems to be improvement for all symptoms (low quality
evidence), a moderate-sized benefit for nasal blockage and a small benefit for rhinorrhoea (moderate quality evidence). The risk of
epistaxis is increased (high quality evidence), but these data included all levels of severity; small streaks of blood may not be a major
concern for patients. It is unclear whether there is a difference in the risk of local irritation (low quality evidence).
P L A I N L A N G U A G E S U M M A R Y
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Review question
We reviewed the evidence for the benefits and harms of intranasal (in the nose) steroids given to people with chronic rhinosinusitis.
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Background
Chronic rhinosinusitis is a common condition that is defined as inflammation of the nose and paranasal sinuses (a group of air-filled
spaces behind the nose, eyes and cheeks). Patients with chronic rhinosinusitis experience at least two or more of the following symptoms
for at least 12 weeks: blocked nose, discharge from their nose or runny nose (rhinorrhoea), pain or pressure in their face and/or a
reduced sense of smell (hyposmia). Some people will also have nasal polyps, which are grape-like swellings of the normal nasal lining
inside the nasal passage and sinuses. Topical (intranasal) corticosteroids are used with the aim of reducing inflammation in order to
improve patient symptoms.
Study characteristics
We included 18 randomised controlled trials (RCTs) with a total of 2738 participants in this review. Most studies were relatively small,
with as few as 9 or 10 patients per intervention arm. The largest study had 748 patients in total. Most were conducted in tertiary
referral centres in northern Europe, the US and Canada. Fourteen studies only included participants with chronic rhinosinusitis with
nasal polyps and four studies had participants without nasal polyps. Only one study was conducted in children. The studies looked at
a range of types, doses and methods of administration (e.g. spray, drops) of intranasal corticosteroids.
Key results and quality of the evidence
One study (20 participants) reported no statistically significant difference in disease-specific health-related quality of life. Another
measured general health-related quality of life and reported a statistically significant benefit only on a subscale for general health. Both
studies recruited participants with chronic rhinosinusitis without nasal polyps. The quality of the evidence was very low (we have very
little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect).
Disease severity was measured in one study (chronic rhinosinusitis without nasal polyps, 134 participants), which found no important
difference. Another study (chronic rhinosinusitis with nasal polyps) reported an increased chance of improvement in the intranasal
corticosteroids group. The quality of the evidence was low (our confidence in the effect estimate is limited: the true effect may be
substantially different from the estimate of the effect).
When each type of symptom was measured separately (nasal blockage, rhinorrhoea, loss of sense of smell, facial pain/pressure), benefit
was shown in the intranasal corticosteroids group. The quality of the evidence was moderate for nasal blockage, rhinorrhoea and loss
of sense of smell, but low for facial pain/pressure (moderate quality evidence means we are moderately confident in the effect estimate:
the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different).
There was an increased risk of nosebleeds (epistaxis) with intranasal corticosteroids (high quality evidence). However, it was unclear
whether there was a difference in the risk of local (nose or throat) irritation (low quality evidence).
None of the studies treated or followed up patients long enough to provide meaningful data on the risk of osteoporosis (fragile bones)
or stunted growth (in children).
Conclusions
Most of the evidence available was from studies in patients with chronic rhinosinusitis with nasal polyps. There is little information
about quality of life and the quality of this evidence is very low. For disease severity, there seems to be improvement for all symptoms
(low quality evidence), a moderate-sized benefit for nasal blockage and a small benefit for rhinorrhoea (moderate quality evidence). The
risk of nosebleeds is increased (high quality evidence), but this included all levels of severity; for some patients small streaks of blood
may not be a major concern. It is unclear whether there is a difference in the risk of local irritation (low quality evidence).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Intranasal corticosteroids for people with chronic rhinosinusitis
Patient or population: chronic rhinosinusit is
Setting: all
Intervention: intranasal cort icosteroids
Comparison: placebo
Outcomes
of participants
(studies)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Quality What happens
With placebo With intranasal corti-
costeroids
Difference
Disease-specif ic HRQL
measured as median
change f rom baseline
(RSOM-31)
of part icipants: 20
(1 RCT)
- Median 5 points lower Median 62 points lower - ⊕©©©
VERY LOW 1,5
Not enough information
to conclude whether
there is a dif ference
Disease severity - mea-
sured as change f rom
baseline using the
Chronic Sinusit is Sur-
vey at 20 weeks
of part icipants: 134
(1 RCT)
- Chronic Sinusit is Sur-
vey score was 7.35
- MD 2.84 higher (5.02
lower to 10.7 higher)
than placebo
⊕⊕©©
LOW 1,2
There was no clinically
important dif f erence
Disease severity - anal-
ysed as the propor-
t ion of pat ients who re-
ported improvement on
a global symptom score
of part icipants:109
(1 RCT)
RR 2.78
(1.76 to 4.40)
Study populat ion ⊕⊕©©
LOW 1,2
There was an increased
chance of improvement
with intranasal cort i-
costeroids
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273 per 1000 758 per 1000
(480 to 1000)
485 more per 1000
(207 more to 927 more)
Disease severity measured as average change f rom baseline at 12 to 20 weeks (range 0 to 3 points) for a combinat ion of symptoms*
• All 4 EPOS
domains
of part icipants: 243
(2 RCTs)
- - - MD 0.26 lower (0.37
lower to 0.15 lower)
than placebo
⊕⊕©©
LOW 1,2
The improvement in
the intranasal cort i-
costeroids group was
higher (moderate ef fect
size). Lower score =
less severe symptoms
• 3 EPOS domains -
nasal blockage,
rhinorrhoea, loss of
sense of smell
of part icipants: 1345
(4 RCTs)
- - - MD 0.31 lower (0.38
lower to 0.23 lower)
than placebo
⊕⊕⊕©
MODERATE 2
The improvement in
the intranasal cort i-
costeroids group was
higher (moderate ef fect
size)
• 2 EPOS domains -
nasal blockage and
rhinorrhoea
of part icipants: 1702
(6 RCTs)
- - - MD 0.31 lower (0.38
lower to 0.24 lower)
than placebo
⊕⊕⊕©
MODERATE 2
The improvement in
the intranasal cort i-
costeroids group was
higher (moderate ef fect
size)
Disease severity measured as average change f rom baseline at 12 to 20 weeks (range 0 to 3 points) for individual symptoms*
• Nasal blockage
of part icipants: 1702
(6 RCTs)
- - - MD 0.4 lower (0.52
lower to 0.29 lower)
than placebo
⊕⊕⊕©
MODERATE 2
The improvement in
the intranasal cort i-
costeroids group was
higher (moderate ef fect
size)
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• Rhinorrhoea
of part icipants: 1702
(6 RCTs)
- - - MD 0.25 lower (0.33
lower to 0.17 lower)
than placebo
⊕⊕⊕©
MODERATE 2
The improvement in
the intranasal cort i-
costeroids group was
higher (small ef fect
size)
• Loss of sense of
smell
of part icipants: 1345
(4 RCTs)
- - - MD 0.19 lower (0.28
lower to 0.11 lower)
than placebo
⊕⊕⊕©
MODERATE 2
The improvement in
the intranasal cort i-
costeroids group was
higher (small ef fect
size)
• Facial pain/
pressure
of part icipants:243
(2 RCTs)
- - - MD 0.27 lower (0.56
lower to 0.02 higher)
than placebo
⊕⊕©©
LOW 1,2,6
The improvement in
the intranasal cort i-
costeroids group was
higher (moderate ef fect
size)
Generic HRQL - mea-
sured using SF-36
of part icipants: 134
(1 RCT)
Stat ist ical signif icance only for the general health sub-scale. No stat ist ically signif icant dif f erence
for the other sub-scales
⊕©©©
VERY LOW 1,5
Unclear whether there
is a dif ference in gen-
eral HRQL
Adverse events - epis-
taxis
of part icipants: 2508
(13 RCTs)
RR 2.74
(1.88 to 4.00)
Study populat ion ⊕⊕⊕⊕
HIGH
The risk of epistaxis is
higher in the intranasal
cort icosteroids group29 per 1000 79 per 1000
(54 to 115)
50 more per 1000
(25 more to 86 more)
Moderate
39 per 1000 105 per 1000
(72 to 154)
67 more per 1000
(34 more to 115 more)
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Adverse events - local
irritat ion
of part icipants: 2124
(11 RCTs)
RR 0.94
(0.53 to 1.64)
Study populat ion ⊕⊕©©
LOW 3,4
It is uncertain whether
there is an impor-
tant dif f erence between
the intranasal cort icos-
teroids and placebo
groups in the risk of lo-
cal irritat ion
21 per 1000 20 per 1000
(11 to 34)
1 fewer per 1000
(10 fewer to 13 more)
Moderate
26 per 1000 24 per 1000
(14 to 42)
2 fewer per 1000
(12 fewer to 16 more)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; EPOS: European Posit ion Paper on Rhinosinusit is and Nasal Polyps 2012; HRQL: health-related quality of lif e; OR: odds rat io; RCT: randomised
controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Evidence only came f rom small t rial(s). The overall sample size is very small.
2Outcome was not measured using a validated tool.
3Inconsistency in how outcome was reported across studies. The number of overall events is likely to be underest imated.
4Overall event rates likely to have been underest imated. The conf idence interval is wide.
5Evidence only f rom one study, which had a high risk of report ing bias for this outcome.
6Unexplained heterogeneity observed for this outcome.
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B A C K G R O U N D
Description of the condition
Chronic rhinosinusitis is defined as inflammation of the nose and
paranasal sinuses characterised by two or more symptoms, one of
whichmust be nasal blockage/obstruction/congestion or nasal dis-
charge (anterior/posterior nasal drip). The other possible symp-
toms include facial pain/pressure, reduction or loss of sense of
smell (in adults) or cough (in children). Symptomsmust have con-
tinued for at least 12 weeks. In addition people must have either
mucosal changes within the ostiomeatal complex and/or sinuses as
evidenced by a computerised tomography (CT) scan and/or endo-
scopic signs of at least one of the following: nasal polyps, mucop-
urulent discharge primarily from middle meatus or oedema/mu-
cosal obstruction primarily in the middle meatus (EPOS 2012).
Chronic rhinosinusitis represents a common source of ill health;
11% of UK adults reported chronic rhinosinusitis symptoms in a
worldwide population study (Hastan 2011). Symptoms, including
nasal obstruction, nasal discharge, facial pain, anosmia and sleep
disturbance, have a major impact on quality of life, reportedly
greater in several domains of the SF-36 than angina or chronic res-
piratory disease (Gliklich 1995). Acute exacerbations, inadequate
symptom control and respiratory disease exacerbation are com-
mon. Complications are rare, but may include visual impairment
and intracranial infection.
Two major phenotypes of chronic rhinosinusitis have been iden-
tified based on the presence or absence of nasal polyps on ex-
amination. Nasal polyps are tumour-like hyperplastic swellings of
the nasal mucosa, most commonly originating from within the
ostiomeatal complex (Larsen 2004). Chronic rhinosinusitis with
nasal polyps (CRSwNP) is diagnosed when polyps are seen (on
direct or endoscopic examination) bilaterally in the middle mea-
tus. The acronym CRSsNP is used for the condition in which no
polyps are present.
Although the aetiology of chronic rhinosinusitis is not fully un-
derstood, it may involve abnormalities in the host response to ir-
ritants, commensal and pathogenic organisms and allergens, ob-
struction of sinus drainage pathways, abnormalities of normal mu-
cociliary function, loss of the normal mucosal barrier or infection.
Two typical profilesmay be observed with respect to inflammatory
mediators; in eosinophilic chronic rhinosinusitis, which is typi-
cally associated with nasal polyps, high levels of eosinophils, im-
munoglobulin E (IgE) and interleukin (IL)-5 may be found, while
in neutrophilic chronic rhinosinusitis, more often associated with
chronic rhinosinusitis without polyps, neutrophils predominate,
with elevated interferon (IFN) gamma, IL-8 and tumour necrosis
factor (TNF) (EPOS 2012).
While treatment decisions should be made based on an under-
standing of the patient’s chronic rhinosinusitis phenotype and
likely aetiology, in practice treatment may be initiated without
knowledge of the polyp status, particularly in primary care. This
review (and most of its companion reviews) consider patients with
and without polyps together in the initial evaluation of treatment
effects. However, subgroup analyses explore potential differences
between them.
The most commonly used interventions for chronic rhinosinusitis
are used either topically (sprayed into the nose) or systemically (by
mouth) and include steroids, antibiotics and saline.
Description of the intervention
Anti-inflammatory therapy plays a significant role in the treatment
of chronic rhinosinusitis. This includes corticosteroids and low-
dosemacrolides. Topical corticosteroids are more widely used than
oral steroids because treatment can be given for longer without
significant adverse effects.
Intranasal corticosteroid therapy is often prescribed for patients
with chronic rhinosinusitis, but with considerable variability in
timing, frequency, dose, topical delivery method and the specific
agent used (Benninger 2003; Spector 1998). The topical delivery
method may affect the amount of steroid that comes into contact
with the paranasal sinus mucosa (Grobler 2008; Harvey 2009).
The simplest nasal delivery methods are drops, sprays, aerosols,
nebulisers and atomisers. These contrast with methods involving
direct sinus cannulation and nasal irrigation with squeeze bottles
and neti pots, which are likely to provide better delivery to the
sinuses, especially in the post-sinus surgery setting (Grobler 2008;
Harvey 2009; Thomas 2013).
Classes of topical corticosteroid include first-generation intranasal
steroids (beclomethasone dipropionate, triamcinolone acetonide,
flunisolide and budesonide) and newer preparations (fluticas-
one propionate, mometasone furoate, ciclesonide and fluticasone
furoate).
How the intervention might work
The use of topical (intranasal) corticosteroids has been widely ad-
vocated for the treatment of chronic rhinosinusitis given the be-
lief that inflammation is a major component of this condition
(Fokkens 2007; Hamilos 2000; McNally 1997). The mechanism
of action is a combination of anti-inflammatory effects (for ex-
ample, reducing pro-inflammatory, and increasing anti-inflamma-
tory, gene transcription and reducing airway inflammatory cell
infiltration) and suppression of the production of pro-inflamma-
tory mediators, cell chemotactic factors and adhesion molecules
(Mullol 2009). Several factors could affect the relative levels of
effectiveness or harm from using intranasal corticosteroids. It has
been suggested that the type of steroid, dose and method of deliv-
ery (which affects the bioavailability)may contribute to the relative
effectiveness of the treatment. In addition, it is unclear whether
patient characteristics will affect levels of effectiveness (i.e. whether
they have polyps and whether they are adults or children). Another
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uncertainty is whether the duration of treatment is important. If
heterogeneity in effects was indeed observed, we planned to ex-
plore these factors through subgroup analyses.
Why it is important to do this review
Intranasal corticosteroids are the mainstay and currently recom-
mended treatment for chronic rhinosinusitis. This review incor-
porates an update of two previous Cochrane reviews (Kalish 2012;
Snidvongs 2011). Unlike the previous reviews, this review focuses
on the effects of intranasal corticosteroids when compared to no
treatment or placebo, to establish their effectiveness in the treat-
ment of chronic rhinosinusitis. The relative effects of different
types, doses and methods of delivery are investigated in a separate
review (Chong 2016a).
This review is one of a suite of reviews looking at management
options for patients with chronic rhinosinusitis (Chong 2016a;
Chong 2016b; Head 2016a; Head 2016b; Head 2016c), and we
use the same outcome measures across the reviews. We have not
included studies designed to evaluate interventions in the immedi-
ate peri-surgical period, which are focused on assessing the impact
of the intervention on the surgical procedure or on modifying the
post-surgical results (preventing relapse).
O B J E C T I V E S
To assess the effects of intranasal corticosteroids in people with
chronic rhinosinusitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies with the following design characteristics:
• randomised controlled trials, including cluster-randomised
trials and quasi-randomised trials (cross-over trials were only to
be included if the data from the first phase were available); and
• patients were followed up for at least two weeks.
We excluded studies with the following design characteristics:
• randomised patients by side of nose (within-patient
controlled) because it is difficult to ensure that the effects of any
of the interventions considered can be localised; or
• perioperative studies, where the sole purpose of the study
was to investigate the effect of intranasal corticosteroids on
surgical outcome.
Types of participants
Patients with chronic rhinosinusitis, whether with or without
polyps.
We excluded studies that included a majority of patients with:
• cystic fibrosis;
• allergic fungal sinusitis/eosinophilic fungal/mucinous
rhinosinusitis;
• aspirin-exacerbated respiratory disease;
• antrochoanal polyps (benign polyps originating from the
mucosa of the maxillary sinus);
• malignant polyps;
• primary ciliary dyskinesia;
• a history of surgery for nasal polyps within six weeks of
entry to the study.
Types of interventions
All intranasal corticosteroids; this included nasal sprays and nasal
drops.
First-generation intranasal corticosteroids:
• Beclomethasone dipropionate
• Triamcinolone acetonide
• Flunisolide
• Budesonide
Second-generation intranasal corticosteroids:
• Ciclesonide
• Fluticasone furoate
• Fluticasone propionate
• Mometasone furoate
• Betamethasone sodium phospate
If other interventions were used, these should have been used in
both treatment arms. Allowed co-interventions included:
• nasal saline irrigation;
• antibiotics;
• intermittent nasal decongestants.
The comparators were placebo or no intervention.
The main comparison pair was:
• intranasal corticosteroids versus placebo or no intervention.
Other possible comparison pairs included:
• intranasal corticosteroids plus co-intervention A versus
placebo plus co-intervention A.
This review is part of a larger series of six reviews for the treatment
of chronic rhinosinusitis.
• Intranasal steroids versus placebo or no intervention for
chronic rhinosinusitis (this review).
• Different types of intranasal steroids for chronic
rhinosinusitis (Chong 2016a). This review compares different
classes, doses and delivery methods of intranasal corticosteroids
for chronic rhinosinusitis.
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• Short-course oral steroids alone for chronic rhinosinusitis
(Head 2016a). This review compares short-course oral steroids
alone with placebo or no intervention, or against other
pharmacological interventions such as antibiotics or nasal saline
irrigation.
• Short-course oral steroids as an adjunct therapy for chronic
rhinosinusitis (Head 2016b). This review compares oral steroids
where they have been used as add-on therapy to other treatments
for chronic rhinosinusitis (such as intranasal corticosteroids,
antibiotics or saline solution).
• Saline irrigation for chronic rhinosinusitis (Chong 2016b).
This review compares nasal saline irrigation for chronic
rhinosinusitis with both placebo/no intervention and with
intranasal corticosteroids or antibiotics.
• Systemic and topical antibiotics for chronic rhinosinusitis
(Head 2016c). This review compares both topical and systemic
antibiotics with placebo/no treatment, two different antibiotics
with each other and antibiotics with intranasal corticosteroids.
Types of outcome measures
We analysed the following outcomes in the review, but we did not
use them as a basis for including or excluding studies.
Primary outcomes
• Health-related quality of life, using disease-specific health-
related quality of life scores, such as the Sino-Nasal Outcome
Test-22 (SNOT-22), Rhinosinusitis Outcome Measures-31
(RSOM-31) and SNOT-20.
• Disease severity, as measured by patient-reported symptom
score (such as the Chronic Sinusitis Survey (CSS) questionnaire
and visual analogue scales).
• Significant adverse effect: epistaxis.
Secondary outcomes
• Health-related quality of life, using generic quality of life
scores, such as the SF-36, EQ-5D and other well-validated
instruments.
• Other local adverse effects: local irritation (including oral
thrush, sore throat and other local nasal irritation such as
dryness, itchiness etc.).
• Other systemic adverse effects:
◦ in children - stunted growth (minimum time point:
six months of treatment and follow-up);
◦ in adults - osteoporosis.
• Nasal endoscopic score (depending on population, either
nasal polyps size score or endoscopy score, e.g. Lund-Mackay/
Lund-Kennedy).
• Computerised tomography (CT) scan score (e.g. Lund-
Mackay).
Outcomes were measured at three to six months, six to 12 months
and more than 12 months. For adverse events, we analysed data
from the longest time periods.
Search methods for identification of studies
The Cochrane ENT Information Specialist conducted systematic
searches for randomised controlled trials and controlled clinical
trials. There were no language, publication year or publication
status restrictions. The date of the search was 11 August 2015.
Electronic searches
The Information Specialist searched:
• the Cochrane Register of Studies ENT Trials Register
(searched 11 August 2015);
• the Cochrane Central Register of Controlled Trials
(CENTRAL 2015, Issue 7);
• Ovid MEDLINE (1946 to July week 5 2015);
◦ Ovid MEDLINE (In-Process & Other Non-Indexed
Citations) (searched 11 August 2015);
◦ PubMed (as a top up to searches in Ovid MEDLINE)
(searched 11 August 2015);
• Ovid EMBASE (1974 to 2015 week 32);
• ClinicalTrials.gov, www.clinicaltrials.gov (search via the
Cochrane Register of Studies) (searched 11 August 2015);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (searched 11 August 2015);
• Google Scholar (searched 11 August 2015).
The Information Specialist modelled subject strategies for
databases on the search strategy designed for CENTRAL. Where
appropriate, theywere combined with subject strategy adaptations
of the highly sensitive search strategy designed by Cochrane for
identifying randomised controlled trials and controlled clinical tri-
als (as described in theCochraneHandbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011). Search
strategies for major databases including CENTRAL are provided
in Appendix 1.
Searching other resources
We scanned the reference lists of identified publications for addi-
tional trials and contacted trial authors where necessary. In addi-
tion, the Information Specialist searched PubMed, The Cochrane
Library and Google to retrieve existing systematic reviews relevant
to this systematic review, so that we could scan their reference lists
for additional trials.
Data collection and analysis
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Selection of studies
At least two review authors independently screened all titles and
abstracts of the studies obtained from the database searches to
identify potentially relevant studies. At least two review authors
evaluated the full text of each potentially relevant study to deter-
mine if it met the inclusion and exclusion criteria for this review.
We resolved any differences by discussion and consensus, with
the involvement of a third author for clinical and/methodological
input where necessary.
Data extraction and management
Two review authors independently extracted data from each study
using a standardised data collection form (see Appendix 2).When-
ever a study had more than one publication, we retrieved all pub-
lications to ensure complete extraction of data. Where there were
discrepancies in the data extracted by different review authors, we
checked these against the original reports and resolved differences
by discussion and consensus, with the involvement of a third au-
thor or amethodologist where appropriate.We contacted the orig-
inal study authors for clarification or for missing data whenever
possible. If differences were found between publications of a study,
we contacted the original authors for clarification. We used data
from the main paper(s) if no further information was found.
We included key characteristics of the studies, such as study design,
setting, sample size, population and how outcomes were defined
or collected in the studies. In addition, we also collected baseline
information on prognostic factors or effect modifiers. For this
review, this included:
• presence or absence of nasal polyps;
• baseline polyp score (where appropriate);
• whether the patient has had previous sinus surgery.
For the outcomes of interest to the review, we extracted the find-
ings of the studies on an available case analysis basis; i.e. we in-
cluded data from all patients available at the time points based on
the treatment randomised whenever possible, irrespective of com-
pliance or whether patients had received the treatment as planned.
In addition to extracting pre-specified information about study
characteristics and aspects of methodology relevant to risk of bias,
we extracted the following summary statistics for each trial and
each outcome:
• For continuous data: the mean values, standard deviations
and number of patients for each treatment group. Where
endpoint data were not available, we extracted the values for
change from baseline. We analysed data from measurement
scales such as SNOT-22 and EQ-5D as continuous data.
• For binary data: the numbers of participants experiencing
an event and the number of patients assessed at the time point.
• For ordinal scale data: if the data appeared to be
approximately normally distributed or if the analysis that the
investigators performed suggested parametric tests were
appropriate, then we treated the outcome measures as
continuous data. Alternatively, if data were available, we planned
to convert into binary data.
We prespecified the time points of interest for the outcomes in
this review. While studies may have reported data at multiple time
points, we only extracted the longest available data within the time
points of interest. For example, for ’short’ follow-up periods, our
time pointwas defined as ’three to sixmonths’ post-randomisation.
If a study reported data at three, four and six months, we only
extracted and analysed the data for the six-month follow-up.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of each
included study. We followed the guidance in the Cochrane Hand-
book for Systematic Reviews of Interventions (Handbook 2011) and
we used theCochrane ’Risk of bias’ tool.With this tool we assessed
the risk of bias as ’low’, ’high’ or ’unclear’ for each of the following
six domains:
• sequence generation;
• allocation concealment;
• blinding of participants, personnel and outcome assessment;
• incomplete outcome data;
• selective reporting;
• other sources of bias.
Measures of treatment effect
We summarised the effects of dichotomous outcomes (e.g. propor-
tion of patients with symptom resolution) as risk ratios (RR) with
CIs. For the key outcomes that we presented in the ’Summary of
findings’ table, we also expressed the results as absolute numbers
based on the pooled results and compared to the assumed risk. We
also planned to calculate the number needed to treat to benefit
(NNTB) using the pooled results. The assumed baseline risk is
typically either (a) the median of the risks of the control groups
in the included studies, this being used to represent a ’medium
risk population’ or, alternatively, (b) the average risk of the control
groups in the included studies is used as the ’study population’
(Handbook 2011). If a large number of studies were available,
and where appropriate, we also planned to present additional data
based on the assumed baseline risk in (c) a low-risk population
and (d) a high-risk population.
For continuous outcomes, we expressed treatment effects as amean
difference (MD) with standard deviation (SD) or as standardised
meandifference (SMD) if different scales had beenused tomeasure
the same outcome. We provided a clinical interpretation of the
SMD values.
Unit of analysis issues
This review did not use data from phase II of cross-over studies or
from studies where the patient was not the unit of randomisation,
i.e. studies where the side (right versus left) was randomised.
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If we had found cluster-randomised trials, we would have analysed
these according to the methods in section 16.3.3 of the Cochrane
Handbook for Systematic Reviews of Interventions (Handbook
2011).
Dealing with missing data
We tried to contact study authors via email whenever the outcome
of interest was not reported, if the methods of the study suggested
that the outcome had been measured. We did the same if not all
data required for meta-analysis had been reported, unless themiss-
ing data were standard deviations. If standard deviation data were
not available, we approximated these using the standard estima-
tion methods from P values, standard errors or 95% CIs if these
are reported as detailed in the Cochrane Handbook for Systematic
Reviews of Interventions (Handbook 2011). If it was impossible to
estimate these, we contacted the study authors.
Apart from imputations for missing standard deviations, we con-
ducted no other imputations. However, we carried out calcula-
tions relating to disease severity (measured by patient-reported
symptom scores) as most of the data measured individual symp-
toms rather than using validated instruments (see ’Imputing total
symptom scores’ below). We extracted and analysed data for all
outcomes using the available case analysis method.
Imputing total symptom scores
Where a paper did not present information for the total dis-
ease severity in terms of patient-reported symptom scores but did
present data for the results of individual symptoms, we used the
symptoms covering the important domains of the EPOS chronic
rhinosinusitis diagnosis criteria (EPOS 2012) to calculate a total
symptom score. The EPOS 2012 criteria for chronic rhinosinusitis
require at least two symptoms. One of the symptoms must be ei-
ther nasal blockage or nasal discharge; other symptoms can include
facial pressure/pain, loss of sense of smell (for adults) or cough (for
children). Where mean final values or changes from baseline were
presented in the paper for the individual symptoms we summed
these to calculate a ’total symptom score’. We calculated standard
deviations for the total symptom score as if the symptoms were in-
dependent, random variables that were normally distributed. We
acknowledge that there is likely to be a degree of correlation be-
tween the individual symptoms, however we used this process be-
cause the magnitude of correlation between the individual symp-
toms is not currently well understood (no evidence found). If the
correlation is high, the summation of variables as discrete vari-
ables is likely to give a conservative estimate of the total variance
of the summed final score. If the correlation is low, this method
of calculation will underestimate the standard deviation of the to-
tal score. However, the average patient-reported symptom scores
have a correlation coefficient of about 0.5; if this is also applica-
ble to chronic rhinosinusitis symptoms, the method used should
have minimal impact (Balk 2012). As this method of calculation
does not take into account weighting of different symptoms (no
evidence found), we downgraded all the disease severity outcomes
for lack of use of validated scales whenever this occurred.
Assessment of heterogeneity
We assessed clinical heterogeneity (which may be present even
in the absence of statistical heterogeneity) by examining the in-
cluded trials for potential differences between studies in the types
of participants recruited, interventions or controls used and the
outcomes measured.
We assessed statistical heterogeneity by visually inspecting the for-
est plots and by considering the Chi² test (with a significance level
set at P value < 0.10) and the I² statistic, which calculates the
percentage of variability that is due to heterogeneity rather than
chance, with I² values over 50% suggesting substantial heterogene-
ity (Handbook 2011).
Assessment of reporting biases
We assessed reporting bias as between-study publication bias and
within-study outcome reporting bias.
Outcome reporting bias (within-study reporting bias)
We assessed within-study reporting bias by comparing the out-
comes reported in the published report against the study protocol,
whenever this could be obtained. If the protocol was not available,
we compared the outcomes reported to those listed in themethods
section. If results are mentioned but not reported adequately in a
way that allows analysis (e.g. the report only mentions whether the
results were statistically significant or not), bias in a meta-analysis
is likely to occur. We sought further information from the study
authors. If no further information could be found, we noted this
as being a ’high’ risk of bias. Quite often there was insufficient
information to judge the risk of bias; we noted this as an ’unclear’
risk of bias (Handbook 2011).
Publication bias (between-study reporting bias)
We planned to assess funnel plots if sufficient trials (more than 10)
were available for an outcome. If we had observed asymmetry of the
funnel plot, we would have conducted more formal investigation
using the methods proposed by Egger 1997.
Data synthesis
We conducted all meta-analyses using Review Manager 5.3
(RevMan 2014). For dichotomous data, we planned to analyse
treatment differences as a risk ratio (RR) calculated using theMan-
tel-Haenszel methods. We analysed time-to-event data using the
generic inverse variance method.
For continuous outcomes, if all the data were from the same scale,
we planned to poolmean values obtained at follow-upwith change
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outcomes and report this as a MD. However, if the SMD had to
be used as an effect measure, we did not plan to pool change and
endpoint data.
When statistical heterogeneity is low, random-effects versus fixed-
effect methods yield trivial differences in treatment effects. How-
ever, when statistical heterogeneity is high, the random-effects
method provides a more conservative estimate of the difference.
Subgroup analysis and investigation of heterogeneity
We planned to conduct some subgroup analyses regardless of
whether statistical heterogeneity was observed, as these are widely
suspected to be potential effect modifiers. For this review, this in-
cluded:
• phenotype of patients: whether patients have chronic
rhinosinusitis without nasal polyps, chronic rhinosinusitis with
nasal polyps, a mixed group or the status of polyps is not known
or not reported. We planned to undertake the subgroup analysis
because although there appears to be a considerable overlap
between the two forms of chronic rhinosinusitis with regards to
inflammatory profile, clinical presentation and effect of
treatment (Cho 2012; DeMarcantonio 2011; Ebbens 2010;
Fokkens 2007; Ragab 2004; Ragab 2010; van Drunen 2009),
there is some evidence pointing to differences in the respective
inflammatory profiles (Kern 2008; Keswani 2012; Tan 2011;
Tomassen 2011; Zhang 2008; Zhang 2009), and potentially
even differences in treatment outcome (Ebbens 2011).
We planned to present the main analyses of this review according
to the subgroups of phenotypes of chronic rhinosinusitis in forest
plots and all other subgroup analysis results in tables.When studies
had a mixed group of patients, we analysed the study as one of
the subgroups (rather than as a mixed group) if more than 80% of
patients belonged to one category. For example, if 81% of patients
had chronic rhinosinusitis without nasal polyps, we analysed the
study as that subgroup.
In addition to polyps status, we also planned to conduct the fol-
lowing subgroup analyses in the presence of statistical heterogene-
ity:
• patient age (children versus adults);
• dose;
• duration of treatment;
• method of delivery.
Sensitivity analysis
We planned to carry out sensitivity analyses to determine whether
the findings were robust to the decisions made in the course of
identifying, screening and analysing the trials. We planned to con-
duct sensitivity analysis for the following factors, whenever possi-
ble:
• impact of model chosen: fixed-effect versus random-effects
model;
• risk of bias of included studies: excluding studies with high
risk of bias (we defined these as studies that had a high risk of
allocation concealment bias and a high risk of attrition bias
(overall loss to follow-up of 20%, differential follow-up
observed);
• how outcomes were measured: we planned to investigate
the impact of including data where the validity of the
measurement is unclear.
If any of these investigations found a difference in the size of the
effect or heterogeneity, we would mention this in the Effects of
interventions section.
GRADE and ’Summary of findings’ table
We used the GRADE approach to rate the overall quality
of evidence for each outcome using the GDT tool (http://
www.guidelinedevelopment.org/) for the main comparison pairs
listed in the Types of interventions section. The quality of evi-
dence reflects the extent to which we are confident that an esti-
mate of effect is correct and we applied this in the interpretation
of results. There are four possible ratings: ’high’, ’moderate’, ’low’
and ’very low’. A rating of ’high’ quality evidence implies that we
are confident in our estimate of effect and that further research is
very unlikely to change our confidence in the estimate of effect.
A rating of ’very low’ quality implies that any estimate of effect
obtained is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision;
• publication bias.
The ’Summary of findings’ table presents only the seven top prior-
ity outcomes (disease-specific health-related quality of life, disease
severity score, adverse effects and generic quality of life score). We
did not include the outcomes of endoscopic score and CT scan
score in the ’Summary of findings’ table.
R E S U L T S
Description of studies
Results of the search
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The searches retrieved a total of 2470 references after removal
of duplicates. We identified one additional reference from other
sources. We screened the titles and abstracts and subsequently
removed 2297 references. We assessed 87 full texts for eligibility.
We excluded 45 studies (55 references), with reasons. We included
18 studies (24 references).We identified three ongoing studies and
there are five studies awaiting assessment because we cannot locate
the full-text papers.
A flow chart of study retrieval and selection is provided in Figure
1.
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Figure 1. Process for sifting search results and selecting studies for inclusion.
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Included studies
Design
All studies included studies were double-blinded randomised con-
trolled trials. All but three studies (Holmberg 1997; Lang 1983;
Lund 2004) had a treatment and follow-up duration of between
12 to 16 weeks. Holmberg 1997 and Lund 2004 had a treatment
duration of 20 and 26 weeks respectively.
Some of these studies hadmultiple treatment arms: four compared
different doses of intranasal corticosteroids against placebo (Chur
2013; Penttilla 2000; Small 2005; Stjarne 2006), whereas Johansen
1993 compared two different types of delivery methods (nasal
spray versus nasal drops) against placebo.
Setting
Most studies were published more than 10 years ago (Aukema
2005; Holmberg 1997; Holopainen 1982; Johansen 1993; Keith
2000; Lang 1983; Lund 1998; Lund 2004; Parikh 2001; Penttilla
2000; Small 2005). Most of these were conducted in tertiary refer-
ral centres in northern Europe, the US and Canada. Chur 2013,
Lund 2004, Small 2005 and Stjarne 2006 included other centres
around the world, while Zhou 2015 was conducted in China.
Population and sample size
One study recruited 127 children aged 6 to 17 (Chur 2013); the
rest were conducted in adults. Most studies were relatively small,
with as few as 9 or 10 patients per intervention arm. The largest
study was Zhou 2015, with 748 patients in total.
The populations included in the studies with regards to pheno-
types of chronic rhinosinusitis were:
• with polyps: Aukema 2005; Chur 2013; Holmberg 1997;
Johansen 1993; Keith 2000; Lang 1983; Lund 1998; Penttilla
2000; Small 2005; Stjarne 2006; Stjarne 2006a; Vlckova 2009;
Holopainen 1982; Zhou 2015;
• without polyps: Hansen 2010; Lund 2004; Mosges 2011;
Parikh 2001.
Intervention and comparison
The following types of intranasal corticosteroids were used:
• Fluticasone propionate: 400 µg per day given as nasal drops
in Aukema 2005, Keith 2000 and Penttilla 2000, nasal spray in
Holmberg 1997, Lund 1998 and Parikh 2001, and as a 800 µg/
day dose using a breadth actuated inhaler in Hansen 2010 and
Vlckova 2009. Penttilla 2000 also had a higher-dose treatment
arm of 800 µg per day.
• Beclomethasone propionate: 400 µg per day delivered as
nasal sprays in Holmberg 1997 and Lund 1998. Lang 1983 used
nasal drops at 800 µg per day.
• Mometasone furoate nasal spray, given as 200 µg once daily
in Small 2005, Stjarne 2006 and Stjarne 2006a. 400 µg per day
was used in Mosges 2011, Zhou 2015 and in the higher-dose
arm of Stjarne 2006. Chur 2013 used either 100 µg a day for
children aged 6 to 11 or 200 µg per day for children aged 12 to
17. It also had a group using a higher dose, doubling the doses to
200 µg and 400 µg per day respectively.
• Budesonide nasal spray was used in Johansen 1993,
Holopainen 1982 (400 µg per day) and Lund 2004 (128 µg per
day).
Outcomes
Health-related quality of life, using disease-specific health-
related quality of life scores
One study used the Rhinosinusitis Outcome Measure (RSOM-
31) (Hansen 2010). Stjarne 2006a reported that scores for qual-
ity of life were recorded at every study visit using an investiga-
tor-administered scale with the following items: “nose breathing”,
“experience of smell and taste”, “interference with daily activities
caused by nasal symptoms” and “sleep disturbance”. It is unlikely
that this is a validated quality of life instrument.
Disease severity, as measured by patient-reported symptom
score
All studies but one (Lang 1983) measured disease severity as re-
ported by patients, but only Lund 2004 used a validated scale
(Chronic Sinusitis Survey - CSS). However, Lund 2004 reported
that at the time of the study, a validated version of the Hungarian
questionnaire was not available (the study was conducted in 19
centres, six of which were in Hungary).
Most studies presented the results (partially) in graphs as median
or mean values. The method of measurement was reported in
several ways and differed in the choice of scale, type/combination
of symptoms measured, timing of measures and scoring/analysis
method (see Appendix 3).
Due to these variations, it was unclear whether the total scores
between studies were comparable with each other and we had to
make modifications in order to standardise scores before meta-
analysis could be conducted (see Methods and Potential biases in
the review process).
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Significant adverse effect: epistaxis
All but five studies reported the number of patients with epis-
taxis and these could bemeta-analysed (Holmberg 1997; Johansen
1993; Lang 1983; Lund 1998; Parikh 2001). Holmberg 1997 and
Johansen 1993 did not provide enough information about the
types of adverse effects experienced and howmany patients experi-
enced them, whereas the other three studies were very small (fewer
than 15 patients per treatment arm) and it was unclear whether
epistaxis was not experienced by any patients or not reported.
The studies included nosebleeds of all severities, including mild.
Health-related quality of life, using generic quality of life
scores, such as the SF-36, EQ-5D and other well-validated
instruments
Lund 2004 used the SF-36, but only reported for which subscale
a statistically significant difference was found.
Other local adverse effects: local irritation (including oral
thrush, sore throat and other local nasal irritation such as
dryness, itchiness etc.)
A variety of types of possible local irritation symptoms were re-
ported in the studies, ranging from “itchiness” to “nasal burns”
and “nasopharyngeal pain/discomfort”. Some studies used broader
classifications whereas others used more specific description. For
example, Vlckova 2009 reported an unusual combination of “ad-
verse events”, listing “rhinalgia” and “nasal discomfort” separately
alongside headache; they also reported “rhinitis” as an adverse
event alongside “sneezing” and “rhinorrhoea”.
Other systemic adverse effects (in children - stunted growth,
in adults - osteoporosis)
Only one study followed up patients in the longer term (Lang
1983), and this adverse effect was not reported or relevant in the
other studies.
Nasal endoscopic score (either nasal polyps size score or
endoscopy score, e.g. Lund-Kennedy)
Lund 1998 and Stjarne 2006a did not report any endoscopy re-
sults.
Studies that recruited patients with nasal polyps mostly used a
0- to 3-point scale. In most studies, this was the Lildholdt scale,
but the definitions were not reported clearly in the other studies.
Whenever studies reported these as mean values at endpoint or
change from baseline, they summed the scores from both sides of
the nose (0 to 6 range). However, no definitions were given in the
studies that reported the results as proportions of people who had
improved.
One study used a 0 to 4 scale (Holmberg 1997), after some modi-
fication to the Lildholdt scale. The investigators in Aukema 2005
scored the volume of polyps on a 0 to 10 cm visual analogue scale
after conducting endoscopy.
Studies that included patients without polyps used the Lund-
Kennedy scale (Hansen 2010; Mosges 2011; Parikh 2001). It was
unclear whether Lund 2004 used endoscopy scores as an outcome
- this was not reported.
Computerised tomography (CT) scan score (e.g. Lund-
Mackay)
Only one study reported a CT scan score (Aukema 2005). The
Lund-Mackay score was used (0 to 24 points, higher score = more
severe).
Excluded studies
We excluded 55 papers (45 studies) after reviewing the full text.
Further details of the reasons for exclusion can be found in the
Characteristics of excluded studies table.
We excluded 23 studies due to the population, most of these (19
studies) because all patients received surgery at the start of the
trial and the intranasal steroids were used to try to prevent re-
currence of polyps (Bross-Soriano 2004; Cassano 1996; Dijkstra
2004; Drettner 1982; el Naggar 1995; Gulati 2001; Hartwig
1988; Jorissen 2009; Jurkiewicz 2004; Kang 2008; Karlsson 1982;
Malmberg 1988; Passali 2003; Rotenberg 2011; Rowe-Jones
2005; Slifirski 2009; Stjarne 2009; Vento 2012; Virolainen 1980).
Other reasons for excluding studies based on the population were
related to patients not meeting the current criteria for chronic
rhinosinusitis (ALA 2015), chronic allergic or bacterial sinusitis
where less than 50% of patients had chronic disease (Cuenant
1986), aspirin-induced asthma and chronic eosinophilic rhini-
tis (Mastalerz 1997), and recurrent or chronic maxillary sinusitis
(Qvarnberg 1992). We excluded three studies because the studies
were designed to look at the impact of intranasal corticosteroids
on outcomes when given perioperatively: all patients underwent
surgery during the period of the trial (Albu 2010; Ehnhage 2009;
Saunders 1999). Two studies compared steroids with placebo or no
treatment but we excluded them as they used a catheter or tube to
administer steroids directly to the participant’s sinuses (Furukido
2005; Lavigne 2002). One study was a clinical trial that appeared
to meet the inclusion criteria but the clinical trials registry website
stated that the trial had been terminated early (Optinose 2012).
The reason for early termination is not provided.
We excluded the remaining 16 papers as they did not meet the
minimum requirements for the duration of treatment and follow-
up. Ten of these studies had a follow-up time of one month or
less (Chalton 1985; Johansson 2002; Kapucu 2012; Keith 1995;
Lildholdt 1995; Mygind 1975; Ruhno 1990; Taub 1968; Toft
1982; Wang 2015), whereas the remaining six treated and fol-
lowed up patients for between six and eight weeks (Filiaci 2000;
Jankowski 2001; Jankowski 2009; Man 2013; Meltzer 1993; Tos
1998).
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Ongoing studies
We identified three relevant ongoing studies, all of which
are in adults with chronic rhinosinusitis with nasal polyps
(NCT01622569;NCT01624662;NCT01013701). Two of these
are large, multicentre trials each with a planned population of
over 300 patients (NCT01622569; NCT01624662). These two
trials will make the same comparisons, comparing three different
doses of fluticasone proportionate (400 µg bid, 200 µg bid and
100 µg bid) with placebo. All of the arms will use a novel bi-
directional device. The studies were completed in October 2015
but no study data were available at the time of writing this review.
The other trial compares fluticasone furoate with placebo for 16
weeks (NCT01013701). The trial information was registered in
2009 and the ClinicalTrials.gov website reports that the recruit-
ment status of the trial is unknown as the information has not
been recently validated. We attempted to contact the investigators
but we did not receive a response.
Risk of bias in included studies
We included 18 studies in this review. Nine of these had low risk
of bias for both selection and blinding (Keith 2000; Lund 2004;
Mosges 2011; Parikh 2001; Penttilla 2000; Small 2005; Stjarne
2006; Stjarne 2006a; Zhou 2015). Lang 1983 was only available
as an abstract and therefore there was insufficient information to
judge the risk of bias for most domains. We didmost of the ratings
based solely on the study report(s), as the trials were not registered
and no protocols were available.
See Figure 2 for the ’Risk of bias’ graph (our judgements about
each risk of bias item presented as percentages across all included
studies) and Figure 3 for the ’Risk of bias’ summary (our judge-
ments about each risk of bias item for each included study).
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
Six of the studies only stated that the trialswere randomised but did
not provide further information about how sequence generation
was conducted. We therefore judged them to be at an unclear
risk of bias (Hansen 2010; Holmberg 1997; Holopainen 1982;
Johansen 1993; Lang 1983; Vlckova 2009).
Another two studies also did not provide details of their randomi-
sation procedures, but we judged this to be a low risk of bias be-
cause these studies were conducted quite recently as multinational
trials and therefore should have used adequate methodology to en-
sure adequate sequence generation (Penttilla 2000; Small 2005).
The rest of the studies either specified that the randomisation was
conducted by another unit supporting clinical trials (the pharmacy
for Parikh 2001) or provided a clear description of how comput-
erised sequence generation was used.
Allocation concealment
We also rated nine studies as low risk of bias for allocation con-
cealment (Keith 2000; Lund 2004; Mosges 2011; Parikh 2001;
Penttilla 2000; Small 2005; Stjarne 2006; Stjarne 2006a; Zhou
2015). As for sequence generation, we considered the large multi-
national RCTs to have adequate methodology although they did
not provide specific information about the allocation concealment
method (Penttilla 2000; Small 2005; Stjarne 2006a). An excep-
tion to this is Chur 2013, which we rated as unclear risk of bias
for allocation concealment. Despite the adequate methods used
to generate a random sequence, blocked randomisation was used
and the effectiveness of the blinding was unclear in the absence of
a ’double-dummy’ design in this multi-arm trial.
We rated the other studies as unclear risk of bias due to lack of
information.
Blinding
The ratings for the risk of performance bias versus detection bias
were closely related for this review. Most of the outcomes were
assessed by the patients and the overall risks of bias were low when
both participants and investigators were adequately blinded. We
did not find information to suggest that the clinicians could have
obtained extra information from blood tests etc. to allow them to
’guess’ which treatment the patients were allocated.We considered
themajority (16) of the studies to be at low risk of bias for blinding.
We considered two studies to be at unclear risk: Chur 2013 did
not use a double-dummy design to mask the regimens and there
was no information in Lang 1983.
Incomplete outcome data
We considered only four trials to have a low risk of attrition bias:
Holopainen 1982; Keith 2000; Vlckova 2009 and Zhou 2015.
Eleven studies had a high risk of attrition bias due to unbal-
anced drop-out rates between the placebo and treatment groups,
with higher drop-out rates in the placebo groups (Aukema 2005;
Hansen 2010; Penttilla 2000, Small 2005; Stjarne 2006; Stjarne
2006a), an overall high rate of drop-outs (Lund 2004), or a com-
bination of these factors (Holmberg 1997; Lund 1998; Parikh
2001). In Mosges 2011, only 10% of patients did not complete
the full study, but it was unclear why the study only included 75%
of the sample in intention-to-treat (ITT) analysis due to “major
protocol violation” and 61% in the per protocol population due
to “minor protocol violation”.
The risk of attrition bias was unclear for three of the included
studies (Chur 2013; Johansen 1993; Lang 1983). These studies did
not provide enough information to adequately judge the risk. For
example, Johansen 1993 reported that 5/91 (5.5%) participants
did not complete the study. There was no information on how
many were randomised to each group in Johansen 1993 and so
it is difficult to determine whether this could have affected the
results.
Selective reporting
Many of the study reports presented effectiveness outcomes only
in graphs and only provided limited, selective information, for
example P values or mean values only when statistical significance
was noted.
We considered only two studies to have low risk of bias, with all
expected outcomes reported (Small 2005; Zhou 2015).
We considered the risk of selective reporting to be high in eight
studies (Aukema 2005; Chur 2013; Holmberg 1997; Holopainen
1982; Lang 1983; Lund 1998;Mosges 2011; Parikh 2001). These
studies either presented outcomes that were not pre-specified in
the methods section or downplayed and provided insufficient in-
formation about prespecified outcomes. Others used an unclear or
arbitrary method to combine data or report some of the outcomes
(or both).
The primary endpoint in Chur 2013 was “safety” (cortisol levels)
and despite presenting the mean change values for effectiveness
outcomes, they did not provide any P values or standard devia-
tions. The study’s rationale for collecting the data and not fully
reporting them was: “No statistical analysis of efficacy end points
was pre-specified in the study protocol, and only descriptive effi-
cacy statistics were collected.”We observed that these values (mean
changes) were similar between groups and unlikely to be statis-
tically significant and so poor reporting due to lack of beneficial
effects cannot be ruled out.
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We considered the remaining eight studies to be at unclear risk.
Therewas not enough information in themethods and/or protocol
and we found it difficult to judge whether there was a risk of
reporting bias.
Other potential sources of bias
Use of validated outcome measures
The lack of use of validated outcome measures is a major bias
concern in this review. If an instrument is insensitive to measuring
differences, this biases towards a finding of ’no difference’ in the
studies and also in this review.
None of the included studies mentioned using validated outcome
measures, for either of the primary effectiveness outcomes (disease-
specific health-related quality of life and disease severity/symptom
scores).
Almost all studies attempted tomeasure change in symptom scores
as measured by patients, but none reported validation of the in-
struments being used. Most studies used a 0 to 3 scale in the “di-
aries”, but used different methods to calculate the result (period
of time, combination of scores). There is no evidence that a 0- to
3-point scale, especially when used as a single scale, has the sen-
sitivity to distinguish between groups of patients who improved
versus those who did not (discriminant validity) or whether the
different method of scoring was valid.
The scales used to measure nasal polyps were generally well de-
scribed. However, it is again unclear whether a 0- to 3-point scale
has the discriminant validity to detect a difference in the small
trials seen.
Effects of interventions
See: Summary of findings for the main comparison Intranasal
corticosteroids for people with chronic rhinosinusitis
Where the range of scales and values for minimal important
differences were unclear, we used the standardised mean differ-
ence (SMD) as a guide to estimate the effect sizes. As suggested
in the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011), we used standard rules of thumb in the inter-
pretation of effect sizes (SMD, or Cohen’s effect size of < 0.41 =
small, 0.40 to 0.70 = moderate, > 0.70 = large) (Cohen 1988).
Established scales such as the SF-12may have other rules of thumb
to estimate the minimal important difference (MID = 0.5 SMD)
and we use those to guide our interpretation whenever available
(Jaeschke 1989; Revicki 2008).
Although we had planned to present data for patients with our
without polyps in subgroups as a visual comparison, this was not
necessary for the effectiveness outcomes because nomore than one
study contributed to the analysis, with the exception of polyps
score data.
Intranasal corticosteroids compared to placebo or no
intervention
Three of the 18 studies did not contribute any data for meta-anal-
ysis (Holmberg 1997; Johansen 1993; Parikh 2001). In our proto-
col, we had specified that results from studies of participants with
chronic rhinosinusitis with nasal polyps and without nasal polyps
would be presented as subgroups in the forest plots (Chong 2015).
However, this was only possible for the outcomes of epistaxis and
local irritation. Of the four studies in patients with chronic rhinos-
inusitis without nasal polyps (Hansen 2010; Lund 2004; Mosges
2011; Parikh 2001), only Lund 2004 contributed data for the ef-
fectiveness outcomes (disease severity).
Health-related quality of life, using disease-specific health-
related quality of life scores
Hansen 2010 (chronic rhinosinusitis without nasal polyps) was
the only study reporting the used of a disease-specific health-re-
lated quality of life questionnaire, the Rhinosinusitis Outcome
Measures-31 (RSOM-31). Themedian change frombaseline (me-
dian 178 points) was -62 points for the intranasal corticosteroids
group (n = 10) and -5 points for the placebo group (n = 10, from
a median baseline score of 187 points). The difference was not
statistically significant (Mann-Whitney U test).
Disease severity, as measured by patient-reported symptom
score (such as the Chronic Sinusitis Survey (CSS)
questionnaire and visual analogue scales)
Chronic Sinusitis Survey
Lund 2004 (chronic rhinosinusitis without nasal polyps) reported
that at the time of the study, a validated version of the Hungarian
questionnaire was not available (the study was conducted in 19
centres, six of which were inHungary). Only themean change and
95%confidence interval (CI) for each groupwas reported,without
a sample size. We imputed the sample size based on the number
of patients available at the end of the study and it seems that
all available patients had filled in the CSS. The mean difference
(MD) was 2.84 points (95% CI -5.02 to 10.70; 134 participants)
between groups (range 0 to 100, higher values = better) (Analysis
1.1). The magnitude of the difference is insignificant.
Global rating scale
Vlckova 2009 used a five-point global rating scale (very much
improved, improved, same, worse or very much worse). At 12
weeks, 76% of patients in the treatment group were “improved”
or “very much improved” compared to 27% of patients in the
placebo group (risk ratio (RR) 2.78, 95% CI 1.76 to 4.40; 109
participants; one study) (Analysis 1.2).
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Combined symptom scores
Six studies provided information on mean and standard deviation
values, or had enough information in their graphs for us to esti-
mate these values for various symptom scores (Aukema2005; Lund
2004; Small 2005; Stjarne 2006; Vlckova 2009; Zhou 2015). Of
these, only Vlckova 2009 and Lund 2004 (chronic rhinosinusitis
without nasal polyps) reported an overall combined score for all
four groups of symptoms covered by EPOS 2012 (nasal block-
age, nasal discomfort (facial and sinus pain/pressure) and rhinitis
symptoms (nasal secretion, itching, irritation and sneezing), and
loss of sense of smell). Parikh 2001 also included these symptoms
in their diary card and symptom scores, but it is less clear how
these were calculated. Although themeans and standard deviations
were reported for this study, we did not include it in the meta-
analysis because the values were obviously skewed (mean of 29.4
(standard deviation (SD) 37) for intranasal corticosteroids group
(n = 9), mean of 16.9 (SD 48.5) (n = 13) for placebo group, P
value = 0.39 using Mann Whitney U test).
Therefore we only included six studies in our analysis. We report
the average values when all four types of symptoms mentioned in
EPOS were measured versus when only three types (loss of sense
of smell, nasal blockage and nasal discharge) and two types of
symptoms (nasal blockage and nasal discharge) were measured. All
studies used 0- to 3-point scales in their diaries, except for Aukema
2005, which used a 0 to 100 visual analogue scale (VAS)measured
during follow-up. All studies reported change frombaseline, except
for Aukema 2005, which reported the mean difference at the end
of the study. To allow for ease of interpretation, we converted these
0 to 100 VAS scores into 0 to 3 by a division of 33.333. All studies
used the ’usual dose’ of intranasal steroids, except for Vlckova
2009,which only used a higher dose of fluticasone propionate (800
µg/day), delivered in two divided doses. Two studies, Small 2005
and Stjarne 2006, had two treatment arms using mometasone
furoate nasal spray with low (200 µg/day) and high (400 µg/day)
doses. Only one study included patients without nasal polyps (
Lund 2004). All studies were conducted in adults.
The pooled results are as follows:
• Combined symptom score for four EPOS domains, average
score: MD -0.26 (95% CI -0.37 to -0.15; 243 participants; two
studies; I2 = 46%), scale range: 0 to 3, lower = better, indicating
less severe symptoms in the intranasal corticosteroids group
(Analysis 1.3).
• Combined symptom score for three EPOS domains (nasal
blockage, rhinorrhoea and loss of sense of smell), average score:
MD -0.31 (95% CI -0.38 to -0.23; 1345 participants; four
studies; I2 = 0%), scale range: 0 to 3, lower = better (Analysis
1.3).
• Combined symptom score for two EPOS domains (only
nasal blockage and rhinorrhoea), average score: MD -0.31 (95%
CI -0.38 to -0.24; 1702 participants; six studies; I2 = 0%), scale
range: 0 to 3, lower = better (Analysis 1.3).
The observed mean differences correspond to a moderate effect
size (the SMDwas about 0.4 for the two and three domain average
symptom scores and 0.6 for the four domain average symptom
score). The quality of the evidence is low for the four domain
scores and moderate for the three and two domains scores (facial
pain/pressure not considered), with the main concerns being the
use of non-validated symptom scores and a high risk of reporting
bias (many studies did not publish the results in detail and this
could be linked to a lack of observed efficacy).
Individual symptom scores
• Nasal blockage: MD -0.40 (95% CI -0.52 to -0.29; 1702
participants; six studies; I2 = 47%) (Analysis 1.4).
• Rhinorrhoea: MD -0.25 (95% CI -0.33 to -0.17; 1702
participants; six studies; I2 = 6%) (Analysis 1.4).
• Loss of sense of smell: MD -0.19 (95% CI -0.28 to -0.11;
1345 participants; four studies; I2 = 0%) (Analysis 1.4).
• Facial pain/pressure: MD -0.27 (95% CI -0.56 to 0.02; 243
participants; two studies; I2 = 78%). Of these two studies, Lund
2004 included patients with chronic rhinosinusitis without nasal
polyps, whereas Vlckova 2009 included patients with chronic
rhinosinusitis with nasal polyps. Due to the differences in type,
dose and delivery method (fluticasone propionate 800 µg per day
using breadth actuated inhaler versus budesonide 128 µg per day
as a nasal spray), the source of heterogeneity was unclear.
We used a random-effects model to conduct the analysis; if a fixed-
effect model is used the statistical significance of the pooled MD
for facial pain is -0.24 (95% CI -0.37 to -0.11). The quality of
the evidence is moderate for nasal blockage, rhinorrhoea and loss
of sense of smell, but low for facial pain/pressure.
Significant adverse effect: epistaxis
The risk of epistaxis was higher in the intranasal corticosteroids
group (RR 2.74, 95% CI 1.88 to 4.00; 2508 participants; 13
studies; I2 = 0%) (Analysis 1.5). The quality of the evidence is
high.
Health-related quality of life, using generic quality of life
scores, such as the SF-36, EQ-5D and other well-validated
instruments
Lund 2004 used the SF-36, but only stated that there was a sta-
tistically significant improvement in the general health subscale in
patients on intranasal corticosteroids compared to placebo. Apart
from stating that no other significant differences were observed,
no other details were reported.
Other local adverse effects: local irritation (including oral
thrush, sore throat and other local nasal irritation such as
dryness, itchiness etc.)
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It is unclear whether there is an important difference in the risk
of local irritation between participants taking intranasal corticos-
teroids or placebo (RR 0.94, 95% CI 0.53 to 1.64; 2124 par-
ticipants; 11 studies; I2 = 0%) (Analysis 1.6). The quality of the
evidence is low (we are uncertain about this estimate), because the
reporting of local irritation effects varied a lot between studies.
This was sometimes finely split into many types of local irritation
and we could only use the numbers for the most commonly re-
ported types of irritation to avoid double counting in this review.
The actual event rate for all types of local irritation is higher than
reported in this analysis.
Other systemic adverse effects (in children - stunted growth,
in adults - osteoporosis)
None of the studies treated or followed up patients for long enough
to report these adverse events.
Nasal endoscopic score (depending on population, either
nasal polyps size score or endoscopy score, e.g. Lund-
Mackay/Lund-Kennedy)
Three studies reported polyps score results as the mean change
from baseline on a 0- to 6-point scale. Five studies reported this
as the proportion of patients who had an improvement. Vlckova
2009 reported both the mean improvement and the proportion of
patientswith an improvement. Aukema 2005measured polyps size
on a 0 to 10 cm visual analogue scale and seems to have reported
the values at the end of the study. We did not include this in the
analysis as it was unclear what the scale was and whether it was
valid. The MD was -24.70 (95% CI -48.00 to -1.40, n = 47) and
we observed heterogeneity when it was combined with the other
studies.
Chronic rhinosinusitis with nasal polyps - reduction in
polyps size
The MD in polyps score was -0.58 (95% CI -0.90 to -0.26; 1417
participants; four studies; I2 = 83%) indicating less severity for the
intranasal corticosteroids group (Analysis 1.7). All reported the
sum of polyps score from both sides of the nose (range 0 to 6). One
study, Vlckova 2009, had an effect that was larger than the other
studies, with a mean difference of -1.21 (95% CI -1.56 to -0.86)
points between treatment arms in the reduction of polyps size
score. When this study is removed, the heterogeneity is resolved
and the observed effect size is smaller (MD -0.35, 95% CI -0.47
to -0.24; 1308 participants; three studies; I2 = 0%).
Five studies reported the proportion of participants who had an
improvement in their polyps scores. The chance of an improve-
mentwas higher in patients on intranasal corticosteroids (RR1.77,
95% CI 1.06 to 2.95; 676 participants; five studies; I2 = 66%)
(Analysis 1.8). The observed heterogeneity was resolved when we
removed a study with an outlier effect (Vlckova 2009), but the
RR became slightly smaller (RR 1.46, 95% CI 1.12 to 1.90; 567
participants; four studies; I2 = 0%).
Using a method recommended in the Cochrane Handbook for Sys-
tematic Reviews of Interventions, we converted the continuous out-
come data into proportions and analysed them together using the
generic inverse variance method. For Vlckova 2009, which re-
ported both themean difference and proportions, we used the val-
ues reported for proportions to avoid double counting and tomin-
imise imputations. The overall pooled odds ratio (OR) was 2.07
(95% CI 1.48 to 2.91; 1984 participants; eight studies) (Analysis
1.9). The observed heterogeneity was quite substantial (> 50%).
We observed that Vlckova 2009 seemed to have a larger effect than
the other studies. If this study is removed from the analysis, the
OR is slightly lower (OR 1.71, 95% CI 1.43 to 2.04; 1875 par-
ticipants; seven studies) and heterogeneity is no longer observed.
Chronic rhinosinusitis without nasal polyps - endoscopy
score
The studies that included patients without polyps, such as Hansen
2010, Mosges 2011 and Parikh 2001, used a modified Lund-
Kennedy score. However, the results were either only partially re-
ported or could not be meta-analysed due to highly skewed dis-
tribution (very small sample sizes). Lund 2004 did not report the
endoscopy score as an outcome and it was unclear whether this
was measured.
Parikh 2001 reported the percentage of change and standard de-
viation. This was -22.3% (SD 61.8) (n = 9) for the intranasal
corticosteroids group and +19.9% (SD 58.3) (n = 13). This was
not statistically significant (Mann Whitney U test). Mosges 2011
showed the total endoscopy score for redness, oedema and dis-
charge on a chart. There were no statistically significant differences
between groups. Similarly, Hansen 2010 reported no statistically
significant differences between groups for different aspects of the
assessment, except for oedema.
Computerised tomography (CT) scan score (e.g. Lund-
Mackay)
Only one study reported the CT scan score (Aukema 2005). The
MDwas -4.82 (95%CI -7.27 to -2.37; 47 participants; one study;
I2 = 0%) (Analysis 1.10). The Lund-Mackay score was used (0 to
24 points, higher score = more severe).
D I S C U S S I O N
Summary of main results
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This review includes a total of 18 studies. However, many studies
were very small and did not measure and/or report data in a way
that allowed for meta-analysis.
Only one very small study (n=20) reported disease-specific health-
related quality of life, using the Rhinosinusitis Outcome Mea-
sures-31 (RSOM-31). Lund 2004 described using the SF-36, but
reported that only the general health subscale showed a statistically
significant difference between groups.
We found that intranasal corticosteroids improved patient symp-
tom scores, when these were measured as a combined score, with
scores for individual items or as a global score (non-validated
scales). Apart from rhinorrhoea and loss of sense of smell, which
had small effect sizes whenmeasured as individual items, the effect
sizes observed using other parameters corresponded to moderate
effect sizes. However, because these data could only be obtained
from a few studies (many studies did not report enough detail
when the results were not ’significant’) there is a risk of reporting
bias.
Epistaxis was probably the most consistently reported outcome,
with 13 out of 18 studies reporting this. The risk was increased
in patients using intranasal corticosteroids (risk ratio (RR) 2.74,
95% confidence interval (CI) 1.88 to 4.00; 2508 participants; 13
studies).However, local irritationwas very inconsistently reported,
with studies using various definitions to report the data. The RR
obtained was 0.94 (95% CI 0.53 to 1.64; 2124 participants; 11
studies; I2 = 0%) and it is unclear whether there is an important
increase in risk. None of the studies treated or followed up patients
for long enough to provide meaningful data on osteoporosis risk
or risk of stunted growth.
There seemed to be an increased odds of polyp improvement in
people who had chronic rhinosinusitis with nasal polyps. How-
ever, the results for endoscopy score were not well reported in stud-
ies that included participants with chronic rhinosinusitis without
polyps.
Overall completeness and applicability of
evidence
A good range of types and doses of intranasal corticosteroids are
included in this review. However, the main body of evidence is in
patientswith chronic rhinosinusitiswith polyps. Studies in chronic
rhinosinusitis without polyps tended to be smaller, had poorer
reporting and did not contribute enough information to themeta-
analyses to allow us to evaluate whether there are differences in
effectiveness between these subgroups. Only one of these studies
was conducted in children (up to 18 years old) and therefore it
is again unclear whether the evidence is applicable to children.
Most studies were conducted for three to four months, with the
exception of three studies that were conducted for 20 weeks (
Aukema 2005), 26 weeks (Lund 2004), and two years (Lang
1983), respectively. Therefore, it is unclear whether the observed
effectiveness is maintained if intranasal corticosteroids are used
over longer periods and whether these benefits can be maintained
after patients stop treatment.
Most of the studies did not make any reference to whether saline
irrigation could be used. However, Vlckova 2009 specified that
patients could not use nasal saline. This study showed larger effect
sizes than the other studies and unlike most studies, where partic-
ipants in both the intervention and placebo groups showed some
improvement over time, the participants in the placebo group in
this study got worse with time. It is unclear whether this is a ran-
dom observation or due to the patient population, the high doses
used or the exclusion of normal saline.
Quality of the evidence
The studies included in this review were relatively well conducted,
with most using good methodology for selection of patients and
blinding.
However, we had serious concerns about how the effectiveness out-
comes were measured, analysed and reported. The validity of the
tools used to measure outcomes is a major concern. Most studies
did not use validated tools to measure and score symptom severity
scales and this reduces our confidence in the estimates of effect.
Moreover, there is also a possibility of reporting bias, as studies
only tended to report enough detail to allow for meta-analysis
when they found a statistical significant result. These reasons sig-
nificantly reduced our confidence in the estimates of effect sizes
and we rated the quality of the evidence as moderate for disease
severity outcomes. The exception was those outcomes involving
facial pain/pressure, but there was some unexplained heterogene-
ity and there were fewer data. For quality of life, the quality of the
evidence is very low.
The reporting methodology for ’local irritation’ was also a con-
cern and along with the imprecision observed we considered the
evidence for this outcome to be of low quality.
However, we considered the evidence for the risk of epistaxis to
be of high quality; this is an outcome that appears to have been
collected and reported consistently across studies.
Potential biases in the review process
There were two major challenges to meta-analysis in the review
of effectiveness outcomes: 1) the lack of use of validated tools and
variations in how outcomes were measured and reported and 2)
the outcomes were often not fully reported.
Lack of use of validated tools and variations in how
outcomes were measured and reported
The lack of use of validated instruments to measure patient-im-
portant outcomes, such as the impact on quality of life and disease
severity, is probably the single most important issue that hampers
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our ability to meta-analyse results or to compare results between
studies. Studies used a variety of scales, timings and analysis meth-
ods to measure different combinations of symptoms. Some stud-
ies may have measured one group of symptoms (e.g. nasal dis-
charge) as several separate items (anterior rhinorrhoea, post-nasal
drip), but not measured other types of symptoms at all (e.g. loss
of sense of smell and facial pain/pressure). In the absence of ev-
idence for both disease-specific health-related quality of life and
disease severity measured with validated tools (only one study re-
spectively, Hansen 2010 and Lund 2004, reported these), some
’standardisation’ of these measures had to be conducted in order
to allow the results to be pooled. We took the decision to com-
bine the scores for individual symptoms to create a total symp-
toms score. The methods we used to do this are described in the
methods section (Dealing with missing data). The symptoms we
included were based on the EPOS 2012 diagnostic criteria, but
this score was not a validated measure and the correlation between
symptoms was not accounted for in the results.
In addition to making an assumption of no correlation between
symptoms, we also had to make other decisions to standardise the
data:
• Most studies only specified that diaries were completed in
the morning, whereas others were completed in the morning and
evening and may, or may not, have reported the results
separately. Where studies presented both morning and evening
scores, we only used the morning score values in this review, to
allow for standardisation across studies. We avoided taking an
average of morning and evening data and estimating the standard
deviations, since these should be taken as paired data and this
may further overestimate the size of the standard deviation (see
below for considerations when imputing standard deviations).
• Some studies only measured the outcomes at the endpoint.
We had to assume that the difference between changes and
endpoints would produce a similar mean difference between
groups and therefore could be pooled. We made this assumption
for Aukema 2005.
• Aukema 2005 used a 10 cm visual analogue scale. Since this
was only one small study, we had to assume that the scales were
linear and could be converted to a 0- to 3-point scale; we tested
this in a sensitivity analysis. Although the effect size observed for
this study was larger, it did not have an impact on the results.
Fortunately, most of the studies had measured symptom severity
using diaries with a 0- to 3-point scale and we could use the mean
differences to look at the size of the effect. However, what is a min-
imal important difference (MID) for a 0- to 3-point scale is not
known and to assist interpretation we still had to look at the stan-
dardised mean difference (SMD) and used Cohen’s effect size as a
rule of thumb. Bearing in mind that we did factor in correlations
(which will result in smaller standard deviations), this means that
the effect sizes could be larger than estimated. Nevertheless, we
still found moderate to large effect sizes in disease severity scores.
In fact, a moderate effect size was found in Lund 2004 using the
individual or combined scores, even though the study did not find
a clinically important difference using the Chronic Sinusitis Sur-
vey (CSS), a validated tool.
Local irritation is another outcome where there were many varia-
tions in reporting, in terms of categorisation and descriptions used.
Where studies reported more than one type of local irritation (e.g.
nasal burning and nasal irritation were both reported), we took
the data for the outcome with the higher total event rate. If rates
were the same for both outcomes, we chose the one terminology
that was closest to the description of general irritation (e.g. nasal
irritation would be used in this example), with the review author
blinded to the data.
Outcomes were often not fully reported
Many of the data for the included studies were presented in the pa-
pers in graphs or charts. Where this was the case, we extracted the
data from the paper using anonline program (http://arohatgi.info/
WebPlotDigitizer/app/). There will inevitably be a degree of error
in using these data, both from inaccuracies during the printing
process and the process used to collect the data. Where P values
were reported as less than a certain threshold (e.g. P value < 0.05),
calculations were based on P value = 0.05. This is a conservative
estimate for standard deviation values and we were conscious of
the need to minimise imputations as much as possible. For exam-
ple, Small 2005 had two arms (a high-dose and a low-dose group)
and only reported the P values compared to placebo for many out-
comes. Rather than trying to estimate what these P values may be
when ’combined’ and risk inflating the standard deviation further,
we entered this study twice as a high-dose and low-dose group,
and halved the sample size in the placebo group to avoid double-
counting.
Agreements and disagreements with other
studies or reviews
This review aimed to answer the clinical question of whether in-
tranasal corticosteroids are effective in patients who have chronic
rhinosinusitis. It is one of a series of reviews looking at the (rela-
tive) effectiveness and safety of different medical interventions for
chronic rhinosinusitis.
Although the intranasal steroids included in this review comprised
different types ofmolecules, doses, regimens anddeliverymethods,
we observed no statistical heterogeneity that suggested that these
factors could result in different levels of effectiveness and adverse
events such as epistaxis and local irritation. This observation about
the impact of variations in the types and doses of intranasal corti-
costeroids is consistent with our companion review, which looks
at different types and doses of intranasal corticosteroids (Chong
2016a). Chong 2016a also did not find any important differences
between high and low doses and there was very little evidence to
draw conclusions about the other aspects. However, Chong 2016a
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did find it possible that the risk of adverse effects is increased when
higher doses are used, whereas in this review we did not observe
any heterogeneity.
This review only compared intranasal steroids against placebo.We
have compared short-course oral steroids against intranasal cor-
ticosteroids in Head 2016a and Head 2016b; antibiotics against
intranasal corticosteroids in Head 2016c; and nasal saline against
intranasal corticosteroids in Chong 2016b. When compared to
oral corticosteroids, patients who received oral corticosteroids in-
stead of intranasal corticosteroids seemed to benefit more in terms
of reduced disease severity and polyps size for short follow-up peri-
ods (two to three weeks), but it was uncertain whether the benefit
persisted (difference minimises by three months) (Head 2016a).
The antibiotics review only found one very small study comparing
antibiotics (12 weeks of 250 mg clarithromycin) against 200 µg of
mometasone furoate spray and did not find an important differ-
ent between groups for overall disease severity, but found the en-
doscopy score to be slightly better in the antibiotics group (Head
2016c). The saline review only found one very small study com-
paring intranasal corticosteroids versus nebulised saline; intranasal
corticosteroids were much more effective than nebulised saline
(Chong 2016b). However, most of the evidence for intranasal cor-
ticosteroids compared against other interventions is of very low
quality (we have very little confidence in the effects estimated -
the evidence is inconclusive).
Unlike previous reviews of intranasal steroids, which focused
on either patients with polyps (Kalish 2012) or without polyps
(Snidvongs 2011), this review includes all types of chronic rhi-
nosinusitis patients. However, we limited inclusion to studies that
had followed up patients for at least threemonths and we excluded
patients who had just undergone surgery. The impact of intranasal
steroids in reducing recurrence in patients who have just had sinus
surgery is not the clinical question addressed by this review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Patients with chronic rhinosinusitis with nasal polyps showed an
improvement in symptoms on intranasal corticosteroids. How-
ever, data are lacking for patients without polyps and it is unclear
whether they derive a similar level of benefit.
The risk of adverse effects such as epistaxis and local irritation is
increased in people taking intranasal corticosteroids, although the
severity of the epistaxis is unknown, as is whether patients discon-
tinue usage as a result. If epistaxis is limited to streaks of blood in
themucus itmay be tolerated by the patient andbe safe to continue
treatment. However, it may be a factor that affects compliance.
Ensuring good technique in usage of spray by patients may help
to reduce these effects, especially where spraying of the septum is
avoided. Different intranasal corticosteroid delivery nozzles may
also have a bearing on this.
Implications for research
As of August 2015, most studies of intranasal steroids have been
conducted in participants with chronic rhinosinusitis with nasal
polyps. The evidence we found suggests that chronic rhinosinusi-
tis patients show an improvement in symptoms with intranasal
corticosteroids. Recent international trials using the Optinose de-
vice (Navigate trials I and II) have been completed and they in-
clude different doses within their protocols and a comparison with
placebo. Further information will therefore be forthcoming once
these results are published (NCT01622569; NCT01624662).
Future research should recruit patients with chronic rhinosinusi-
tis diagnosed using the EPOS 2012 criteria and include both pa-
tients with and without nasal polyps (stratified randomisation by
subgroup). Intranasal corticosteroids should be compared against
placebo and this should be considered against a background of
nasal irrigation, including in the placebo arm. The intervention
and follow-up should be carried out for at least three or sixmonths,
since intranasal corticosteroids are used as a long-term treatment
for a chronic condition.
A key area of weakness across all of the included studies was the
absence of both disease-specific and generic health-related quality
of life tools as outcome measures. It is recommended that any fu-
ture research uses primary outcome measures that are relevant to
patients and any disease-specific instruments used should be vali-
dated in people with chronic rhinosinusitis. Many studies chose to
use polyp scores as their primary outcome measure yet the correla-
tion between endoscopic results and patient symptoms is unclear.
The methods for defining and recording adverse events should
be considered at the protocol stage and adverse events recorded
should include epistaxis and local irritation; longer-term effects
such as osteoporosis should also be considered.
This review is one of a suite of reviews of medical treatments for
chronic rhinosinusitis, each of which features its own research rec-
ommendations. Across all reviews, key features of future research
are as follows:
• Trials should be adequately powered and imbalances in
prognostic factors (for example, prior sinus surgery) must be
accounted for in the statistical analysis.
• Study participants should be diagnosed with chronic
rhinosinusitis using the EPOS 2012 criteria and should
primarily be recruited based on their symptoms. Different
patient phenotypes (that is, those with and without nasal polyps)
should be recognised and trials should use stratified
randomisation within these subgroups or focus on one or other
of the phenotypes.
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• Studies should focus on outcomes that are important to
patients and use validated instruments to measure these.
Validated chronic rhinosinusitis-specific health-related quality of
life questionnaires exist, for example the Sino-Nasal Outcome
Test-22 (SNOT-22). Patients may find dichotomised outcomes
easiest to interpret; for example the percentage of patients
achieving a minimal clinically important difference (MCID) or
improvement for that outcome. Such MCIDs or cut-off points
should be included in the study protocol and clearly outlined in
the methods section.
• Trials and other high-quality studies should use consistent
outcomes and adhere to reporting guidelines, such as
CONSORT, so that results can be compared across future trials.
The development of a standardised set of outcomes, or core
outcome set, for chronic rhinosinusitis, agreed by researchers,
clinicians and patients, will facilitate this process.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aukema 2005
Methods Double-blinded, parallel-group RCT, with 12 weeks duration of treatment and follow-
up
Participants Location: Netherlands, single side
Setting of recruitment and treatment: patients awaiting FESS at a university hospital
Sample size:
• Number randomised: 27 in intervention, 27 in comparison
• Number completed: 26 in intervention, 21 in comparison
Participant (baseline) characteristics:
• Age: median 44 (range 18 to 68)
• Gender: 28 males, 26 females
• Main diagnosis: polyposis and/or CRS requiring FESS
• Polyps status: CT score ≥ 3 on at least one side on Lund-Mackay
• Previous sinus surgery status: 78% in treatment, 88% in placebo
• Other important effect modifiers, if applicable:
◦ Atopy (increased specific serum IgE): 19% in treatment and 26% in placebo
group
Inclusion criteria:
Patient on waiting list for FESS (recent CT score of ≥ 3 on one side, prior treatment
with corticosteroid spray ≥ 3 months, total VAS score of ≥ 200 mm on 6 scales (range
of 0 to 100 mm))
“...investigator had observed and approved the administration method (of the single dose
nasal drops)” during the run-in period
Interventions Intervention (n = 27): Nasules (fluticasone propionate single dose nasal drops, admin-
istered once daily at night)
Comparator group (n = 27): placebo
Patients were instructed to lie on their back with their head hanging down in a vertical
position on the edge of a bed while administering the drops
Use of additional interventions (common to both treatment arms): not described
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Disease severity as measured by VAS of 0 to 100 mm for 6 symptoms (nasal blockage,
rhinorrhoea, facial pain, mucus in throat, loss of sense of smell and headache)
2. Significant adverse effect: epistaxis
Secondary outcomes:
3. Other adverse effects: local irritation
4. Endoscopy score (polyp volume) using a VAS
5. CT scan score measured using Lund-Mackay score (max 24 points)
Other outcomes reported by the study:
• Number of patients who “finally needed FESS” (after a minimum follow-up of 6
months, median of 20 months); but actual length in both arms not reported
• PNIF
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Aukema 2005 (Continued)
Notes Study had a 2-week run-in period; patient’s method of application was assessed before
randomisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Medications were numbered by
means of computerized randomization and
were assigned in numeric order.”
Comment: likely to be adequately gener-
ated
Allocation concealment (selection bias) Unclear risk Quote: “All investigations were carried out
by one investigator”
Comment: no specific description pro-
vided. Sequence generation adequate;
likely to depend on whether medications
and packaging looked identical. Baseline
risks potentially different
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “All investigations were carried
out by one investigator...Double-blind ran-
domization to FPNDs or placebo took
place after the investigator had observed
and approved the administration method
…Randomisation codeswere not disclosed
until a year after all the patients had fin-
ished the study”
Comment: likely to be adequate
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All investigations were carried
out by one investigator...…Randomisation
codes were not disclosed until a year after
all the patients had finished the study”
Comment: likely to be adequate
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “At the end of the study, 6 patients
of the placebo group and 1 of the FPND
group had dropped out. Of the placebo
group, 5 patients dropped out because they
had a lot of complaints and did not want
to complete the study. Three were prema-
turely scheduled for FESS (2 after 6 weeks
and 1 after 2 weeks of treatment). Two
patients resumed intranasal corticosteroids
(after 4 and 8 weeks of treatment). One
patient received oral steroids from her pul-
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Aukema 2005 (Continued)
monologist because she did not tolerate in-
haled steroids (after 8 weeks of treatment)
and was scheduled for FESS as well. The
one dropout in the FPND group failed to
return for the last visit, despite repeated re-
quests. At the second-to-last visit, he was
not much improved compared with inclu-
sion, and he finally underwent surgery.”
Comment: it is unclear whether those pa-
tients considered “dropped out” were in-
cluded in the analysis of the results for
symptom score. The drop-out was not bal-
anced and was very likely to be related to
lack of efficacy
Selective reporting (reporting bias) High risk Comment: methods section did not spec-
ify which and how outcomes would be
reported. Numerical data for 3 symptom
scores (facial pain, loss of sense of smell and
headache) was not shown. The total score
on the VAS across 6 symptoms was not re-
ported in the results (although it was used
as a criterion to determine eligibility for
surgery)
Methods states that “Mann Whitney test
was used to test a difference in CT score
between treatment groups at the end of
study”, and “Wilcoxon signed rank test to
test changes in CT score from baseline in
either treatment group” but results reports
mean difference and SD
Other bias Unclear risk Quote: “VAS of 0-100 mm”, “Lund
Mackay”
Comment: standard scales used formeasur-
ing outcomes. Inadequate information on
the baseline characteristics to judge. There
were slightly more current smokers, atopic
patients and patients who had had surgery
in the placebo group. Baseline data for out-
comes not reported, e.g. “…the CT scores
in the FPND patients were better at the
start of the study” (page 1022)
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Chur 2013
Methods 4 arm, “double blind”, international, multicentre, parallel-group RCT, with 4 months’
duration of treatment and follow-up
Participants Location: 9 countries: Colombia, Guatemala, Honduras, Panama, Peru, Russia, South
Africa, Ukraine, United States. No. of sites not presented
Setting of recruitment and treatment: not stated
Sample size:
6 to 11 years
Number randomised (6 to 11 years): 18 in intervention 1, 18 in intervention 2, 10 in
comparison
Number completed (6 to 11 years): no information
12 to 17 years
Number randomised (12 to 17 years): 32 in intervention 1, 33 in intervention 2, 16
in comparison
Number completed (12 to 17 years): no information
Participant (baseline) characteristics:
6 to 11 years
Age: twice daily group 9.6, once daily group 9.7, PL group 12.7
Gender M/F: twice daily group 5/13, once daily group 8/10, PL group 12/14
Main diagnosis: nasal polyps
Polyps status: 100% with polyps
Previous sinus surgery status: no information
Other important effect modifiers:
o Asthma: twice daily group 1, once daily group 3, PL group 6
o Eosinophilic: twice daily group 3, once daily group 5, PL group 9
12 to 17 years
Age: twice daily group 14.4, once daily group 14.4, PL group 12.7
Gender M/F: twice daily group 15/18, once daily group 14/18, PL group 12/14
Main diagnosis: bilateral nasal polyps
Polyps status: 100% with polyps
Previous sinus surgery status: no information
Other important effect modifiers:
o Asthma: twice daily group 4, once daily group 9, PL group 6
o Eosinophilic: twice daily group 3, once daily group 9, PL group 9
Inclusion criteria: children aged 6 to 17 years with nasal polyposis
Exclusion criteria: children younger than 6 years. Antrochoanal polyps, cystic fibrosis,
acute rhinosinusitis, rhinitis medicamentosa, dyskinetic ciliary syndromes and aspirin
allergy
Participants with asthma who received inhaled corticosteroids were required to be on
no more than a moderate dosage regimen as defined by the 2005 Global Initiative for
AsthmaGuidelines (GINA) for 1month before screening and to remain on it throughout
the study (16); other forms of corticosteroids were prohibited
Interventions 6 to 11 years
Intervention 1 (n = 18): mometasone furoate nasal spray, 100 µg once per day for 4
months
Intervention 2 (n = 18): mometasone furoate nasal spray, 100 µg twice per day for 4
months
Comparator group (n = 9): placebo once or twice daily (combined), for 4 months
12 to 17 years
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Chur 2013 (Continued)
Intervention 1 (n = 26): mometasone furoate nasal spray, 200 µg once per day for 4
months
Intervention 2 (n = 32): mometasone furoate nasal spray, 200 µg twice per day for 4
months
Comparator group (n = 16): placebo once or twice daily (combined) for 4 months
Use of additional interventions (common to both treatment arms): inhaled corti-
costeroids for patients with asthma (up to the equivalent of moderate dosage regimen
according to GINA 2005)
Outcomes Outcomes of interest in the review:
All outcomes were measured at 4 months
Primary outcomes
1. Disease severity, measured as participant-rated signs/symptoms including nasal con-
gestion/obstruction, anterior rhinorrhoea/postnasal drip and loss of sense of smell; rated
daily by participants on a 4-point scale
2. Significant adverse effect: epistaxis
Secondary outcomes:
3. Other adverse effects: local irritation (including oral thrush, sore throat)
4. Polyps size; no details on scores used
Other outcomes reported by the study:
(Primary outcome) Effects on hypothalamic-pituitary-adrenal (HPA) axis function (24-
hour urinary free cortisol change frombaseline and24-hour urinary free cortisol corrected
for creatinine/adverse events
Investigator-evaluated polyp size (on a 4-point scale)
Investigator assessment of overall therapeutic response (on a 5-point scale ranging from
0 (complete relief ) to 4 (no relief )
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Subjects were randomly assigned
to one of four treatment groups in a 4:4:1:
1 ratio... stratified by age”
Comment: pg 34, col 1, para 4
Allocation concealment (selection bias) Unclear risk Comment: no information about alloca-
tion concealment provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “received MFNS 200 mcg once
daily, MFNS 200 mcg twice daily, placebo
once daily, or placebo twice daily”
Comment: the abstract mentioned “dou-
ble-blind” and a placebo was used. How-
ever, instead of using a double-dummy de-
sign, where all participants received the
medication twice daily (with a placebo
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Chur 2013 (Continued)
given for those who had once daily treat-
ment), groups either had medication once
or twice daily. Therefore, there was no
blinding of participants in terms of know-
ing whether they were on the once daily or
twice daily regimen
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: as above
Comment: most of the outcomes are pa-
tient-reported and therefore blinding of
outcome assessment is affected
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: no information about loss to
follow-up or exclusion.However, only 119/
127 randomised patients (93%) were in-
cluded in their primary endpoint analy-
sis. There were more exclusions/drop-outs
from the 100 µg group compared with the
higher-dose group (6 (12%) versus 1) but
no reasons were provided
Adverse effects and symptoms were re-
ported based on 127 participants. It is un-
clear whether there were any imputations
Selective reporting (reporting bias) High risk Quote: “No statistical analysis of effi-
cacy end points was pre-specified, in the
study protocol, and only descriptive effi-
cacy statistics were collected.”
Comment: we identified the protocol
(NCT00378378) and the purpose was “to
evaluate the safety and efficacy of Na-
sonex® (Mometasone Furoate Nasal Spray
(MFNS)) in the treatment of nasal polyps
in pediatric subjects between the ages of 6
and less than 18 years old. Safety will be
the primary focus of this study.” The study
only reported the change from baseline in
points andpercentages but not the standard
deviations and P values. The values from
the treatment groups were very similar to
the placebo group for some outcomes (e.g.
for rhinorrhoea -43% for once daily versus
-42%) and poor reporting due to lack of
beneficial effects cannot be ruled out
Results for the “young (6-11 years)” group
and the “older (12-17 years)” group were
pooled together for the adverse events re-
sults and compared against the results sep-
arated by age group. This does not appear
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to be prespecified in the methods section
Other bias Unclear risk Comment: there is no information regard-
ing the validation of the symptom score
Hansen 2010
Methods 2-arm, double-blind, placebo-controlled, parallel-groupRCTwith 12weeks of treatment
and 14 weeks of follow-up
Participants Location: Netherlands, single site
Setting of recruitment and treatment: ENT clinic in the Netherlands (Academic Med-
ical Centre, Amsterdam)
Sample size:
Number randomised: 10 in intervention, 10 in comparison
Number completed: 9 in intervention, 7 in comparison
Participant (baseline) characteristics:
• Age, mean (range): FP: 49.2 (25 to 61); PL: 46.7 (37 to 62)
• Gender, M/F: FP: 6/4; PL: 8/2
• Main diagnosis: recalcitrant CRS without nasal polyps or only cobble-stoned
mucosa
• Polyps status: no nasal polyps
• Previous sinus surgery status: all had surgery before
◦ Sinus surgery, median (range): FP: 4 (1 to 10); PL: 3 (1 to 8)
◦ Polypectomy (%): FP: 2 (20); PL: 0
• Previous courses of steroids: no information
• Other important effect modifiers:
• Current asthma, n (%): FP: 4 (40); PL: 3 (30)
• Allergy, n (%): FP: 5 (50); PL: 5 (50)
• ASA intolerance, n (%): FP: 3 (30); PL: 1 (10)
Inclusion criteria:
• Between 18 and 65 years of age
• Chronic rhinosinusitis defined as at least a 12-week history of 2 or more of:
blockage/congestion, discharge: anterior/post nasal drip, facial pain/pressure, reduction
or loss of sense of smell and either mucopurulent discharge from the middle meatus or
oedema/mucosal obstruction primarily in the middle meatus
Exclusion criteria:
• Visible nasal polyps on endoscopy, except cobble-stoned mucosa
• Surgical treatment for nasal polyps during the previous 3 months
• A diagnosis of cystic fibrosis
• Depot or oral steroids during the previous 2 months
• A requirement for more than 1000 µg beclomethasone (or equivalent) per day for
the treatment of asthma, or not on a stable dose for ≥ 3 months
Interventions Intervention (n = 10): fluticasone propionate, administered using a breath actuated
inhaler (Optinose) 400 µg twice daily (800 µg total daily dose), duration of treatment
Comparator group (n = 10): matching placebo, administered twice daily
Use of additional interventions (common to both treatment arms):
Participants using saline rinses were permitted to continue to do so; 5 in the placebo
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group and 7 in the treatment group continued using nasal saline irrigation twice daily
during the study
Loratadine 10 mg tablets provided as rescue medication
If a participant experienced a severe acute nasal blockage the investigator could authorise
the use of a short course of oxymetazoline drops or spray for a maximum of 7 consecutive
days and a maximum total of 10 days during the treatment period. Oxymetazoline was
not to be used within 24 hours of a scheduled study visit
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Health-related quality of life, disease-specific using RSOM-31. A reduction in the
average total symptom impact score > 1 is considered clinically relevant
2. Disease severity symptom score, measured using
a. A 10 cm VAS (not troublesome to most troublesome imaginable) “How troublesome
are your symptoms of rhinosinusitis?”
b. A diary (0 to 3 scale): 0 (none), 1 (mild - symptoms present but not troublesome),
2 (moderate - symptoms frequently troublesome but not interfering with daily activity
or night-time sleep) or 3 (symptoms troublesome and interfering with daily activity
or night-time sleep) to record nasal blockage, nasal discomfort and rhinitis symptoms.
Participants also recorded sense of smell: 0 (normal), 1 (slightly impaired), 2 (moderately
impaired) or 3 (absent)
3. Significant adverse effect: epistaxis
Secondary outcomes:
4. Endoscopy (polyps size or overall score) using the Lund-Mackay score
Other outcomes reported by the study:
• Peak nasal inspiratory flow (PNIF)
• Acoustic rhinometry
• MRI scans of the paranasal sinuses
• Use of rescue medication
Notes Study had a 14- to 16-day treatment-free run-in period at the beginning
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “…subjects who met the eligibility
criteria were randomized 1:1 …”
Comment: no information on randomisa-
tion method provided
Allocation concealment (selection bias) Unclear risk Comment: no information on how to
maintain allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “…The Opt-FP and placebo de-
vices were identical in appearance. The
spray pump in the Opt-FP contained …
Placebo matched FP exactly, except for the
active ingredient... To deliver a dose of FP
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400 µg bd. or placebo, subjects made two
administrations per nostril, morning and
evening. ”
Comment: matched placebo - identical-
looking and same formulation except for
not including the active ingredient. Pa-
tients using the placebo administered it ex-
actly the same number of times as the treat-
ment group
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: as above
Comment: key outcomes are patient-re-
ported - should remain well blinded until
end of study
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “…The majority of subjects (9
Opt-FP, 7 PBO) completed the study.”
Comment: the drop-out rate is high (20%)
and unbalanced (10% in active group and
30% in placebo group) enough to af-
fect the findings of this small study (re-
sults were presented as medians). All with-
drawals were related to adverse effects or
worsening of symptoms
Selective reporting (reporting bias) Unclear risk Comment: unclear why study reported
“combined nasal symptoms” (rhinitis and
blockage) only, whereas other symptoms
(discomfort and smell) were reported sepa-
rately. This was not prespecified. Reporting
of some outcomes was confusing or incom-
plete. The results for the for “symptoms of
rhinosinusitis” asmeasured on a 10 cmVAS
were reported as having reduced 13 points
in the treatment group. It was not clear if
this was a mistake or whether it was 13%.
For endoscopic evaluation, the study only
showed data for the oedema score, which
was statically significant, but not the nasal
discharge score, which was not statistically
significant
Other bias Low risk Comment: instruments for the main pa-
tient-reported symptoms were validated
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Methods 3-arm, double-blind, parallel-group RCT, with a 26-week duration of treatment and 2
additional weeks of follow-up
Participants Location: Sweden
Setting of recruitment and treatment: outpatient clinics; single-centre
Sample size:
Number randomised: 19 in FP group, 18 in BDP group, 18 in PL group
Number completed: 15 in FP group, 16 in BDP group, 11 in PL group
Participant (baseline) characteristics:
Age mean (range): FP group: 54 (27 to 74); BDP group: 49 (26 to 68); PL group: 47
(21 to 71)
Gender (M/F): FP group: 15/4; BDP group: 13/5; PL group: 14/4
Main diagnosis: bilateral polyposis with a polyp score of 1 or 2
Polyps status: 100% with polyps
Previous sinus surgery status: 100% had a history of at least 1 polypectomy within the
previous 5 years
Other important effect modifiers:
o Positive skin prick test (%): FP group: 3 (16%); BDP group: 6 (33%); PL group: 5/
18 (27%)
Inclusion criteria: bilateral polyposis with a polyp score of 1 or 2
Exclusion criteria:nasal polyposiswith a score of 3 or 4 (or 0); concurrent nasal infection;
an inability to cease treatment with systemic, inhaled or intranasal steroids or sodium
cromoglycate on visit 1; had used antihistamines in the 48 hours prior to visit 1; had a
contraindication to steroids or had any serious or unstable concurrent disease
Interventions FP group (n = 19): fluticasone propionate, aqueous nasal spray, 2 actuations of 50 µg
each to each nostril morning and evening (400 µg/day) for 26 weeks
BDP group (n = 18): beclomethasone dipropionate, aqueous nasal spray, 2 actuations
of 50 µg each to each nostril morning and evening (400 µg/day) for 26 weeks
PL group (n = 18): placebo, actuations to each nostril morning and evening, containing
the same vehicle as the intervention solutions including benzalkonium chloride as a
preservative, for 26 weeks
Use of additional interventions (common to all treatment arms):
A 4-week run-in period during which there was no treatment for polyposis except for
rescue loratadine, which could be used by the patients
All patients were supplied with rescue loratadine tablets to use as relief medication, 10
mg loratadine once daily. Any use of rescue medication was documented on the patients’
daily record cards
Outcomes Outcomes of interest in the review:
Primary outcomes
1.Disease severity, measured by daily records of all nasal symptoms including: nasal
blockage; sense of smell; sneezing and rhinorrhoea using a 4-point rating system (0 = no
symptoms; 1 = mild symptoms; 2= moderate symptoms; 4 = severe symptoms)
2. Physician assessment of symptoms. No details were provided on how these were
measured. Measured at 26 weeks
3. Significant adverse effect: epistaxis
Secondary outcomes:
4. Polyp size by endoscopy (0- to 4-point scale)
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Other outcomes reported by the study:
5. Polyp score
6. Peak nasal inspiratory flow
7. Physician’s assessment of change in symptoms
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized”
Comment: pg 271, col 1, para 3
No further details provided
Allocation concealment (selection bias) Unclear risk Comment: no information provided in the
paper
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “placebo: 2 actuations to each nos-
tril morning and evening containing the
same vehicle, as the fluticasone and be-
clomethasone solutions including benza-
lkonium chloride as a preservative. The
placebo solution was therefore identical to
the active treatments but did not contain
any active drug.”
Comment: pg 271, col 1, last para
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: no further information. Should
also be low if there is adequate blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 13/54 patients (24%) did not
complete trial; 4/19 in fluticasone, 2/18
in beclomethasone, 7/18 (39%) in placebo
group. Uneven drop-out numbers (very
high in placebo group)
Selective reporting (reporting bias) High risk Quote: “The primary efficacy endpointwas
the physician’s assessments of symptoms
and polyp score on all clinic visits”
Comment: the methods section described
assessment of polyps and patient-reported
symptom scores. However, “physician as-
sessment of outcomes and polyps score”
were reported as primary outcomes in
the results section. The results focused
on “physician assessment of symptoms”
and barely mentioned the results for the
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polyps (only “significant” for visit 5 on
beclomethasone, not for fluticasone). In
addition, there were some outcomes that
seemed to have arbitrary, non-predefined
cut-off points (% of days with symptom
score < 2 in results). The denominator
for the reported symptom scores outcome
measures is not identified
Other bias High risk Comment: primary outcome of physician
assessment of outcomes was not well de-
scribed in the paper with little information
on the criteria used or any validation/inter-
rater reliability
Holopainen 1982
Methods 2-arm, double-blind, parallel-group RCT, with a 16-week duration of treatment and
follow-up
Participants Location: Sweden, no information on number of sites
Setting of recruitment and treatment: unclear
Sample size:
Number randomised: 10 in intervention, 9 in comparison
Number completed: 10 in intervention, 8 in comparison
Participant (baseline) characteristics:
Age mean (range): group A: 43.5 (26 to 60); group B: 40 (18 to 62)
Gender (M/F): group A: 6/4; group B: 4/5
Main diagnosis: perennial, intrinsic nasal symptoms associated with small nasal polyps
Polyps status: 100% with polyps
Previous sinus surgery status: unclear (there is a comment, “When necessary the number
of polyps was reduced by surgical measures so that the test solution could easily be
administered”, but no further details are given)
Other important effect modifiers: none provided
Inclusion criteria: no further details available
Exclusion criteria: none stated
Interventions Intervention (n = 10): budesonide nasal spray 400 µg daily, 2 puffs into each nostril,
twice a day, for 16 weeks
Comparator group (n = 9): placebo nasal spray (same solvent as intervention but
without the active ingredient), 2 puffs into each nostril, twice a day, for 16 weeks
Use of additional interventions (common to both treatment arms): all patients un-
derwent a wash-out period of 2 weeks before the study
Outcomes Outcomes of interest in the review:
Primary outcomes
1. Disease severity, measured by patient-reported symptom score cards recording nasal
blocking, running, sneezing, itching and side effects according to a 0 to 3 scale daily for
2 weeks prior to check-up. Last check-up at 16 weeks
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2. Disease severity, measured by physician rhinoscopy to assess mucosal congestion and
nasal discharge
3. Significant adverse effect: epistaxis
Secondary outcomes:
4. Size of polyps (on a 0 to 3 scale)
Other outcomes reported by the study:
Saccharin test for measuring mucociliary activity
Nasal smear for evaluating epithelial changes
Biopsy of the nasal polyps
Plasma cortisol determination
Peak nasal inspiratory flow
Notes Although the paper states “Whennecessary the number of polypswas reduced by surgical
measures so that the test solution could be easily administered”, there was no report of
this having been carried out
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “…randomly assigned…”
Comment: no further information
Allocation concealment (selection bias) Unclear risk Comment: no information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The placebowas identical with the
active spray but without budesonide… the
other a correspondent dose of only the sol-
vent”
Comment: identical-looking and solvent
used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: low risk, since blinding is ade-
quate
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “One patient with severe nasal
blocking and obstructing polyps had to
withdraw from the trial after 12 weeks of
placebo treatment.” This patient was not
reported in the safety outcomes
Comment: only 1 drop-out (5%). Unlikely
to have an important impact on outcomes
Selective reporting (reporting bias) High risk Comment: methods section reports that
nasal dischargewould be physician-assessed
by rhinoscopy (pg 222, bullet point 1). No
results are reported for this outcome
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Other bias Unclear risk Comment: no information regarding the
validation of the disease severity measures
Only limited information provided in the
study about baseline characteristics, pre-
randomisation procedures etc
Johansen 1993
Methods 3-arm, double-blind, multicentre, parallel-group RCT, with 3 months duration of treat-
ment and follow-up
Participants Location: 4 sites in Denmark, 1 site in Sweden
Setting of recruitment and treatment: unclear
Sample size:
Number randomised: 91 (numbers allocated to each group unknown)
Number completed: 86 (numbers allocated to each group unknown)
Participant (baseline) characteristics:
• Age median (range): 52 (18 to 78)
• Gender (M/F): 70/21
• Main diagnosis: eosinophilic nasal polyposis with polyp score of 2 or less on each
side
• Polyps status: 100% with polyps
• Previous sinus surgery status: not provided in the paper
• Other important effect modifiers:
◦ 22 patients had asthma (allocation between groups unknown)
◦ 8 patients were known to be acetylsalicylic acid (ASA) sensitive
Inclusion criteria: clinical diagnosis of eosinophilic nasal polyposis with polyp scores
of 2 or less on each side. Eosinophilic polyposis was confirmed by nasal smear and/or
biopsy.
Exclusion criteria:
Polyps surgically removed within 2 months
Neutrophilic polyposis
Systemic or topical nasal corticosteroid therapy within 2 months
Interventions Group A (n = unknown): budesonide aqua (Rhinocort Aqua), 50 µg in each nostril x
2, twice daily (400 µg/day), 3 months
Group B (n = unknown): budesonide aerosol (Rhinocort Aerosol), 50 µg in each nostril
x 2, twice daily (400 µg/day), 3 months
Group C (n = unknown): placebo (aqua or aerosol), unclear dose, 3 months
Use of additional interventions (common to all treatment arms): no information was
provided about additional interventions
Outcomes Outcomes of interest in the review:
Primary outcomes
1. Disease severity, measured weekly by patients. Symptoms included were nasal obstruc-
tion, sneezing and nasal secretions, recorded for each nasal cavity (scale 0 to 3).
Change in sense of smell was recorded at clinical visits using a 0 to 3 scale
2. Significant adverse effect: epistaxis
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Secondary outcomes:
3. Other adverse effects: local irritation (including oral thrush, sore throat)
4. Polyps size (assessed using a 0 to 3 scale - definitions provided)
Other outcomes reported by the study:
• Nasal and oral peak inspiratory flow
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “...randomised…”
Comment: mentioned in abstract but no
further mention
Allocation concealment (selection bias) Unclear risk Comment: no information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The patients were treated with ei-
ther budesonide aqua (Rhinocort Aqua)
or budesonide aerosol (Rhinocort Aerosol)
, 50 mcg x 2 in each nostril, twice daily =
400 mcg/day or placebo aqua or aerosol.”
Comment: there should be adequate blind-
ing for treatment versus placebo, but not
for different forms of treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: no further information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Five patients withdrew from the
study…”
Comment: low (5%)drop-out rate.No rea-
sons given for withdrawals. Patients who
withdrew were not included in any of the
outcomes (including safety outcomes)
Selective reporting (reporting bias) Unclear risk Comment: all outcomes reported in the
methods are mentioned in the results sec-
tion, but numerical information for the re-
sults is not provided
Other bias High risk Comment: no comment on the validation
of outcome measurements
The paper does not provide clear back-
ground characteristics for each group. The
number randomised to each group was not
provided
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Methods 2-arm, double-blind,multicentre, parallel-groupRCT,with 12-week duration of blinded
treatment and 12-week duration of open treatment, with the active intervention followed
by a final assessment 2 weeks after treatment had completed
Participants Location: 11 sites in Canada and Finland
Setting of recruitment and treatment: outpatient clinics
Sample size:
Number randomised: 52 in intervention, 52 in comparison
Number completed: 51 in intervention, 47 in comparison
Participant (baseline) characteristics:
Age (mean ± SD): FP group: 49 ± 12; PL group: 47 ± 13
Gender (M/F): FP group: 38/14; PL group: 35/17
Main diagnosis: small or medium bilateral nasal polyposis
Polyps status: 100% with polyps
Previous sinus surgery status (n (%)): FP group: 38 (73%); PL group: 34 (65%)
Other important effect modifiers:
o 22% were atopic and allergic to one or more allergens
o 2 patients in the study were reportedly aspirin-sensitive (no information on which
groups)
o 52% in FP group and 44% in PL group had a polyposis history of > 10 years
Inclusion criteria: outpatients aged 16 years and over with bilateral nasal polyposis.
Polyps were graded by clinical assessment during rhinoscopic examination. Patients with
a severity score of 1 (small) or 2 (medium) were included.
Exclusion criteria: exclusion criteria included:
Large (grade 3) polyps, indicating severe nasal obstruction
Surgical treatment for nasal polyps during the last 3 months
Cystic fibrosis
Purulent nasal infection
Allergic rhinitis
Any disease likely to interfere with the study parameters or which gave evidence of any
serious or unstable concurrent disease or psychological disorder
Hypersensitivity or contraindication to steroids
Currently receiving inhaled corticosteroids or those who had received depot or oral
steroids during the previous 3 months
Unable to cease treatment with intranasal steroids, or inhaled or intranasal sodium
cromoglycate, at the screening visit
Astemizole during the last 6 weeks or other antihistamines within the last 48 hours, or
received any other research medication during the previous month
Pregnant, lactating or, in the investigator’s opinion, were not taking adequate contracep-
tive measures to avoid becoming pregnant during the study
Had not correctly completed the daily diary card during the run-in period
Interventions Intervention (n = 52): fluticasone propionate (unpreserved), nasal drops using head
down and forwards position, 400 µg divided between both nostrils, once daily in the
morning for 12 weeks
Comparator group (n = 52): placebo nasal drops using head down and forwards posi-
tion, to both nostrils once daily in the morning for 12 weeks
Use of additional interventions (common to both treatment arms): loratadine tablets
were provided as rescue medication for the relief of troublesome symptoms of rhinitis,
to be used as needed, at a maximum dose of 10 mg once daily. No other medication was
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allowed for polyposis or rhinitis
Outcomes Outcomes of interest in the review:
Primary outcomes
1. Disease severity, patient-reported through daily diaries (nasal blockage, nasal discom-
fort and rhinitis symptoms) measured on a 4-point scale (0 = none, 1 = mild, 2 = mod-
erate, 3 = severe) at 12 weeks. Sense of smell was recorded as 0 (normal), 1 (slightly
impaired), 2 (moderately impaired) or 3 (absent)
2. Significant adverse effect: epistaxis
Secondary outcomes:
3. Other adverse effects: local irritation (including oral thrush, sore throat)
4. Polyp size (0 to 3 score): 0 (no polyps), 1 (mild polyposis) = small polyps not reaching
the upper edge of the inferior turbinate and causing only slight obstruction, 2 (moderate
polyposis) = medium polyps reaching between the upper and lower edge of the inferior
turbinate and causing troublesome obstruction, 3 (severe polyposis) = large polyps reach-
ing below the lower edge of the inferior turbinate and causing almost/total obstruction
Other outcomes reported by the study:
• Peak nasal inspiratory flow
• Olfactory function
• Daily use of loratadine tablets
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “… computer randomized number
…”
Comment: proper sequence generation
Allocation concealment (selection bias) Low risk Quote: “… Each investigator was given a
block of treatments, precoded with com-
puter randomized numbers, which were as-
signed in ascending numerical order as pa-
tients presented.”
Comment: allocation concealment likely to
be well maintained despite blocked ran-
domisation; adequate blinding
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “… FPND (400 mg unit dose
preservative-free suspension) and placebo
solution were supplied in identical opaque
nasal drop containers, in a foil pack …”
Comment: adequate blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: most outcomes are patient-re-
ported therefore blinding was likely to be
well maintained
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 6/104 (5.8%) patients did not
complete the study, 2 of these patients re-
quired polypectomy and so the last avail-
able outcome measures were reported for
the efficacy outcomes. All patients were in-
cluded in the safety analysis
Selective reporting (reporting bias) Unclear risk Comment: results are presented in a differ-
ent format to those presented in the meth-
ods section. For example the methods pro-
vides scales for each symptom but the re-
sults presents the percentage of time the
value was below a certain value on the scale.
It was unclear if this change was pre-spec-
ified in the protocol or whether the study
authors decided once the results had been
processed
Other bias Unclear risk Comment: no information is available re-
garding the validation of the scales used
Lang 1983
Methods 2-arm, double-blind, parallel-groupRCT,with a 2-year durationof treatment and follow-
up
Participants Location: unclear
Setting of recruitment and treatment: unclear
Sample size:
Number randomised: 14 in intervention, 18 in comparison
Number completed: unclear number of participants completed
Participant (baseline) characteristics:
Age (mean): 42
Gender (M/F): 17/15
Main diagnosis: clinical simple nasal polyps
Polyps status: 100% with polyps
Previous sinus surgery status: no details
Other important effect modifiers: no details
Inclusion criteria: no details
Exclusion criteria: no details
Interventions Intervention (n = 14): beclomethasone dipropionate 400 µg twice daily for 2 years. No
information on method of administration other than “Beconase topically in the nose”
Comparator group (n = 18): placebo nasal insufflation twice daily for 2 years
Use of additional interventions (common to both treatment arms): none mentioned
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Outcomes Outcomes of interest in the review:
Primary outcomes
1. Disease severity, measured by subjective assessment of nasal obstruction, sneezing and
nasal discharge. No details of scale used. Assessment made every 4 weeks for 2 years
Secondary outcomes:
2. Size of nasal polyps - reported as the number of patients with “resolution”
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Support for judgement
Allocation concealment (selection bias) Unclear risk Quote: “… randomly allocated …”
Comment: no mention of method of ran-
domisation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: no information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “This allocation was kept blind
from both patient and investigator.”
Comment: mentions a “placebo” was used
but there was no information about precau-
tions taken to make the products as similar
as possible
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “This allocation was kept blind
from both patient and investigator.”
Comment: method not specified
Selective reporting (reporting bias) High risk No information was provided about losses
to follow-up.Unlikely to have had no losses
during a 2-year study
Other bias High risk Comment: abstract only. No information
provided about adverse events. Very limited
information provided
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Methods Double-blind, parallel-group RCT, with 12 weeks of treatment
Participants Location: UK
Setting of recruitment and treatment: tertiary referral centre (Royal National ENT
Hospital London)
Sample size:
Number randomised: 10 in fluticasone propionate, 10 in beclomethasone dipropionate,
9 in placebo
Number completed: unclear, likely to be all
Participant (baseline) characteristics:
Age (mean, range): 52 (32 to 71, 46 (22 to67) and50 (27 to 69) influticasone propionate,
beclomethasone dipropionate and placebo arms
Gender (M/F): 7/3, 9/1 and 7/2 in fluticasone propionate, beclomethasone dipropionate
and placebo arms
Main diagnosis: “severe polyposis”
Polyps status: all had polyps, median total polyps score of 4 (both nostrils) using Lund-
Mackay CT score
Previous sinus surgery status: 66% had surgery (7/10 in fluticasone propionate and
beclomethasone dipropionate arms, 5/9 in placebo)
59% had condition for more than 10 years
All had allergy
Inclusion criteria:
Older than 16 years with a diagnosis of bilateral nasal polyposis requiring surgical inter-
vention, meeting one or more of the following criteria:
• a total polyp score of 4 or higher plus a CT scan score > 12;
• a total polyp score of 3 or higher, a nasal blockage score of 2 or higher, plus a CT scan
score >12; and
• a total polyp score of 2 or higher, a nasal blockage score of 2 or higher, a CT scan >
than 12, plus an UPSIT score > 32
Exclusion criteria:
• Concurrent purulent nasal infection
• A requirement for more than 1000 µg beclomethasone (or equivalent) per day for the
treatment of asthma
• An inability to cease treatment with parenteral and intranasal corticosteroids or cro-
molyn sodium (sodium cromoglycate) at visit 1, used astemizole in the 6 weeks before
the study or other antihistamines in the 48 hours before visit 1, or a contraindication to
corticosteroid medications
Interventions Intervention 1 (n = 10): fluticasone propionate aqueous nasal spray 400 µg per day, 2
actuations into each nostrils morning and night
Intervention 2 (n = 10): beclomethasone dipropionate aqueous nasal spray 400 µg per
day, 2 actuations into each nostrils morning and night
Comparator (n = 9): placebo 2 sprays into each nostril twice a day
Use of additional interventions (common to both treatment arms): terfenadine 60
mg as rescue medicine
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Disease severity - collected patient diaries on a 0 to 4 scale for different symptoms,
but only partially reported symptom-free days
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Secondary outcomes:
• Adverse events - local irritation
• Endoscopy - polyps size (scale not reported)
Other outcomes reported by the study:
• PNIF, physician-reported score for symptom severity
Notes Study had a 4-week run-in period
34 patients met criteria, 5 withdrew before randomisation (1 AE, 1 require polypectomy,
1 lack of efficacy, 2 did not return)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly allocated,
using a computer-generated random code
and a block size of 6, to receive 1 of 3 treat-
ments”
Allocation concealment (selection bias) Unclear risk Quote: “Patients were randomly allocated,
using a computer-generated random code
and a block size of 6, to receive 1 of 3 treat-
ments”
Comment: method not specified; blocked
randomisation but adequate blinding
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The placebo was identical to the
active formulations with the active ingredi-
ent omitted andwas indistinguishable from
the active treatments, which were them-
selves identical in appearance, taste, and
smell.”
Comment: there was a 4-week pre-treat-
ment period where all patients were ex-
posed to the placebo, but blinding should
still be adequate
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: the same investigator did all the
clinical assessments at all visits, but an iden-
tical placebo was used
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “last value carried forward tech-
nique” was used. Drop-outs not balanced:
3/10 in fluticasone, 0/10 in beclometha-
sone and 4/9 in placebo
Selective reporting (reporting bias) High risk Comment: patient-reported symptoms
(using diaries) were collected, but it was
not specified how these were planned to
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be reported. Study only reported percent-
age of patients with 100% of days without
nasal blockage, and the median % of days
without nasal symptoms (different criteria)
. Other outcomes not reported at all
There was also a higher percentage of pa-
tients in the fluticasone group (70%) com-
pared to 33% and 30% in the beclometha-
sone and placebo groups, but details were
not reported. Only stated that 1 of the ad-
verse events in the fluticasone group (throat
irritation) was “predictable”
Other bias High risk Quote: “overall rhinitis symptoms (sneez-
ing, rhinorrhoea, nasal itching)”
Comment: symptoms scores (by patients
and clinicians) were used but no mention
of validation. Some items seem to be sin-
gle symptom (e.g. nasal blockage), but oth-
ers seems to encompass a few things (e.g.
“overall rhinitis symptoms”)
Quote: “There was evidence, particularly
from the acoustic rhinometric and PNIF
data, that the patients randomly allocated
to receive BDANS had milder symptoms
than those randomly allocated to receive
FPANSor placebo, even though all patients
had been listed for surgical treatment on an
equal basis before the study.”
Comment: baseline symptoms and other
assessment scores were not reported. Un-
able to judge for other aspects
Lund 2004
Methods Double-blind, multicentre, parallel-group RCT, with 20 weeks of treatment
Participants Location: multicentre (19), UK (7), Hungary (6), South Africa (6)
Setting of recruitment and treatment: all were ENT specialists, except 1 (in South
Africa)
Sample size:
Number randomised: 81 in intervention, 86 in comparison
Number completed: 67 in intervention, 67 in comparison
Participant (baseline) characteristics:
Age (mean): group A: 38; group B: 43
Gender (M/F): group A: 35/46; group B: 41/45
Main diagnosis: patients aged 18 years or over with chronic rhinosinusitis
Polyps status: 0% with polyps
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Previous sinus surgery status: not provided
Inclusion criteria:
No nasal polyposis
≥ 18 years, with ≥ 12 weeks with at least 2 major symptoms
Patients with a symptom score of ≥ 2 on a 4-point scale for at least 1 of the symptoms
for ≥ 4 out of 7 days during the last 7 days of the run-in period
Exclusion criteria:
Sinonasal surgery within the previous 12 months
Interventions Intervention (n = 81): budesonide aqueous nasal spray, 128 µg (64 µg in each nostril
twice daily), for 20 weeks
Comparator group (n = 86): placebo nasal spray, for 20 weeks
Use of additional interventions (common to both treatment arms):
During the first 2 weeks of the run-in period, all patients received co-amoxiclav 250/
125 mg three times daily, or 500 mg erythromycin twice daily
The same antibiotics could be given for 2 weeks as needed to treat exacerbations (defined
as episodes of worsening symptoms requiring a course of antibiotic therapy)
Outcomes Outcomes of interest in the review:
Primary outcomes
1. Disease severity, measured by Chronic Sinusitis Survey (CSS) questionnaire at baseline
and 20-week time point (note: English-speaking participants only as the survey was not
validated in Hungarian) and patient-reported scores for individual symptoms
2. Disease severity, measured by patient-reported symptoms (facial pain, pressure or
headache; facial congestion, nasal obstruction or blockage; nasal discharge; impairment
of sense of smell). A combined symptom score (sum of the scores for the 4 domains of
the symptoms above)
3. Significant adverse effect: epistaxis
Secondary outcomes:
4. Health-related quality of life, measured with the SF-36 at baseline and 20-week time
point
5. Other adverse effects: local irritation (including oral thrush, sore throat)
Other outcomes reported by the study:
• Compliance with medication
• Overall patient-reported evaluation of efficacy
• Peak nasal inspiratory flow
• Skin prick test before and after treatment
• Blood tests
Notes “Financial support” from AstraZeneca
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was performed in
balanced blocks of 4 by means of a com-
puter program at the Department of Bio-
statistics…”
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Comment: pg 59, col 1, para 2
Allocation concealment (selection bias) Low risk Quote: “Patients were allocated a treatment
number in consecutive order and randomi-
sation was performed in balanced blocks of
4 by means of a computer program…”
“The treatment codes were known only to
the persons responsible for packaging, who
were not involved in the study in any other
way”
Comment: pg 59, col 1, para 2
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “BANS and placebo aqueous sprays
were identical in appearance and were both
administered via the same vehicle.”
“The treatment codes were known only to
the persons responsible for packaging, who
were not involved in the study in any other
way”
Comment: pg 59, col 1, para 2, para 3
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The treatment codes were known
only to the persons responsible for packag-
ing, who were not involved in the study in
any other way ”
Comment: pg 59, col 1, para 2, para 3
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 14/81 (17.3%) in intervention
arm and 19/86 (22.1%) in comparison arm
did not complete the study (overall rate
20%). No reasons for dropping out were
provided
Selective reporting (reporting bias) Unclear risk Comment: the methods section outlines
the individual symptoms assessed, but the
results are also presented as a “combined
score” for which no information is avail-
able as to how it was calculated. Addition-
ally, although all outcomes presented in the
methods section are mentioned in the out-
comes, this is not always in great detail, for
example the results for the SF-36 were pre-
sented as “There was a significant improve-
ment in the general health sub-scale of the
SF-36 questionnaire in the BANS treated
group comparedwith placebo, but noother
significant differences were observed.”
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Other bias Unclear risk Comment: no information about the val-
idation of the combined symptom score.
There is some information about validation
of the chronic sinusitis score
2 subgroups were reported (those with CT
evidence of opacification and allergic versus
non-allergic patients). Not all outcomes are
presented for these subgroups
There were pre-randomisation procedures
but these excluded patients with less symp-
tomatic disease
Mosges 2011
Methods 2-arm, double-blind, multicentre, parallel-group RCT, with a 16-week duration of treat-
ment and follow-up
Participants Location: Germany, 9 sites
Setting of recruitment and treatment: ear, nose and throat departments in university
hospitals or ENT specialists’ practices
Sample size:
Number randomised: 30 in intervention, 30 in comparison
Number completed: 29 in intervention, 30 in comparison
Participant (baseline) characteristics:
Age: group A: 40 (19 to 63); group B: 44 (22 to 64)
Gender (M/F): group A: 10/19; group B: 17/13
Main diagnosis: chronic rhinosinusitis (symptoms for a period longer than 8 weeks, or
more than 4 episodes of a minimum length of 10 days each, over a 1-year period; Lund
score ≤ 10)
Polyps status: 0% with polyps (exclusion criteria)
Previous sinus surgery status: Discussion states “… only around 10% underwent preced-
ing surgical treatment.” However, surgery within 6 months and extensive surgery were
exclusion criteria
Other important effect modifiers: Discussion states: “Allergy was present in only around
1 in 3 patients, who were distributed evenly between both treatment groups.”. No other
details provided
Inclusion criteria:
Patients aged 18 to 65 years
Clinical diagnosis of chronic sinusitis (a total symptom score of at least 5) confirmed at
baseline by a coronal CT scan not older than 6 months. The scan was evaluated using
the Lund scale
Exclusion criteria:
Nasal polyps visible on endoscopic examination at baseline
Patients with pansinusitis, Lund score > 10
Undergone nasal surgery within 6 months prior to study enrolment
Patients who had undergone sinus surgery with opening of the lateral nasal wall at any
time
Inhalant or intranasal steroid therapy within 2 weeks prior to screening; systemic steroid
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therapy within 8 weeks prior to screening; antihistamine use within 12 hours to 14 days
prior to screeningdepending onmedication; regular use of decongestants within 24hours
to 3 days depending on medication; acute sinusitis or concurrent acute nasal infection,
or upper respiratory tract infection, ongoing or within 2 weeks prior to screening
Interventions Intervention (n = 29): mometasone furoate nasal spray, 200 µg twice daily (morning
and evening) to the lateral nasal wall (not to the septum), in the ’vertex to floor’ position,
over 16 weeks
Comparator group (n = 30): placebo nasal spray, twice daily (morning and evening) to
the lateral nasal wall (not to the septum), in the ’vertex to floor’ position, over 16 weeks
Use of additional interventions (common to both treatment arms): no information
Outcomes Outcomes of interest in the review:
Primary outcomes
1. Total symptom score (TSS): sum of the 5 individual symptom score values (rhin-
orrhoea, postnasal drip, nasal obstruction, facial pain or pressure, and headache). Each
symptom score was assessed on a 4-point scale (0 = no symptoms; 1 =mild; 2 =moderate;
3 = severe)
2. Significant adverse effect: epistaxis
Secondary outcomes:
3. Endoscopy score (endoscopic evaluation at every visit)
Other outcomes reported by the study:
4. Patient evaluation of therapeutic response
5. Compliance of medication used (measured by weighing bottles)
6. Other adverse events
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “All qualified patients were ran-
domized, according to a computer-gener-
ated code in a 1:1 ratio…”
Allocation concealment (selection bias) Low risk Quote: “all patients who met the protocol
requirements were assigned a randomiza-
tionnumber that corresponded to the treat-
ment unit they were given… The random-
ization schedule for blinding of treatments
was maintained by the sponsor”
Comment: no description of allocation
concealment but should be low risk, as
there is adequate sequence generation and
double-blinding
Blinding of participants and personnel
(performance bias)
Low risk Quote: “The bottles of MFNS or placebo
for the 16-week treatment period had iden-
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All outcomes tical labels
The randomization schedule for blinding
of treatments was maintained by the spon-
sor, and was disclosed only after study com-
pletion and database closure.”
Comment: sealed envelopes containing in-
dividual patient allocations were provided
as a safetymeasure but whether any of these
were opened is not stated; it is not likely to
be enough to affect to affect blinding since
only 6 (10%) withdrew
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: as above
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: only 6 patients dropped out
from the study. However, the study ex-
cluded patients with “major protocol vio-
lation” (not defined) resulting in an “ITT”
population of only 75% and an even lower
per protocol population (39% excluded)
Selective reporting (reporting bias) High risk The following outcomes are stated in the
methods section but not reported in paper:
“patient compliance, Rhinosinusitis Dis-
ability Index, Work Productivity and Ac-
tivity Impairment questionnaires”
Comment: pg 242, col 2, para 1
Other bias Unclear risk Comment: there is no mention of the val-
idation of the “total symptom score” mea-
sure
Parikh 2001
Methods 2-arm, double-blind, parallel-group RCT, with a 16-week duration of treatment and
follow-up
Participants Location: UK, single site
Setting of recruitment and treatment: tertiary ENT clinic
Sample size:
Number randomised: 14 in intervention, 15 in comparison
Number completed: 9 in intervention, 13 in comparison
Participant (baseline) characteristics:
Age: FP: 45.1 ± 10.7; PL: 48 ± 20
Gender (M/F): FP: 2/7; PL: 7/6
Main diagnosis: chronic rhinosinusitis
Polyps status: FP: 2/9; PL: 2/13
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Previous sinus surgery status, mean ± SD: FP: 3 ± 6.2; PL: 2.8 ± 3.4
Previous courses of steroids: no information
Other important effect modifiers
o Skin prick test positive: FP: 7/9; PL: 8/11
o Asthma: FP: 2/9; PL: 3/13
Inclusion criteria:
More than 3months history of recurrent discoloured rhinorrhoea (> 2 weeks per episode)
, accompanied by more than 2 of the following symptoms: nasal obstruction, headache,
facial pain, fever
Endoscopy or CT scan evidence of CRS
Exclusion criteria:
Acute exacerbation in the previous 2 weeks, on oral or depot corticosteroids in the
previous 3 weeks, on INCS in the previous 2 weeks
Other severe concurrent illness
Interventions Intervention (n = 9): fluticasone propionate nasal spray, 400 µg per day, administered
twice daily
Comparator group (n = 13): placebo, administered twice daily
Use of additional interventions (common to both treatment arms): not described
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Disease severity symptom score - measured using a 10 cm VAS for blockage, sense
of smell, sneezing, discharge from the front of nose, discharge from the back of nose,
headache, facial pain. Also used diary cards
2. Significant adverse effect: epistaxis
Secondary outcomes:
3. Endoscopy: Lund-Kennedy score
4. Local irritation - itchiness of the nose, throat and ear
Other outcomes reported by the study:
Middle meatus swabs
Acoustic rhinometry
Blood tests
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “…randomisation code was gener-
ated and maintained by personnel in the
pharmacy. The investigators were not in-
volved in the process of randomisation”
Comment: adequate randomisation
Allocation concealment (selection bias) Low risk Comment: no specific information; should
be adequate since the investigators were
not involved in randomisation and blind-
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ing was adequate
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Placebo spray had benzalkonium
chloride in the same concentration as fluti-
casone propionate, and other had rose scent
to mask any differences in smell. The study
medications were prepared and supplied by
Glaxo…”
Comment: identical-looking, with the
same composition and smell masking
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: as above, since most outcomes
were patient-reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 5/14 (36%) in treatment group
and 2/15 (13%) in placebo group dropped
out. The percentage is high and unbal-
anced. Most did not turn up for follow-up
Selective reporting (reporting bias) High risk Adverse effects such as epistaxis and lo-
cal irrigation were mentioned as measured
by one of the VAS, but were not reported
separately. Unclear which symptoms were
added up into the overall score for “symp-
tom score” or “diary card score”
Other bias Unclear risk Comment: study used a 10 cm VAS for
symptom scores. Although not formally
validated, it should provide adequate dis-
criminant validity for each item. Unclear
which symptoms were added up into the
overall score
Penttilla 2000
Methods 3-arm, single-blind, international, multicentre, parallel-group RCT, with a 12-week du-
ration of treatment
Participants Location: 12 centres in Denmark (3 centres), Finland (1 centre) and Sweden (1 centre)
Setting of recruitment and treatment: outpatient clinics
Sample size:
Number randomised: 47 in 400 µg FPND twice daily, 48 in 400 µg FPND once daily,
47 in placebo
Number completed: 45 in 400 µg FPND twice daily, 47 in 400 µg FPND once daily,
41 in placebo
Participant (baseline) characteristics:
Age: mean 51, range 22 to 83
Gender: M/F; 107/35 (%M: 75.4%)
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Main diagnosis: nasal polyposis
Polyps status: 100% with polyps
Previous sinus surgery status: 72% previous polypectomy (not within 3 months of trial)
Inclusion criteria: at least 16 years old, bilateral mild or moderate nasal polyposis
Exclusion criteria: severe polyposis (large polyps reaching below the lower edge of the
inferior turbinate, causing total obstruction), concurrent purulent nasal infection, unable
to cease treatment with intranasal steroids or sodium cromoglycate during run-in period.
Also excluded: people currently receiving inhaled corticosteroids or who had received
depot or oral steroids within previous 3 months, patients who had received astemizole
in the 6 weeks prior to the first clinic visit, patients who had undergone nasal polyp
surgery in the previous 3 months, patients with hypersensitivity or contraindication
to steroids, patients with allergic rhinitis or any other disease likely to interfere with
outcomes, patients who were pregnant, lactating or likely to become pregnant during
the study period
Interventions Intervention A (n = 47): fluticasone propionate nasal drops (FPND), 400 µg twice daily
for 12 weeks
Intervention B (n = 48): fluticasone propionate nasal drops (FPND), 400 µg once daily
for 12 weeks plus placebo drops once daily for 12 weeks
Comparator group C (n = 47): placebo nasal drops twice daily for 12 weeks
Process: contents were divided between both nostrils (200 µg per nostril) in the head
down and forward position
Use of additional interventions (common to both treatment arms): all patients un-
derwent a 2-week run-in period during which they ceased all medication for polyposis
except loratadine tables for relief of troublesome symptoms (10 mg daily maximum)
Initial visit: physical and oropharyngeal examinations and details of clinical history
Initial and 12-week visit: blood and urine samples
Outcomes Outcomes of interest in the review:
Primary outcomes
1. Disease severity, measured by assessing nasal blockage (0 to 3 scale) and overall rhinitis
symptoms including sneezing, rhinorrhoea and nasal itching (0 to 3 scale) and sense of
smell (0 to 3 scale) at 12 weeks after treatment
2. Nasal blockage, overall rhinitis
2. Significant adverse effect: epistaxis
Secondary outcomes:
3. Other adverse effects: local irritation
5. Polyps size
Other outcomes reported by the study: peak nasal inspiratory flow (PNIF), olfactory
function, rescue medication usage and adverse events
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “…double blind randomised treat-
ment...”, Figure 1, pg 95
Comment: no further information pro-
vided, but this is an “international, multi-
centre” study in 12 centres across 3 coun-
tries with regional monitors. Should have
adequate sequence generation procedures
Allocation concealment (selection bias) Low risk Quote: “…double blind randomised treat-
ment...”, Figure 1, pg 95
Comment: no further information pro-
vided. As above, allocation concealment
should be adequate
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “active and placebo nasal drops
were provided in identical single-dose con-
tainers …”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: no further information pro-
vided. Should be adequate with use of ad-
equate double-blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Sixteen patients were withdrawn
during the randomized treatment phase,
the majority due to lack of efficacy (five
placebo, one FP 400 mg o.d., two FP 800
mg b.i.d.) or adverse events (five placebo,
one FP 400mg o.d., two FP 400mg b.i.d.).
One patient in the placebo group withdrew
due to requirement for polypectomy. Two
patients withdrew during the open phase,
one requiring a polypectomy, the other for
unspecified reasons”, pg 97, col 2
Comment: 16/142 (11.3%) withdrew: 10/
47 placebo, 4/47 400 µg twice daily and 2/
48 400 µg once daily did not completed the
study. All of these patients were included as
the ITT population with imputation. Un-
balanced drop-out rates (21% in placebo)
versus 8.5% and 4% in the twice and once
daily active treatment groups
Selective reporting (reporting bias) Unclear risk Comment: all outcome measures in the
methods were discussed in the results sec-
tion. However the diary card data were in-
terpreted by using different cut-off points,
which do not appear to be pre-specified
in the methods section. Significant results
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were reported but not those that were not
significant
Other bias Unclear risk Comment: no mention of validation of
symptom criteria used for the primary out-
comes
Small 2005
Methods 3-arm, double-blind, multicentre, parallel-group RCT, with 4-month duration of treat-
ment and follow-up
Participants Location: 44 medical centres “worldwide”
Setting: no information
Sample size:
Number randomised: 122 in 400 µg, 115 in 200 µg, 117 in placebo group respectively
Number completed: 109 in 400 µg, 101 in 200 µg, 95 in placebo group respectively
Participant (baseline) characteristics:
• Main diagnosis: bilateral nasal polyps and clinically significant congestion/
obstruction
• Age (mean): 400 µg: 48.3; 200 µg: 46.7; placebo: 47.5
• Gender (%M/%F): 400 µg: 61/39; 200 µg: 66/34; placebo: 61/39
• Polyps status: 100% with polyps
• Previous sinus surgery status: no information
• Other important effect modifiers:
◦ Asthma history (%): 400 µg: 21; 200 µg: 18; placebo: 21
◦ Perennial allergic rhinitis history (%): 400 µg: 25; 200 µg: 20; placebo: 17
Inclusion criteria:
≥ 18 years with an endoscopically confirmed diagnosis of bilateral nasal polyps (at least
1 on a scale of 0 to 3) and clinically significant nasal congestion/obstruction (average
morning score 2 or higher on as scale of 0 to 3 for each of the last 7 days of the 14-day
run-in period)
If had asthma, had a documented FEV1 ≥ 80% of the predicted value within the 6
months before screening and no asthma exacerbations within 30 days before screening.
Those treated with inhaled corticosteroids were required to be on a moderate, stable
regimen of beclomethasone dipropionate ≤ 800 mg/d or equivalent for 1 month before
screening and to remain on a stable regimen throughout the study period
Exclusion criteria:
Seasonal allergic rhinitis within the past 2 years
Sinus or nasal surgery within the previous 6 months or 3 nasal surgeries (or any surgical
procedure preventing an accurate grading of polyps)
Presumed fibrotic nasal polyposis, or complete or near complete nasal obstruction
Nasal septal deviation requiring corrective surgery
Nasal septal perforation
Acute sinusitis, nasal infection or upper respiratory tract infection at screening or in the
2 weeks before screening;
ongoing rhinitis medicamentosa
Churg-Strauss syndrome
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Dyskinetic ciliary syndromes
Cystic fibrosis
Glaucoma or a history of posterior subcapsular cataracts; allergies to corticosteroids or
aspirin, or any other clinically significant disease that would interfere with the evaluation
of therapy
Interventions 400 µg group (n = 122):mometasone furoate nasal spray 200 µg twice daily (morning
and evening) for 4 months
200 µg group (n = 115):mometasone furoate nasal spray 200 µg once daily (morning,
matching placebo used in the evening) for 4 months
Placebo group (n = 117): placebo nasal spray twice daily (morning and evening) for 4
months
Use of additional interventions (common to both treatment arms):
Acetaminophen (paracetamol) was encouraged for analgesic purposes; NSAIDs limited
to 5 consecutive days if alternative analgesia was required. Antibiotics were administered
for bacterial infections at the discretion of the principal investigator
Concomitant medications that would interfere with study evaluations were not permit-
ted, including nasal sodium cromolyn; nasal atropine or ipratropium bromide; corticos-
teroids (except oral inhaled corticosteroids for asthma or mild-strength or mid-strength
topical corticosteroids for dermatologic purposes); antihistamines; decongestants; topi-
cal, oral or ocular anti-inflammatory drugs; or topical nasal or oral antifungal agents
Outcomes Outcomes of interest in the review:
Primary outcomes
1. Disease severity, patient evaluation of symptoms (congestion/obstruction, loss of sense
of smell, anterior rhinorrhoea and postnasal drip) measured daily on a diary card on a
4-point scale (0 = none, 3 = severe)
2. Significant adverse effect: epistaxis
Secondary outcomes:
3. Other adverse effects: local irritation
Other outcomes reported by the study:
Polyps grade; bilateral score and proportion of patients demonstrating an improvement
at endpoint
Therapeutic response (rated by investigator)
Peak nasal inspiratory flow
Treatment compliance
Number of withdrawals due to AE and events occurring in more than 2% of participants
in any group
Notes Supported by a grant from the Schering-Plough Research Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “…randomised in a 1:1:1 ratio to
3 treatment arms…”
Comment: no further information. How-
ever, this is a large multinational RCT and
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should have adequate resources to conduct
proper sequence generation
Allocation concealment (selection bias) Low risk Comment: no information provided.
However, this is a multinational trial with
adequate blinding and should have ade-
quate sequence generation and allocation
concealment procedures
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind, double dummy”;
“…matching placebo nasal spray …”
Comment: pg 1276, col 1, para 1 and 2.
“Matching placebo spray” mentioned and
those on the 200 µg/day regimen were also
given placebo nasal spray for the evening
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: no information. Likely to re-
main well blinded until end of study
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: 305/354 patients (86%) patients
“completed 4-month treatment period”
Comment: higher % of patients not com-
pleting in the placebo group 22/117 (19%)
; compared to the twice daily or once daily
groups 13/122 (11%) and 14/114 (12%)
, respectively. Study mentioned analyses
based on “all randomised subjects” using
the “ITT principle” and endpoint was “de-
fined as the last non-missing reading for
the subject” for bilateral polyps score; how-
ever, unlikely all were analysed as numbers
do not tally exactly with the “meta-analysis
subsequently reported”
Selective reporting (reporting bias) Low risk Comment: all outcomes reported in the
methods section were reported in the re-
sults section
Other bias Unclear risk Comment: no information about the vali-
dation of outcome measures
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Methods 3-arm, double-blind, multicentre, parallel-groupRCT, with a 4-month duration of treat-
ment and follow-up
Participants Location: 24 centres in 17 countries worldwide
Setting: study conducted from 25 June 2001 to 20 January 2003
Sample size:
Number randomised: 102 in 400 µg, 102 in 200 µg, 106 in placebo group, respectively
Number completed: 93 in 400 µg, 94 in 200 µg, 87 in placebo group, respectively
Participant (baseline) characteristics:
Main diagnosis: bilateral nasal polyps and clinically significant congestion/obstruction
Age (mean): 400 µg: 47.6; 200 µg: 47.2; placebo: 50.9
Gender (%M/%F): 400 µg: 62/38; 200 µg: 70/30; placebo: 65/35
Polyps status: 100% with polyps
Previous sinus surgery status: not more than 3 times or within past 6 months
Other important effect modifiers:
o Asthma history (%): 400 µg: 19; 200 µg: 15; placebo: 17
o Perennial allergic rhinitis history (%): 400 µg: 18; 200 µg: 14; placebo: 22
Inclusion criteria:
≥ 18 years with an endoscopically confirmed diagnosis of bilateral nasal and clinically
significant nasal congestion/obstruction (average morning score 2 or higher on as scale
of 0 to 3 for each of the last 7 days of the 14-day run-in period). If had asthma, had a
documented FEV1 ≥ 80% of the predicted value within the 6 months before screening
and no asthma exacerbations within 30 days before screening. Those treated with inhaled
corticosteroids were required to be on a moderate, stable regimen of beclomethasone
dipropionate ≤ 800 mg/d or equivalent for 1 month before screening and to remain on
a stable regimen throughout the study period
Exclusion criteria:
Seasonal allergic rhinitis within the past 2 years
Sinus or nasal surgery within the previous 6 months or 3 nasal surgeries (or any surgical
procedure preventing an accurate grading of polyps)
Presumed fibrotic nasal polyposis, or complete or near complete nasal obstruction
Nasal septal deviation requiring corrective surgery or nasal septal perforation
Acute sinusitis, nasal infection or upper respiratory tract infection at screening or in the
2 weeks before screening
Ongoing rhinitis medicamentosa
Churg-Strauss syndrome
Dyskinetic ciliary syndromes
Cystic fibrosis
Glaucoma or a history of posterior subcapsular cataracts
Allergies to corticosteroids or aspirin, or any other clinically significant disease that would
interfere with the evaluation of therapy
Interventions 400 µg group (n = 102):mometasone furoate nasal spray 200 µg twice daily (morning
and evening) for 4 months
200 µg group (n = 102):mometasone furoate nasal spray 200 µg once daily (morning,
matching placebo used in the evening) for 4 months
Placebo group (n = 106): placebo nasal spray twice daily (morning and evening) for 4
months
Use of additional interventions (common to both treatment arms):
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Acetaminophen (paracetamol) was encouraged for analgesic purposes; NSAIDs limited
to 5 consecutive days if alternative analgesia was required. Antibiotics were administered
for bacterial infections at the discretion of the principal investigator
Concomitant medications that would interfere with study evaluations were not permit-
ted, including nasal sodium cromolyn; nasal atropine or ipratropium bromide; corticos-
teroids (except oral inhaled corticosteroids for asthma or mild-strength or mid-strength
topical corticosteroids for dermatologic purposes); antihistamines; decongestants; topi-
cal, oral or ocular anti-inflammatory drugs; or topical nasal or oral antifungal agents
Outcomes Outcomes of interest in the review:
Primary outcomes
1. Disease severity, patient evaluation of symptoms (congestion/obstruction, loss of sense
of smell, anterior rhinorrhoea and postnasal drip) measured daily on a diary card on a
4-point scale (0 = none, 3 = severe)
2. Significant adverse effect: epistaxis
Secondary outcomes:
3. Other adverse effects: local irritation
4. Polyps grade; bilateral score and proportion of patients demonstrating an improvement
at endpoint
Other outcomes reported by the study:
Therapeutic response (rated by investigator)
Peak nasal inspiratory flow
Treatment compliance
Number of withdrawals due to AE and events occurring in more than 2% of participants
in any group
Notes Supported by a grant from the Schering-Plough Research Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed in
blocks of 3 using random numbers gener-
ated by SAS functionUNIFORM(SAS In-
stitute, Cary, NC) with seed based on clock
time. Randomization was stratified by the
presence or absence of concurrent asthma.
”
Comment: computerised randomisation
Allocation concealment (selection bias) Low risk Comment: although randomisation was
blocked, blinding should be adequate
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”; “…matching
placebo nasal spray …”
Comment: “Matchingplacebo spray”men-
tioned; dosing regimen the same across all
groups
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: no information. Likely to re-
main well blinded until end of study
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “More than 85% of subjects com-
pleted the 4-month treatment period, with
more than twice as many placebo recipients
as active drug recipients discontinuing dur-
ing the treatment phase (18% vs 8%).”
Comment: drop-out rates not balanced
Selective reporting (reporting bias) Unclear risk Comment: although all outcomes men-
tioned in the methods were reported, these
were mostly not in sufficient detail (e.g.
only P values)
Other bias Unclear risk Comment: no information about the vali-
dation of outcome measures
Stjarne 2006a
Methods Double-blind, multicentre, parallel-group RCT, with a 4-month duration of treatment
and follow-up
Participants Location: 12 centres in Denmark, Finland, Norway and Sweden
Setting: outpatient clinics
Sample size:
Number randomised: 153 in 200 µg, 145 in placebo group, respectively (298)
Number completed: 134 in 200 µg, 101 in placebo group, respectively (235)
Participant (baseline) characteristics:
Main diagnosis: bilateral nasal polyps and clinically significant congestion/obstruction
Age (mean): 53 (range 20 to 86)
Gender (%M/%F): 200 µg group: 74.5/25.5; placebo group: 71.7/28.3
Polyps status: 100% with polyps
Previous sinus surgery status: > 2 surgeries, 25.5% in 200 µg group 26.2% in placebo
group
Other important effect modifiers:
Inclusion criteria:
Age ≥ 18 years; a diagnosis of bilateral nasal polyps and clinically significant nasal
congestion. Nasal congestion was defined as significant when the symptom score was ≥
2 (on a scale of 0 to 3) for ≥ 4 days per week during the month before screening, at
screening and at the baseline visit
Exclusion criteria:
Nasal polyp surgery within the 6 months before screening; unhealed nasal surgery or
trauma; polyp size of 3 (on a scale of 0 to 3); the presence of polyps that could interfere
with nasal spray application; significant nasal structural abnormalities; ongoing concur-
rent nasal infections; glaucoma with narrow anterior chamber angle of the eye; rhinitis
medicamentosa; or hereditary mucociliary dysfunction
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Interventions 200 µg group (n = 153):mometasone furoate nasal spray 200 µg once daily (morning,
matching placebo used in the evening) for 16 weeks
Placebo group (n = 145): placebo nasal spray twice daily (morning and evening) for 16
weeks
Concomitant medications that would interfere with study evaluations were not permit-
ted, including nasal sodium cromolyn; nasal atropine or ipratropium bromide; corticos-
teroids (except oral inhaled corticosteroids for asthma or mild-strength or mid-strength
topical corticosteroids for dermatologic purposes); antihistamines; decongestants; topi-
cal, oral or ocular anti-inflammatory drugs; or topical nasal or oral antifungal agents
Outcomes Outcomes of interest in the review:
Primary outcomes
1. Disease severity - participants with improvement in score
2. Significant adverse effect: epistaxis
Secondary outcomes:
3. Other adverse effects: local irritation
Other outcomes reported by the study:
Investigator-evaluated nasal congestion, sense of smell and rhinorrhoea
PNIF
Treatment response score
Olfactory threshold
Notes Participants who met the eligibility criteria at the screening visit (visit 1) underwent a 2-
to 4-week no treatment run-in period. Criteria to remain in study/numbers subsequently
excluded not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “…randomized at the baseline visit
(day 0, visit 2) according to a computer-
generated code…”
Comment: adequate randomisation
Allocation concealment (selection bias) Low risk Quote: “The randomization schedule for
the blinded treatments was maintained by
the sponsor and only disclosed after the
study was completed and the database
closed.”
Comment: adequate allocation conceal-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The placebo aqueous nasal spray
was formulated to match MFNS exactly,
except for the active ingredient.”
Comment: matching placebo
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: as above
As key outcomes were patient-reported and
there was adequate blinding, it is likely
there was adequate blinding for outcome
assessment
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Of the 298 subjects randomized
to treatment, 235 (78.9%) completed the
study. Premature withdrawals were more
common in the placebo group than in the
MFNS group (30.3%vs 12.4% of subjects,
respectively).”
Comment: drop-out rates not balanced
across groups
Selective reporting (reporting bias) Unclear risk Comment: all outcomes mentioned in the
methods section were reported in the re-
sults section, although these were mostly
not in sufficient detail
Other bias Unclear risk Quote: “Approximately 10% of subjects
were considered to be noncompliant with
the dosing regimen (defined as missing
study medication doses for ≥7 consecu-
tive days up to a maximum of 10 days, us-
ing rescue medication for≥10 days during
treatment, or using prohibited concomi-
tant medications).”
Comment: there was a 2 to 4-week run-
in period - criteria to remain in study not
reported
There was no information about the valida-
tion of instruments used to measure symp-
toms
Vlckova 2009
Methods Double-blind, placebo-controlled, multicentre, parallel-group RCT, with a 12-week du-
ration of treatment and a 14-week duration of follow-up
Participants Location: Czech Republic, 5 sites
Setting of recruitment and treatment: 5 otorhinolaryngology hospital clinics
Sample size:
Number randomised: 54 in intervention, 55 in comparison
Number completed: 54 in intervention, 52 in comparison
Participant (baseline) characteristics:
Age, mean (range): FP: 48.9 (18 to 65), PL: 47.0 (23 to 63)
Gender (M/F): FP: 74/26; PL: 62/38
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Main diagnosis: mild to moderate bilateral nasal polyposis
Polyps status: all; about 50% in each arm had mild, 50% had moderate grade polyps
Previous sinus surgery status: never had surgery FP: 23 (43%), PL: 15 (27%); had at
least 4 surgeries FP: 4 (7%), PL: 7 (13%)
Previous courses of steroids: no information
Other important effect modifiers, if applicable (e.g. aspirin sensitivity, comorbidities of
asthma): asthma: FP: 17%; PL: 18%
Inclusion criteria:
Age 18 to 65 years, a diagnosis of bilateral nasal polyposis graded as mild or moderate
Verified airflow through both nostrils, an ability to close the soft palate and the ability to
trigger the breath-actuation mechanism of a device in accordance with the instructions
for use
Exclusion criteria:
Large polyps (grade 3)
Nasal polyp surgery during the 3 months before screening
Cystic fibrosis, a purulent nasal infection, allergic rhinitis or other disease likely to in-
terfere with the study parameters
Depot or oral steroids during the previous 3 months
Cleft palate
Concomitantmedications thatwould interferewith study evaluationswere not permitted
Interventions Intervention (n = 54): fluticasone propionate 800 µg/day delivered with breadth actu-
ated inhaler twice a day
Comparator group (n = 55): placebo, twice a day
Use of additional interventions (common to both treatment arms):
Saline rinsing and devices that dilate the nostrils were prohibited
Loratadine 10mg tablets were provided as rescuemedication for the relief of troublesome
acute allergic symptoms. If a participant experienced a severe acute nasal blockage, the
investigator could authorise the use of a short course of oxymetazoline drops or spray for
a maximum of 7 consecutive days and a total maximum of 10 days during the treatment
period. Oxymetazoline was not to be used within 24 hours of a scheduled study visit
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Disease severity symptom score, using both a global rating scale (very much improved;
improved; same; worse or very much worse). Also used a diary with the following scoring
system: 0 (none), 1 (mild - symptoms present but not troublesome), 2 (moderate -
symptoms frequently troublesome but not interfering with daily activity or night time
sleep) or 3 (symptoms troublesome and interferingwith daily activity or night-time sleep)
for nasal blockage, nasal discomfort (facial and sinus pain and pressure) and rhinitis
(nasal secretion, itching, irritation and sneezing). Sense of smell was rated as follows: 0
(normal), 1 (slightly impaired), 2 (moderately impaired) or 3 (absent)
2. Significant adverse effect: epistaxis
Secondary outcomes:
3. Endoscopy: polyp size was graded for each nostril using the Lildholdt scale. Some
authors classify polyps causing total obstruction as grade 4. The score was presented for
each nostril, the worst affected nostril and the summed score for both nostrils
4. Adverse event: local irritation
5. CT scan
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Other outcomes reported by the study:
• PNIF
• Use of rescue medications
Notes Study had a 14- to 16-day treatment-free run-in
Compliance was high with 98.92% of administrations made in the Opt-FP treatment
group and 99.05% made in the placebo group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “…randomized in a 1:1 ratio”
Comment: no further description of ran-
domisation methods
Allocation concealment (selection bias) Unclear risk Comment: no information about alloca-
tion concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “…Opt-FP and placebo breath-ac-
tuated bi-directional delivery devices were
identical in appearance…. The placebo
aqueous nasal spray was formulated to
match FP exactly, except for the active in-
gredient... To deliver a dose of FP 400µg b.
i.d. or matching placebo, the subjects made
two administrations to each nostril in the
morning and the evening...”
Comment: identical-looking devices and
same frequency of administration. Same
formulation, except the omission of the ac-
tive ingredient. Should be able to maintain
good blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: as above
Comment: most are patient-reported out-
comes therefore blinding should be ade-
quate
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “A total of 106 subjects (97%) com-
pleted the study. Three subjects withdrew,
all in the placebo group (one due to wors-
ening of polyps, two withdrew consent).”
Comment: low drop-out rate
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. Most
outcomes are reported in graphs. Global
improvement score dichotomised when re-
ported (not pre-specified)
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Other bias Unclear risk Comment: no mention of validation of
questionnaires
Zhou 2015
Methods 2-arm, double-blind, multicentre, parallel-group RCT, with a 16-week duration of treat-
ment and follow-up
Participants Location: China, 28 sites
Setting of recruitment and treatment: not clear
Sample size: 748
Number randomised: 375 in intervention, 373 in comparison
Number completed: 350 in intervention, 336 in comparison
Participant (baseline) characteristics:
• Mean age ± SD: intervention: 46.8 ± 13.5; control: 46.8 ± 13.8
• Gender male (%): intervention: 224 (59.7%); control: 239 (64.1%)
• Main diagnosis: Chinese patients with bilateral nasal polyps
• Polyps status: 100% with polyps
• Baseline total polyp size: intervention 3.6 ± 1.1; control 3.7 ± 1.1
• % previous sinus surgery status: intervention: 24.5%; 22.8%
• Other important effect modifiers:
◦ % concurrent asthma status: intervention: 2.7%; control: 3.5%
◦ % sensitivity to antigen: intervention: 4.3%; control: 5.1%
Inclusion criteria:
• ≥ 18 years of age, Chinese
• diagnosis of bilateral nasal polyps (graded on a scale of 0 to 3, see below)
• clinically significant nasal congestion/obstruction (average morning score ≥ 2 for
each of the last 7 days of the 14-day run-in period)
• Patients with asthma were included if FEV1 ≥ 80% within 6 months and no
exacerbations within 30 days of screening. Using inhaled corticosteroids, on a
moderate, stable regimen of beclomethasone dipropionate 800 mg/day or equivalent
for 1 month before screening and remained on a stable regimen throughout the study.
• Nasal polyp score: polyps were graded by size and extent in both the left and right
nasal fossa on a scale of 0 to 3 (0 = no polyps; 1 = polyp in middle meatus, not reaching
below the inferior border of the middle turbinate; 2 = polyp reaching below the inferior
border of the middle turbinate but not the inferior border of the inferior turbinate; and
3 = large polyp reaching to or below the lower border of the inferior turbinate or polyps
medial to the middle turbinate). The sum of left and right nasal fossa polyp scores gave
the total bilateral polyps grade.
Exclusion criteria:
• History of seasonal allergic rhinitis within the past 2 years
• Sinus or nasal surgery within the previous 6 months
• History of 3 or more nasal surgeries in the past
• History of any procedure preventing an accurate grading of polyps
• Presumed fibrotic nasal polyps, or complete/near-complete nasal obstruction
• Nasal septal deviation requiring corrective surgery; nasal septal perforation
• Acute sinusitis, nasal infection or upper respiratory tract/nasal infection at (or
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within 2 weeks of ) screening
• Ongoing rhinitis medicamentosa, Churg-Strauss syndrome, dyskinetic ciliary
syndromes, cystic fibrosis
• Glaucoma or a history of posterior subcapsular cataracts; allergies to
corticosteroids or aspirin
• Any other clinically significant disease that would interfere with the evaluation of
therapy
Interventions Intervention (n = 375): mometasone nasal spray, 400 µg per day (200 µg twice daily),
16 weeks
Comparator group (n = 373): matching placebo nasal spray, twice daily for 16 weeks
Use of additional interventions:
The following were prohibited: nasal sodium cromolyn; nasal atropine or ipratropium
bromide; guaifenesin; oral/intramuscular/intranasal corticosteroids (except oral inhaled
corticosteroids for asthma or mild-strength topical corticosteroids for dermatologic pur-
poses); antihistamines; decongestants; topical, oral or ocular antiinflammatory drugs;
nonsteroidal anti-inflammatory drugs; or topical nasal or oral antifungal agents
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Disease severity symptom score; patients reported individual symptom scores at 16
weeks, measured on a scale of 0 to 3 (0 = none; 1 = mild; 2 = moderate; 3 = severe) for
the following symptoms: nasal obstruction, anterior rhinorrhoea, post-nasal drip, loss of
sense of smell
2. Significant adverse effect: epistaxis
Secondary outcomes:
3. Endoscopy (nasal polyps size); measured at 16 weeks in both left and right nasal fossa
on a scale of 0 to 3 (see inclusion criteria for details) and summed for each nasal fossa to
give a total score
4. Adverse effects: local irritation
Other outcomes reported by the study:
• Therapeutic response on a qualitative scale ranging from “complete relief of
symptoms” to “no relief ”
• Compliance defined as 29% to 138% of reference study drug bottle weight
Notes All patients had a 14-day, single-blind placebo run-in period where signs and symptoms
of nasal polyps were evaluated
The compliance rate was similar; 95.5% (MFNS) and 94.8% (placebo)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “At baseline, patients were ran-
domised (1:1 ratio) according to a com-
puter-generated allocation schedule”
Comment: adequate randomisation
method
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Allocation concealment (selection bias) Low risk Quote: “Study medication was supplied
for double-blind administration in a treat-
ment kit labelled with study number, sub-
ject number, and dosing instructions.”
Comment: adequate allocation conceal-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Study medication was supplied
for double-blind administration in a treat-
ment kit labelled with study number, sub-
ject number, and dosing instructions.”
Comment: trial was “double-blind”. Pa-
tients in the control group received a
“matching placebo nasal spray”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: there is no information about
the blinding of outcome assessors. How-
ever, most outcomes were patient-reported
and if there was adequate blinding this
should be sufficient
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 25/375 (6.7%) in the inter-
vention group and 37/336 (9.9%) in the
control group discontinued treatment. The
reasons are provided in the paper and the
small numbers are unlikely to affect the re-
sults significantly
Selective reporting (reporting bias) Low risk Comment: the protocol for this study
was available (https://clinicaltrials.gov/ct2/
show/NCT01386125).
The analysis method, primary outcomes
and reporting of adverse events is well de-
scribed in the protocol and reported as
planned within the paper
Other bias Unclear risk Comment: there is no information within
the paper regarding validation of any of the
outcomes used
AE: adverse event
ASA: acetylsalicylic acid
BDP: beclomethasone dipropionate
CRS: chronic rhinosinusitis
CT: computed tomography
d: day
ENT: ear, nose and throat
F: female
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FESS: functional endoscopic sinus surgery
FEV1: forced expiratory volume in one second
FP: fluticasone propionate
FPND: fluticasone propionate nasal drops
INCS: intranasal corticosteroids
ITT: intention-to-treat
M: male
MRI: magnetic resonance imaging
NSAIDs: non-steroidal anti-inflammatory drugs
PL: placebo
PNIF: peak nasal inspiratory flow
RCT: randomised controlled trial
RSOM-31: Rhinosinusitis Outcome Measures-31 instrument
SD: standard deviation
UPSIT: University of Pennsylvania Smell Identification Test
VAS: visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ALA 2015 POPULATION: children and adults with uncontrolled asthma and CRS. The population did not meet the
EPOS definition of CRS
Albu 2010 DESIGN: perioperative treatment using topical steroids for improvement of surgical outcomes in patients
undergoing surgery
Bross-Soriano 2004 POPULATION: all patients underwent endoscopic polypectomy at the start of the trial
Cassano 1996 POPULATION: all patients had surgery at the start of the trial
Chalton 1985 DURATION: treatment and follow-up only 4 weeks (betamethasone drops)
Cuenant 1986 POPULATION: chronic allergic or bacterial sinusitis
Dijkstra 2004 POPULATION: treatment started 1 week after FESS (continued for 1 year)
Drettner 1982 POPULATION: treatment started 4 weeks after polypectomy surgery (continued for 3 months)
Ehnhage 2009 DESIGN: perioperative study; patients received intranasal corticosteroids/placebo before FESS, and then
carried on intranasal corticosteroids/placebo
el Naggar 1995 STUDY DESIGN: treatment started immediately after intranasal polypectomy; randomised by side of nose
Filiaci 2000 STUDY DESIGN: treatment and follow-up only 8 weeks (budesonide)
Furukido 2005 INTERVENTION: YAMIK sinus catheter for 4 weeks
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Gulati 2001 POPULATION: treatment started 1 week after polypectomy surgery (continued for 3 months)
Hartwig 1988 POPULATION: all patients had polypectomy and treatment started the day after surgery
Jankowski 2001 DURATION: treatment only 8 weeks (budesonide)
Jankowski 2009 DURATION: there was an intranasal corticosteroids (fluticasone) versus placebo comparison only for 8 weeks,
subsequently all patients had intranasal corticosteroids (for 6 months)
Johansson 2002 DURATION: treatment and follow-up only 2 weeks
Jorissen 2009 POPULATION: all participants had FESS at the start of the trial
Jurkiewicz 2004 POPULATION: started treatment after endoscopic polypectomy
Kang 2008 POPULATION: study started directly after FESS
Kapucu 2012 DURATION: follow-up only 1 month (triamcinolone intra-polyp steroid injections or nasal spray versus
placebo)
Karlsson 1982 POPULATION: included patients immediately after polypectomy
Keith 1995 DURATION: treatment and follow-up only 4 weeks (budesonide)
Lavigne 2002 INTERVENTION: sinus irrigation with steroids using MAST tube, for 3 weeks
Lildholdt 1995 DURATION: treatment and follow-up only 4 weeks
Malmberg 1988 POPULATION: all patients had polypectomy within 2 months of the start of the trial
Man 2013 DURATION: treatment and follow-up was for just 6 weeks. The intervention used was 3 mg of fluticasone
in 240 ml of normal saline
Mastalerz 1997 POPULATION: aspirin-induced asthma and chronic eosinophilic rhinitis
Meltzer 1993 DURATION: treatment and follow-up only 7 weeks; patients with maxillary sinusitis had flunisolide spray
versus placebo added to amoxicillin/clavulanate
Mygind 1975 DURATION: treatment and follow-up only 3 weeks
Optinose 2012 OTHER: RCT prematurely ended
Passali 2003 POPULATION: patients started treatment 1 month after surgery
Qvarnberg 1992 POPULATION: did not meet current CRS definitions - “recurrent or chronic maxillary sinusitis” (no nasal
polyps)
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Rotenberg 2011 POPULATION: all patients underwent endoscopic sinus surgery at the start of the trial
Rowe-Jones 2005 POPULATION: all patients underwent endoscopic sinus surgery at the start of the trial
Ruhno 1990 DURATION: treatment and follow-up only 4 weeks
Saunders 1999 DESIGN: perioperative study: patients were given intranasal corticosteroids for 2 weeks before polypectomy
Slifirski 2009 POPULATION: all patients underwent surgery at the start of the trial before randomisation
Stjarne 2009 POPULATION: all patients underwent FESS at the start of the trial
Taub 1968 DESIGN: cross-over study. 4 weeks of treatment followed by dexamethasone spray/placebo, then switched.
Unclear if there was a washout period. Results not presented separately
Toft 1982 DURATION: treatment only 2 weeks (beclomethasone). A cross-over study with 1-week follow-up
Tos 1998 DURATION: treatment and follow-up only 6 weeks (budesonide)
Vento 2012 POPULATION: all patients had surgery around 2 weeks before the treatment started
Virolainen 1980 POPULATION: all patients underwent radical ethmoidectomy surgery 2 days prior to treatment starting
Wang 2015 DURATION: treatment and follow-up only 14 days (budesonide nebulisation)
CRS: chronic rhinosinusitis
EPOS: European Position Paper on Rhinosinusitis and Nasal Polyps 2012
FESS: functional endoscopic sinus surgery
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Bachert 2004
Methods -
Participants -
Interventions -
Outcomes -
Notes Conference proceeding: we cannot locate the abstract
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Methods -
Participants -
Interventions -
Outcomes -
Notes We cannot locate the abstract
Pisano 2000
Methods -
Participants -
Interventions -
Outcomes -
Notes We cannot locate the abstract
Riem 2005
Methods -
Participants -
Interventions -
Outcomes -
Notes We cannot locate the abstract
Ygind 1996
Methods -
Participants -
Interventions -
Outcomes -
Notes We cannot locate the full text
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NCT01013701
Trial name or title ’Compare the effects of fluticasone furoate nasal spray vs placebo in patients with nasal polypoid disease’
Methods Double-blind, parallel assignment, randomised controlled trial
Participants Adults with nasal polyps
Interventions - Fluticasone furoate
- Placebo
Outcomes To evaluate the effect of once daily nasal steroid therapy with fluticasone furoate nasal spray (110 µg/day) in
suppressing nasal polyp-induced symptoms over the course of 16 weeks in patients presenting to the clinic
with active nasal polypoid disease
Starting date 2009
Contact information Peter S. Creticos MD, Johns Hopkins University
Notes ClinicalTrials.gov website indicates that the recruitment status of this study is unknown because the informa-
tion has not been verified recently. We tried to contact the study authors to find out more information but
we did not receive a response
NCT01622569
Trial name or title ’Study evaluating the efficacy and safety of intranasal administration of 100, 200, and 400 µg of fluticasone
propionate twice a day (bid) using a novel bi directional device in subjects with bilateral nasal polyposis
followed by an 8-week open-label extension phase to assess safety’
Methods Double-blind, parallel assignment, randomised controlled trial
Participants Adults with bilateral nasal polyposis
Interventions - Fluticasone propionate 100 µg twice a day
- Fluticasone propionate 200 µg twice a day
- Fluticasone propionate 400 µg twice a day
- Matching placebo
For 16 weeks
Outcomes - Reduction of nasal congestion/obstruction symptoms
- Reduction in total polyp grade (sum of scores from both nasal cavities)
No secondary outcomes were listed in the trial registry entry
Starting date 2013
Contact information Optinose US Inc. No further details provided.
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NCT01622569 (Continued)
Notes Study has been listed as completed on the registry website (October 2015). No results are currently available
NCT01624662
Trial name or title ’Efficacy and safety study of intranasal administration of 100, 200, and 400 µg of fluticasone propionate
twice a day (bid) using a novel bi directional device in subjects with bilateral nasal polyposis followed by an
8-week open-label extension phase to assess safety’
Methods Double-blind, parallel assignment, randomised controlled trial
Participants Adults with bilateral nasal polyposis
Interventions - Fluticasone propionate 100 µg twice a day
- Fluticasone propionate 200 µg twice a day
- Fluticasone propionate 400 µg twice a day
- Matching placebo
For 16 weeks
Outcomes - Reduction of nasal congestion/obstruction symptoms
- Reduction in total polyp grade (sum of scores from both nasal cavities)
No secondary outcomes were listed in the trial registry entry
Starting date 2012
Contact information Optinose US Inc. No further details provided.
Notes Study has been listed as completed on the registry website (October 2015). No results are currently available
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D A T A A N D A N A L Y S E S
Comparison 1. Intranasal corticosteroids versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disease severity - measured as
change from baseline using the
Chronic Sinusitis Survey at 20
weeks
1 134 Mean Difference (IV, Fixed, 95% CI) 2.84 [-5.02, 10.70]
2 Disease severity - global
symptom score, measured as
proportion of patients who
improved
1 109 Risk Ratio (M-H, Fixed, 95% CI) 2.78 [1.76, 4.40]
3 Disease severity - combination
of individual symptom scores,
measured on a 0 to 3 scale as
change from baseline at 12 to
20 weeks
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Average symptom score (4
EPOS domains)
2 243 Mean Difference (IV, Fixed, 95% CI) -0.26 [-0.37, -0.15]
3.2 Average symptom score
(3 EPOS domains - nasal
blockage, rhinorrhoea, loss of
sense of smell)
4 1345 Mean Difference (IV, Fixed, 95% CI) -0.31 [-0.38, -0.23]
3.3 Average symptom score (2
EPOS domains - nasal blockage
and rhinorrhoea)
6 1702 Mean Difference (IV, Fixed, 95% CI) -0.31 [-0.38, -0.24]
4 Disease severity - individual
symptoms, measured as average
change from baseline at 12 to
20 weeks (range 0 to 3 points)
6 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Nasal blockage 6 1702 Mean Difference (IV, Random, 95% CI) -0.40 [-0.52, -0.29]
4.2 Rhinorrhoea 6 1702 Mean Difference (IV, Random, 95% CI) -0.25 [-0.33, -0.17]
4.3 Loss of sense of smell 4 1345 Mean Difference (IV, Random, 95% CI) -0.19 [-0.28, -0.11]
4.4 Facial pain/pressure 2 243 Mean Difference (IV, Random, 95% CI) -0.27 [-0.56, 0.02]
5 Adverse events - epistaxis 13 2508 Risk Ratio (M-H, Fixed, 95% CI) 2.74 [1.88, 4.00]
5.1 With nasal polyps 10 2262 Risk Ratio (M-H, Fixed, 95% CI) 3.03 [2.00, 4.59]
5.2 Without nasal polyps 3 246 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [0.59, 3.78]
6 Adverse events - local irritation 11 2124 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.53, 1.64]
6.1 With nasal polyps 9 2045 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.52, 1.67]
6.2 Without nasal polyps 2 79 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.15, 6.84]
7 Endoscopy score (bilateral
polyps score) measured change
from baseline (range 0 to 6
points)
4 1417 Mean Difference (IV, Random, 95% CI) -0.58 [-0.90, -0.26]
7.1 With nasal polyps 4 1417 Mean Difference (IV, Random, 95% CI) -0.58 [-0.90, -0.26]
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8 Endoscopy score (polyps
size) - measured as numbers
with improvement at longest
available follow-up
5 676 Risk Ratio (M-H, Random, 95% CI) 1.77 [1.06, 2.95]
8.1 With nasal polyps 5 676 Risk Ratio (M-H, Random, 95% CI) 1.77 [1.06, 2.95]
9 Endoscopy score (polyp size)
- measured as numbers with
improvement at longest
available follow-up
8 1984 Odds Ratio (Random, 95% CI) 2.07 [1.48, 2.91]
9.1 With nasal polyps 4 1417 Odds Ratio (Random, 95% CI) 2.43 [1.46, 4.06]
9.2 With nasal polyps from
dichotomous data
4 567 Odds Ratio (Random, 95% CI) 1.73 [1.19, 2.51]
10 CT score (overall) - measured
using Lund-Mackay score (max
24 points) at 3 months
1 47 Mean Difference (IV, Fixed, 95% CI) -4.82 [-7.27, -2.37]
Analysis 1.1. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 1 Disease severity -
measured as change from baseline using the Chronic Sinusitis Survey at 20 weeks.
Review: Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis
Comparison: 1 Intranasal corticosteroids versus placebo
Outcome: 1 Disease severity - measured as change from baseline using the Chronic Sinusitis Survey at 20 weeks
Study or subgroup
Intranasal
corticos-
teroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lund 2004 (1) 67 7.35 (23.4094) 67 4.51 (22.9994) 100.0 % 2.84 [ -5.02, 10.70 ]
Total (95% CI) 67 67 100.0 % 2.84 [ -5.02, 10.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours placebo Favours intranasal corticosteroids
(1) Study only recruited participants without nasal polyps.
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Analysis 1.2. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 2 Disease severity - global
symptom score, measured as proportion of patients who improved.
Review: Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis
Comparison: 1 Intranasal corticosteroids versus placebo
Outcome: 2 Disease severity - global symptom score, measured as proportion of patients who improved
Study or subgroup
Intranasal
corticos-
teroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Vlckova 2009 (1) 41/54 15/55 100.0 % 2.78 [ 1.76, 4.40 ]
Total (95% CI) 54 55 100.0 % 2.78 [ 1.76, 4.40 ]
Total events: 41 (Intranasal corticosteroids), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.39 (P = 0.000011)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours intranasal corticosteroids
(1) Number of patients who reported ”very much improved” or ”improved” on a 5-point scale.
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Analysis 1.3. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 3 Disease severity -
combination of individual symptom scores, measured on a 0 to 3 scale as change from baseline at 12 to 20
weeks.
Review: Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis
Comparison: 1 Intranasal corticosteroids versus placebo
Outcome: 3 Disease severity - combination of individual symptom scores, measured on a 0 to 3 scale as change from baseline at 12 to 20 weeks
Study or subgroup
Intranasal
corticos-
teroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Average symptom score (4 EPOS domains)
Lund 2004 (1) 67 -0.46 (0.43) 67 -0.26 (0.42) 61.1 % -0.20 [ -0.34, -0.06 ]
Vlckova 2009 (2) 54 -0.28 (0.47) 55 0.08 (0.49) 38.9 % -0.36 [ -0.54, -0.18 ]
Subtotal (95% CI) 121 122 100.0 % -0.26 [ -0.37, -0.15 ]
Heterogeneity: Chi2 = 1.85, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 4.57 (P < 0.00001)
2 Average symptom score (3 EPOS domains - nasal blockage, rhinorrhoea, loss of sense of smell)
Lund 2004 (3) 67 -0.5 (0.53) 67 -0.26 (0.27) 29.6 % -0.24 [ -0.38, -0.10 ]
Small 2005 (4) 122 -0.79 (1.18) 58 -0.35 (1.18) 4.4 % -0.44 [ -0.81, -0.07 ]
Small 2005 (5) 115 -0.66 (0.91) 59 -0.35 (0.91) 7.4 % -0.31 [ -0.60, -0.02 ]
Vlckova 2009 (6) 54 -0.3 (0.68) 55 0.03 (0.67) 9.3 % -0.33 [ -0.58, -0.08 ]
Zhou 2015 (7) 375 -0.81 (0.77) 373 -0.48 (0.77) 49.3 % -0.33 [ -0.44, -0.22 ]
Subtotal (95% CI) 733 612 100.0 % -0.31 [ -0.38, -0.23 ]
Heterogeneity: Chi2 = 1.55, df = 4 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 7.76 (P < 0.00001)
3 Average symptom score (2 EPOS domains - nasal blockage and rhinorrhoea)
Aukema 2005 (8) 26 0.83 (0.72) 21 1.58 (0.72) 2.9 % -0.75 [ -1.16, -0.34 ]
Lund 2004 (9) 67 -0.59 (0.52) 67 -0.32 (0.26) 26.0 % -0.27 [ -0.41, -0.13 ]
Small 2005 (10) 115 -0.7 (0.88) 59 -0.4 (0.88) 6.6 % -0.30 [ -0.58, -0.02 ]
Small 2005 (11) 122 -0.92 (1.23) 58 -0.4 (1.23) 3.4 % -0.52 [ -0.90, -0.14 ]
Stjarne 2006 (12) 102 -0.76 (0.86) 53 -0.51 (0.86) 6.2 % -0.25 [ -0.54, 0.04 ]
Stjarne 2006 (13) 102 -0.92 (0.99) 53 -0.51 (0.99) 4.7 % -0.41 [ -0.74, -0.08 ]
Vlckova 2009 (14) 54 -0.33 (0.63) 55 0.03 (0.65) 8.7 % -0.36 [ -0.60, -0.12 ]
Zhou 2015 (15) 375 -0.67 (0.77) 373 -0.4 (0.77) 41.4 % -0.27 [ -0.38, -0.16 ]
Subtotal (95% CI) 963 739 100.0 % -0.31 [ -0.38, -0.24 ]
Heterogeneity: Chi2 = 7.00, df = 7 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 8.49 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.51, df = 2 (P = 0.78), I2 =0.0%
-2 -1 0 1 2
Favours intranasal corticosteroids Favours placebo
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(1) Study only recruited participants without nasal polyps. Value obtained by dividing the total ”combined score” reported by 4.
(2) Value obtained by dividing the total ”combined score” reported by 4.
(3) Study only recruited participants without nasal polyps. SD calculated from 95% CI within group for each symptom.
(4) Data from 400 mcg/day group. SD imputed from P values. Sample size in placebo group halved.
(5) Data from 200 mcg/day group. SD imputed from P values. Sample size in placebo group halved.
(6) SD estimated from SE reported in graphs.
(7) Values obtained by averaging scores for loss of smell, nasal blockage and nasal discharge. SD estimated from SE.
(8) SD estimated from 95% CI for mean difference reported at endpoint.
(9) SD calculated from 95% CI within group for each symptom.
(10) Data from 400 mcg/day group. SD imputed from P values. Sample size in placebo group halved.
(11) Data from 200 mcg/day group. SD imputed from P values. Sample size in placebo group halved.
(12) Data from 200 mcg/day group. Average of anterior rhinorrhoea and obstruction scores. SD estimated from reported P values. Sample size in placebo group halved.
(13) Data from 400 mcg/day group. Average of anterior rhinorrhoea and obstruction scores. SD estimated from reported P values. Sample size in placebo group halved.
(14) SD estimated from SE reported in graphs.
(15) Values obtained by averaging scores for nasal blockage and nasal discharge. SD estimated from SE.
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Analysis 1.4. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 4 Disease severity -
individual symptoms, measured as average change from baseline at 12 to 20 weeks (range 0 to 3 points).
Review: Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis
Comparison: 1 Intranasal corticosteroids versus placebo
Outcome: 4 Disease severity - individual symptoms, measured as average change from baseline at 12 to 20 weeks (range 0 to 3 points)
Study or subgroup
Intranasal
corticos-
teroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Nasal blockage
Aukema 2005 26 0.75 (0.86) 21 1.77 (0.86) 4.7 % -1.02 [ -1.51, -0.53 ]
Lund 2004 (1) 67 -0.67 (0.533) 67 -0.34 (0.533) 17.4 % -0.33 [ -0.51, -0.15 ]
Small 2005 (2) 122 -1.1 (1.3915976) 58 -0.5 (1.3916) 5.8 % -0.60 [ -1.04, -0.16 ]
Small 2005 (3) 115 -0.86 (0.82) 59 -0.5 (0.82) 12.2 % -0.36 [ -0.62, -0.10 ]
Stjarne 2006 (4) 102 -0.86 (0.77) 53 -0.61 (0.77) 12.3 % -0.25 [ -0.51, 0.01 ]
Stjarne 2006 (5) 102 -0.86 (0.83) 53 -0.61 (0.77) 11.9 % -0.25 [ -0.51, 0.01 ]
Vlckova 2009 54 -0.39 (0.651) 55 -0.05 (0.727) 12.1 % -0.34 [ -0.60, -0.08 ]
Zhou 2015 375 -1.08 (0.774597) 373 -0.58 (0.772528) 23.5 % -0.50 [ -0.61, -0.39 ]
Subtotal (95% CI) 963 739 100.0 % -0.40 [ -0.52, -0.29 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 13.15, df = 7 (P = 0.07); I2 =47%
Test for overall effect: Z = 6.77 (P < 0.00001)
2 Rhinorrhoea
Aukema 2005 26 0.9 (0.61) 21 1.38 (0.61) 4.9 % -0.48 [ -0.83, -0.13 ]
Lund 2004 67 -0.505 (0.5125) 67 -0.29 (0.492) 19.0 % -0.22 [ -0.39, -0.04 ]
Small 2005 115 -0.53 (0.93) 59 -0.29 (0.93) 6.9 % -0.24 [ -0.53, 0.05 ]
Small 2005 122 -0.74 (1.044) 58 -0.29 (1.044) 5.6 % -0.45 [ -0.78, -0.12 ]
Stjarne 2006 (6) 102 -0.74 (0.94) 53 -0.4 (0.94) 6.1 % -0.34 [ -0.65, -0.03 ]
Stjarne 2006 (7) 102 -0.66 (0.95) 53 -0.4 (0.95) 6.0 % -0.26 [ -0.58, 0.06 ]
Vlckova 2009 54 -0.27 (0.599) 55 0.11 (0.553) 12.2 % -0.38 [ -0.60, -0.16 ]
Zhou 2015 375 -0.53 (0.774597) 373 -0.37 (0.772528) 39.2 % -0.16 [ -0.27, -0.05 ]
Subtotal (95% CI) 963 739 100.0 % -0.25 [ -0.33, -0.17 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 7.48, df = 7 (P = 0.38); I2 =6%
Test for overall effect: Z = 6.29 (P < 0.00001)
3 Loss of sense of smell
Lund 2004 67 -0.325 (0.5535) 67 -0.14 (0.533) 20.5 % -0.19 [ -0.37, 0.00 ]
Small 2005 115 -0.6 (0.97) 59 -0.27 (0.97) 7.5 % -0.33 [ -0.63, -0.03 ]
-2 -1 0 1 2
Favours intranasal corticosteroids Favours Placebo
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(. . . Continued)
Study or subgroup
Intranasal
corticos-
teroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Small 2005 122 -0.54 (1.06) 58 -0.27 (1.06) 6.3 % -0.27 [ -0.60, 0.06 ]
Vlckova 2009 54 -0.23 (0.776) 55 0.02 (0.695) 9.1 % -0.25 [ -0.53, 0.03 ]
Zhou 2015 375 -0.41 (0.774597) 373 -0.25 (0.772528) 56.6 % -0.16 [ -0.27, -0.05 ]
Subtotal (95% CI) 733 612 100.0 % -0.19 [ -0.28, -0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.50, df = 4 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 4.54 (P < 0.00001)
4 Facial pain/pressure
Lund 2004 67 -0.38 (0.49) 67 -0.25 (0.49) 53.1 % -0.13 [ -0.30, 0.04 ]
Vlckova 2009 54 -0.22 (0.614) 55 0.21 (0.562) 46.9 % -0.43 [ -0.65, -0.21 ]
Subtotal (95% CI) 121 122 100.0 % -0.27 [ -0.56, 0.02 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 4.52, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 1.81 (P = 0.071)
Test for subgroup differences: Chi2 = 8.33, df = 3 (P = 0.04), I2 =64%
-2 -1 0 1 2
Favours intranasal corticosteroids Favours Placebo
(1) Study only recruited participants without nasal polyps.
(2) Data from 400 mcg/day group. Sample size in placebo group halved.
(3) Data from 200 mcg/day group. Sample size in placebo group halved.
(4) Data from 200 mcg/day group. Sample size in placebo group halved.
(5) Data is from 400 mcg/day group. Sample size in placebo group halved.
(6) Data from 400 mcg/day group. Sample size in placebo group halved.
(7) Data from 200 mcg/day group. Sample size in placebo group halved.
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Analysis 1.5. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 5 Adverse events - epistaxis.
Review: Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis
Comparison: 1 Intranasal corticosteroids versus placebo
Outcome: 5 Adverse events - epistaxis
Study or subgroup
Intranasal
corticos-
teroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 With nasal polyps
Aukema 2005 3/27 0/27 1.4 % 7.00 [ 0.38, 129.34 ]
Chur 2013 (1) 9/101 1/26 4.3 % 2.32 [ 0.31, 17.47 ]
Holopainen 1982 1/10 0/8 1.5 % 2.45 [ 0.11, 53.25 ]
Keith 2000 10/52 2/52 5.4 % 5.00 [ 1.15, 21.72 ]
Penttilla 2000 (2) 8/95 1/47 3.6 % 3.96 [ 0.51, 30.72 ]
Small 2005 (3) 22/237 5/117 18.2 % 2.17 [ 0.84, 5.59 ]
Stjarne 2006 (4) 17/204 5/106 17.9 % 1.77 [ 0.67, 4.66 ]
Stjarne 2006a 21/153 6/143 16.8 % 3.27 [ 1.36, 7.87 ]
Vlckova 2009 6/54 0/55 1.3 % 13.24 [ 0.76, 229.35 ]
Zhou 2015 14/375 4/373 10.9 % 3.48 [ 1.16, 10.48 ]
Subtotal (95% CI) 1308 954 81.3 % 3.03 [ 2.00, 4.59 ]
Total events: 111 (Intranasal corticosteroids), 24 (Placebo)
Heterogeneity: Chi2 = 3.70, df = 9 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 5.23 (P < 0.00001)
2 Without nasal polyps
Hansen 2010 1/10 2/10 5.4 % 0.50 [ 0.05, 4.67 ]
Lund 2004 8/81 3/86 7.9 % 2.83 [ 0.78, 10.30 ]
Mosges 2011 1/29 2/30 5.3 % 0.52 [ 0.05, 5.40 ]
Subtotal (95% CI) 120 126 18.7 % 1.49 [ 0.59, 3.78 ]
Total events: 10 (Intranasal corticosteroids), 7 (Placebo)
Heterogeneity: Chi2 = 2.65, df = 2 (P = 0.27); I2 =24%
Test for overall effect: Z = 0.84 (P = 0.40)
Total (95% CI) 1428 1080 100.0 % 2.74 [ 1.88, 4.00 ]
Total events: 121 (Intranasal corticosteroids), 31 (Placebo)
Heterogeneity: Chi2 = 7.90, df = 12 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 5.24 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.86, df = 1 (P = 0.17), I2 =46%
0.01 0.1 1 10 100
Favours intranasal corticosteroids Favours placebo
91Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(1) Combined data from high- and low-dose groups.
(2) Combined data from high- and low-dose groups.
(3) Combined data from high- and low-dose groups.
(4) Combined data from high- and low-dose groups.
Analysis 1.6. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 6 Adverse events - local
irritation.
Review: Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis
Comparison: 1 Intranasal corticosteroids versus placebo
Outcome: 6 Adverse events - local irritation
Study or subgroup
Intranasal
corticos-
teroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 With nasal polyps
Aukema 2005 (1) 1/27 1/27 4.2 % 1.00 [ 0.07, 15.18 ]
Chur 2013 (2) 3/101 1/26 6.6 % 0.77 [ 0.08, 7.12 ]
Holopainen 1982 (3) 2/10 2/8 9.3 % 0.80 [ 0.14, 4.49 ]
Lund 1998 (4) 1/20 0/9 2.8 % 1.43 [ 0.06, 32.05 ]
Small 2005 (5) 4/237 3/117 16.8 % 0.66 [ 0.15, 2.89 ]
Stjarne 2006 (6) 3/204 0/106 2.7 % 3.65 [ 0.19, 70.08 ]
Stjarne 2006a (7) 4/153 8/143 34.6 % 0.47 [ 0.14, 1.52 ]
Vlckova 2009 (8) 0/54 1/55 6.2 % 0.34 [ 0.01, 8.15 ]
Zhou 2015 (9) 6/375 2/373 8.4 % 2.98 [ 0.61, 14.69 ]
Subtotal (95% CI) 1181 864 91.7 % 0.93 [ 0.52, 1.67 ]
Total events: 24 (Intranasal corticosteroids), 18 (Placebo)
Heterogeneity: Chi2 = 4.92, df = 8 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
2 Without nasal polyps
Hansen 2010 (10) 0/10 1/10 6.3 % 0.33 [ 0.02, 7.32 ]
Mosges 2011 (11) 1/29 0/30 2.1 % 3.10 [ 0.13, 73.14 ]
Subtotal (95% CI) 39 40 8.3 % 1.02 [ 0.15, 6.84 ]
0.002 0.1 1 10 500
Favours intranasal corticosteroids Favours placebo
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(. . . Continued)
Study or subgroup
Intranasal
corticos-
teroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 1 (Intranasal corticosteroids), 1 (Placebo)
Heterogeneity: Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.99)
Total (95% CI) 1220 904 100.0 % 0.94 [ 0.53, 1.64 ]
Total events: 25 (Intranasal corticosteroids), 19 (Placebo)
Heterogeneity: Chi2 = 5.91, df = 10 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
0.002 0.1 1 10 500
Favours intranasal corticosteroids Favours placebo
(1) Throat ache.
(2) Pharyngolaryngeal pain
(3) Nasal stinging.
(4) Nasal dryness. Combined data from the 400 mcg/day and 200 mcg/day treatments.
(5) Nasal burning. Combined data from the 400 mcg/day and 200 mcg/day treatments.
(6) Combined data from the 400 mcg and 200 mcg treatments, use the data on nasal burning.
(7) Sore throat.
(8) Nasal discomfort.
(9) Cough.
(10) Nasopharyngitis.
(11) Nasal dryness, increased tendency towards bleeding.
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Analysis 1.7. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 7 Endoscopy score
(bilateral polyps score) measured change from baseline (range 0 to 6 points).
Review: Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis
Comparison: 1 Intranasal corticosteroids versus placebo
Outcome: 7 Endoscopy score (bilateral polyps score) measured change from baseline (range 0 to 6 points)
Study or subgroup
Intranasal
corticos-
teroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 With nasal polyps
Small 2005 (1) 122 -0.96 (1.06) 58 -0.5 (1.06) 19.9 % -0.46 [ -0.79, -0.13 ]
Small 2005 (2) 115 -1.15 (1.5) 57 -0.5 (1.5) 16.2 % -0.65 [ -1.13, -0.17 ]
Stjarne 2006 102 -0.96 (1.19) 106 -0.62 (1.19) 20.1 % -0.34 [ -0.66, -0.02 ]
Vlckova 2009 54 -0.98 (0.882) 55 0.23 (0.964) 19.5 % -1.21 [ -1.56, -0.86 ]
Zhou 2015 375 -0.76 (0.968246) 373 -0.45 (0.96566) 24.2 % -0.31 [ -0.45, -0.17 ]
Total (95% CI) 768 649 100.0 % -0.58 [ -0.90, -0.26 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 23.45, df = 4 (P = 0.00010); I2 =83%
Test for overall effect: Z = 3.52 (P = 0.00042)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours intranasal corticosteroids Favours placebo
(1) Analysed using the 400 mcg arm. SD imputed.
(2) Analysed using the 200 mcg arm, SD imputed.
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Analysis 1.8. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 8 Endoscopy score (polyps
size) - measured as numbers with improvement at longest available follow-up.
Review: Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis
Comparison: 1 Intranasal corticosteroids versus placebo
Outcome: 8 Endoscopy score (polyps size) - measured as numbers with improvement at longest available follow-up
Study or subgroup
Intranasal
corticos-
teroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 With nasal polyps
Keith 2000 14/52 8/50 18.6 % 1.68 [ 0.77, 3.66 ]
Lang 1983 (1) 4/14 6/18 13.7 % 0.86 [ 0.30, 2.46 ]
Penttilla 2000 29/95 11/47 22.5 % 1.30 [ 0.72, 2.38 ]
Stjarne 2006a 63/152 37/139 28.5 % 1.56 [ 1.11, 2.18 ]
Vlckova 2009 31/54 5/55 16.8 % 6.31 [ 2.65, 15.02 ]
Total (95% CI) 367 309 100.0 % 1.77 [ 1.06, 2.95 ]
Total events: 141 (Intranasal corticosteroids), 67 (Placebo)
Heterogeneity: Tau2 = 0.21; Chi2 = 11.80, df = 4 (P = 0.02); I2 =66%
Test for overall effect: Z = 2.19 (P = 0.029)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours intranasal corticosteroids
(1) 2-year data.
95Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.9. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 9 Endoscopy score (polyp
size) - measured as numbers with improvement at longest available follow-up.
Review: Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis
Comparison: 1 Intranasal corticosteroids versus placebo
Outcome: 9 Endoscopy score (polyp size) - measured as numbers with improvement at longest available follow-up
Study or subgroup
Intranasal
corticos-
teroids Placebo log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 With nasal polyps
Small 2005 (1) 115 57 0.779933 (0.291503) 12.5 % 2.18 [ 1.23, 3.86 ]
Small 2005 (2) 122 58 0.779933 (0.29613) 12.3 % 2.18 [ 1.22, 3.90 ]
Stjarne 2006 102 106 0.507863 (0.254487) 13.6 % 1.66 [ 1.01, 2.74 ]
Vlckova 2009 (3) 54 55 2.267247 (0.379417) 10.0 % 9.65 [ 4.59, 20.31 ]
Zhou 2015 375 373 0.435311 (0.134184) 17.3 % 1.55 [ 1.19, 2.01 ]
Subtotal (95% CI) 768 649 65.7 % 2.43 [ 1.46, 4.06 ]
Heterogeneity: Tau2 = 0.27; Chi2 = 21.43, df = 4 (P = 0.00026); I2 =81%
Test for overall effect: Z = 3.39 (P = 0.00069)
2 With nasal polyps from dichotomous data
Keith 2000 52 50 0.6597 (0.4965) 7.4 % 1.93 [ 0.73, 5.12 ]
Lang 1983 (4) 14 18 -0.2231 (0.7746) 4.0 % 0.80 [ 0.18, 3.65 ]
Penttilla 2000 95 47 0.3633 (0.4103) 9.2 % 1.44 [ 0.64, 3.21 ]
Stjarne 2006a 152 139 0.6686 (0.2529) 13.7 % 1.95 [ 1.19, 3.20 ]
Subtotal (95% CI) 313 254 34.3 % 1.73 [ 1.19, 2.51 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.47, df = 3 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.85 (P = 0.0043)
Total (95% CI) 1081 903 100.0 % 2.07 [ 1.48, 2.91 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 23.14, df = 8 (P = 0.003); I2 =65%
Test for overall effect: Z = 4.22 (P = 0.000024)
Test for subgroup differences: Chi2 = 1.11, df = 1 (P = 0.29), I2 =10%
0.01 0.1 1 10 100
Favours placebo Favours intranasal corticosteroids
(1) Analysed using the 200 mcg/day arm.
(2) Analysed using the 400 mcg/day arm.
(3) The continuous outcomes were used due to clearer reporting than the dichotomous data reported in the study.
(4) 2-year data.
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Analysis 1.10. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 10 CT score (overall) -
measured using Lund-Mackay score (max 24 points) at 3 months.
Review: Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis
Comparison: 1 Intranasal corticosteroids versus placebo
Outcome: 10 CT score (overall) - measured using Lund-Mackay score (max 24 points) at 3 months
Study or subgroup
Intranasal
corticos-
teroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Aukema 2005 26 -2.92 (4.48) 21 1.9 (4.09) 100.0 % -4.82 [ -7.27, -2.37 ]
Total (95% CI) 26 21 100.0 % -4.82 [ -7.27, -2.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.85 (P = 0.00012)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours intranasal corticosteroids Favours placebo
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL Ovid MEDLINE
#1 MeSH descriptor: [Sinusitis] explode all trees
#2 MeSH descriptor: [Rhinitis] this term only
#3 MeSH descriptor: [Rhinitis, Atrophic] this term only
#4 MeSH descriptor: [Rhinitis, Vasomotor] this term only
#5 MeSH descriptor: [Paranasal Sinus Diseases] this term only
#6 MeSH descriptor: [Paranasal Sinuses] explode all trees
#7 rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
sphenoiditis
#8 kartagener* near syndrome*
#9 inflamm* near sinus*
#10 (maxilla* or frontal*) near sinus*
#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
#12 MeSH descriptor: [Chronic Disease] explode all trees
#13 MeSH descriptor: [Recurrence] explode all trees
#14 chronic or persis* or recurrent*
1 exp Sinusitis/
2 paranasal sinus diseases/ or rhinitis/ or rhinitis, atrophic/ or
rhinitis, vasomotor/
3 exp Paranasal Sinuses/
4 (rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
sphenoiditis).ab,ti
5 (kartagener* adj3 syndrome*).ab,ti.
6 (inflamm* adj5 sinus*).ab,ti.
7 ((maxilla* or frontal*) adj3 sinus*).ab,ti.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp chronic disease/
10 exp Recurrence/
11 (chronic or persis* or recurrent*).ab,ti.
12 9 or 10 or 11
13 8 and 12
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(Continued)
#15 #12 or #13 or #14
#16 #11 and #15
#17 CRSsNP
#18 (sinusitis or rhinitis) near (chronic or persis* or recurrent*)
#19 #16 or #17 or #18
#20 MeSH descriptor: [Nasal Polyps] explode all trees
#21 MeSH descriptor: [Nose] explode all trees
#22 MeSH descriptor: [Nose Diseases] explode all trees
#23 #21 or #22
#24 MeSH descriptor: [Polyps] explode all trees
#25 #23 and #24
#26 (nose or nasal or rhino* or rhinitis or sinus* or sinonasal) near
(papilloma* or polyp*)
#27 rhinopolyp* or CRSwNP
#28 #19 or #20 or #25 or #26 or #27
#29 MeSH descriptor: [Steroids] explode all trees
#30 MeSH descriptor: [Adrenal Cortex Hormones] explode all
trees
#31 MeSH descriptor: [Glucocorticoids] explode all trees
#32 MeSH descriptor: [Anti-Inflammatory Agents] explode all
trees
#33 MeSH descriptor: [Anti-Inflammatory Agents, Non-
Steroidal] explode all trees
#34 #32 not #33
#35 steroid* or glucocorticoid* or corticosteroid* or glucosteroid*
or cyclocosteroid*
#36 beclomethasone or beclometasone or beclamet or beclocort
or becotide
#37 betamethasone or betadexamethasone or flubenisolone or ce-
leston* or cellestoderm or betnelan or oradexon
#38 dexamethasoneor dexameth or dexone or dexametasone or
decadron or dexasone or hexadecadron or hexadrol or methylflu-
orprednisolone or millicorten
#39 flunisolide or fluticasone or hydrocortisone or cortisol or cor-
tifair or cortril or hyrocortone or cortef or epicortisol or efcortesol
or Cortisone
#40 methylprednisolone or medrol or metripred or urbason
#41 mometasone or prednisolone or precortisyl or deltacortril or
deltastab or prednesol or deltasone or prednisone or cortan or
liquid next pred or meticorten
#42 paramethasone or triamcinolone or aristocort or volon or
atolone or kenacort or orasone or panasol or prednicen
#43 corticoid* or betamethason* or betamethasone or hydrocorti-
son* or celesto* or dexamethason* or hexadecadrol or budesonid*
or horacort or pulmicort or rhinocort or methylfluorprednisolone
or flunisolid* or nasalide or fluticason* or flonase or flounce or
mometason* or nasonex or triamclinolon* or nasacort or tri next
nasal or aristocort or Ciclesonide
#44 #29 or #30 or #31 or #34 or #35 or #36 or #37 or #38 or #
14 CRSsNP.ab,ti.
15 ((sinusitis or rhinitis) adj3 (chronic or persis* or recurrent*)).
ab,ti
16 13 or 14 or 15
17 exp Nasal Polyps/
18 exp Nose/ or exp Nose Diseases/
19 exp Polyps/
20 18 and 19
21 ((nose or nasal or rhino* or rhinitis or sinus* or sinonasal) adj3
(papilloma* or polyp*)).ab,ti
22 (rhinopolyp* or CRSwNP).ab,ti.
23 16 or 17 or 20 or 21 or 22
24 exp Steroids/
25 exp Adrenal Cortex Hormones/
26 exp Glucocorticoids/
27 exp Anti-Inflammatory Agents/
28 exp Anti-Inflammatory Agents, Non-Steroidal/
29 27 not 28
30 (steroid* or glucocorticoid* or corticosteroid* or glucos-
teroid* or cyclocosteroid* orbeclomethasone or beclometasone or
beclamet or beclocort or becotide or betamethasone or betadexam-
ethasone or flubenisolone or celeston* or cellestoderm or betnelan
or oradexon or dexamethasone or dexameth or dexone or dexam-
etasone or decadron or dexasone or hexadecadron or hexadrol or
methylfluorprednisolone or millicorten or flunisolide or fluticas-
one or hydrocortisone or cortisol or cortifair or cortril or hyrocor-
tone or cortef or epicortisol or efcortesol or Cortisone or methyl-
prednisolone or medrol or metripred or urbason or mometasone
or prednisolone or precortisyl or deltacortril or deltastab or pred-
nesol or deltasone or prednisone or cortan or liquid next pred
or meticorten or paramethasone or triamcinolone or aristocort or
volon or atolone or kenacort or orasone or panasol or prednicen)
.ab,ti
31 (corticoid* or betamethason* or betamethasone or hydrocorti-
son* or celesto* or dexamethason* or hexadecadrol or budesonid*
or horacort or pulmicort or rhinocort or methylfluorprednisolone
or flunisolid* or nasalide or fluticason* or flonase or flounce or
mometason* or nasonex or triamclinolon* or nasacort or (tri adj3
nasal) or aristocort or Ciclesonide).ab,ti
32 24 or 25 or 26 or 29 or 30 or 31
33 23 and 32
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(Continued)
39 or #40 or #41 or #42 or #43
#45 #28 and #44
Ovid Embase Trial registries (via CRS)
1 exp sinusitis/ or paranasal sinus disease/
2 atrophic rhinitis/ or chronic rhinitis/ or rhinosinusitis/ or vaso-
motor rhinitis/
3 exp paranasal sinus/
4 (rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
sphenoiditis).tw
5 (kartagener* adj3 syndrome*).tw.
6 (inflamm* adj5 sinus*).tw.
7 ((maxilla* or frontal*) adj3 sinus*).tw.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp chronic disease/
10 exp recurrent disease/
11 (chronic or persis* or recurrent*).tw.
12 9 or 10 or 11
13 8 and 12
14 CRSsNP.tw.
15 ((sinusitis or rhinitis) adj3 (chronic or persis* or recurrent*)).
tw
16 13 or 14 or 15
17 exp nose polyp/
18 exp nose disease/ or exp nose/
19 exp polyp/
20 18 and 19
21 ((nose or nasal or rhino* or rhinitis or sinus* or sinonasal) adj3
(papilloma* or polyp*)).tw
22 (rhinopolyp* or CRSwNP).tw.
23 16 or 20 or 21 or 22
24 exp *corticosteroid/
25 exp steroid/
26 exp antiinflammatory agent/
27 exp nonsteroid antiinflammatory agent/
28 26 not 27
29 (steroid* or glucocorticoid* or corticosteroid* or glucos-
teroid* or cyclocosteroid* or beclomethasone or beclometasone or
beclamet or beclocort or becotide or betamethasone or betadexam-
ethasone or flubenisolone or celeston* or cellestoderm or betnelan
or oradexon or dexamethasone or dexameth or dexone or dexam-
etasone or decadron or dexasone or hexadecadron or hexadrol or
methylfluorprednisolone or millicorten or flunisolide or fluticas-
one or hydrocortisone or cortisol or cortifair or cortril or hyrocor-
tone or cortef or epicortisol or efcortesol or Cortisone or methyl-
prednisolone or medrol or metripred or urbason or mometasone
or prednisolone or precortisyl or deltacortril or deltastab or pred-
nesol or deltasone or prednisone or cortan or liquid next pred
ClinicalTrials.gov
Condition: rhinitis OR sinusitis OR rhinosinusitis OR (nose
AND polyp*) OR (nasal AND polyp*) OR CRSsNP OR CR-
SwNP OR CRS
ICTRP
Title: rhinitis OR sinusitis OR rhinosinusitis OR CRSsNP OR
CRSwNP OR CR
OR
All: (nose AND polyp*) OR (nasal AND polyp*)
NB These searches were run from 1 March 2015 to 11 August 2015,
when these terms were last searched to populate the Cochrane ENT
trials register in CRS
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(Continued)
or meticorten or paramethasone or triamcinolone or aristocort or
volon or atolone or kenacort or orasone or panasol or prednicen)
.tw
30 24 or 28 or 29
31 23 and 30
Appendix 2. Data extraction form
REF ID: Study title:
Date of extraction: Extracted by:
General comments/notes (internal for discussion):
Flow chart of trial
Group A (Intervention) Group B (Comparison)
No. of people screened
No. of participants randomised - all
No. randomised to each group
No. receiving treatment as allocated
No. not receiving treatment as allocated
- Reason 1
- Reason 2
No. dropped out
(no follow-up data for any outcome avail-
able)
No. excluded from analysis1 (for all out-
comes)
- Reason 1
- Reason 2
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(Continued)
1This should be the people who received the treatment and were therefore not considered ’drop-outs’ but were excluded from all
analyses (e.g. because the data could not be interpreted or the outcome was not recorded for some reason)
Information to go into ’Characteristics of included studies’ table
Methods X arm, double/single/non-blinded, [multicentre] parallel-group/
cross-over/cluster-RCT, with x duration of treatment and x dura-
tion of follow-up
Participants Location: country, no of sites etc.
Setting of recruitment and treatment:
Sample size:
• Number randomised: x in intervention, y in comparison
• Number completed: x in intervention, y in comparison
Participant (baseline) characteristics:
• Age:
• Gender:
• Main diagnosis: [as stated in paper]
• Polyps status: x % with polyps/no information [add info on
mean polyps score if available]
• Previous sinus surgery status: [x% with previous surgery]
• Previous courses of steroids: [add info on mean number of
courses if available]
• Other important effect modifiers, if applicable (e.g. aspirin
sensitivity, comorbidities of asthma):
Inclusion criteria: [state diagnostic criteria used for CRS, polyps
score if available]
Exclusion criteria:
Interventions Intervention (n = x): drug name, method of administration, dose
per day/frequency of administration, duration of treatment
Comparator group (n = y):
Use of additional interventions (common to both treatment
arms):
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Health-related quality of life, disease-specific
• Disease severity symptom score
• Significant adverse effects: [review specific]
Secondary outcomes:
• Health-related quality of life, generic
• [Other review specific, pre-specified adverse events]
• [Other review specific, pre-specified adverse events]
• Endoscopy (polyps size or overall score)
• CT scan
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(Continued)
Other outcomes reported by the study:
• [List outcomes reported but not of interest to the review]
Funding sources ’No information provided’/’None declared’/State source of fund-
ing
Declarations of interest ’No information provided’/’None declared’/State conflict
Notes
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Quote: “…”
Comment:
Allocation concealment (selection bias) Quote: “…”
Comment:
Blinding of participants and personnel
(performance bias)
Quote: “…”
Comment:
Blinding of outcome assessment (detection
bias)
Quote: “…”
Comment:
Incomplete outcome data (attrition bias) Quote: “…”
Comment:
Selective reporting (reporting bias) Quote: “…”
Comment:
Other bias (see section 8.15)
Insensitive/non-validated instrument?
Quote: “…”
Comment:
Other bias (see section 8.15) Quote: “…”
Comment:
Findings of study: continuous outcomes
Results (continuous data table)
Outcome Group A Group B Other summary stats/Notes
Mean SD N Mean SD N Mean difference (95% CI), P values etc.
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(Continued)
Disease-spe-
cific HRQL
(instrument
name/range)
Time point:
Generic
HRQL
(instrument
name/range)
Time point:
Symptom
score (overall)
(instrument
name/range)
Time point:
Added total -
if scores re-
ported
separately for
each symptom
(range)
Time point:
Nasal
blockage/
obstruction/
congestion
(instrument
name/range)
Nasal
discharge
(instrument
name/range)
Facial pain/
pressure
(instrument
name/range)
Smell (reduc-
tion)
(instrument
name/range)
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(Continued)
Headache
(instrument
name/range)
Cough (in
children)
(instrument
name/range)
Polyp size
(instrument
name/range)
CT score
(instrument
name/range)
Comments:
Results (dichotomous data table)
Outcome Ap-
plicable review/
intervention
Group A Group B Other summary
stats/notes
No. of people
with events
No. of people
analysed
No. of people
with events
No. of people
analysed
P values, RR
(95% CI), OR
(95% CI)
Epistaxis/nose
bleed
INCS
Saline irrigation
Local irritation
(sore throat, oral
thrush, discom-
fort)
INCS
Saline irrigation
Os-
teoporosis (min-
imum 6months)
INCS
Stunted growth
(children, mini-
mum 6 months)
INCS Can also be mea-
sured as average
height
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(Continued)
Mood
disturbances
OCS
Gastrointestinal
disturbances
(diarrhoea, nau-
sea, vom-
iting, stomach ir-
ritation)
OCS
Antibiotics
Insomnia OCS
Os-
teoporosis (min-
imum 6months)
INCS
OCS
Discomfort Saline irrigation
Skin irritation Antibiotics
Anaphylaxis
or other serious
allergic reactions
such as Stevens-
Johnson
Antibiotics
Comments:
Appendix 3. Methods of measurement
The method of measurement in the included studies was reported in several ways:
• Choice of scale: A variety of scales and choice of symptoms were used across the studies. A 10 cm visual analogue scale (VAS)
was used in Aukema 2005 and Hansen 2010. Holmberg 1997 and Lund 1998 used a five-point scale (0 to 4), and most studies used a
four-point scale (range 0 to 3) to measure the severity of each type of symptom. The most commonly used definition was 0 = none, 1
= mild, 2 = moderate, 3 = severe, with some variation between studies. Parikh 2001 used both a 10 cm VAS and also a diary card
(scale unclear).
• Type/combination of symptoms measured: Of the four possible domains mentioned in EPOS 2012 for adults (nasal
blockage/obstruction, nasal discharge, loss of sense of smell and facial pressure/pain), the most consistently measured and reported
type of symptom was nasal blockage/obstruction. “Nasal discharge” symptoms were also often measured but there were a variety of
ways of measuring this. Some studies reported “rhinitis symptoms” (it was unclear whether this was from a single item or a
combination), whereas others may only have measured this as a single symptom (e.g. rhinorrhoea), or as a combination of slightly
different symptoms (“anterior nasal discharge”, “posterior drip”, “purulent nasal discharge”). Loss of sense of smell was less commonly
measured. Facial pain/pressure was only measured in six studies (Aukema 2005; Lund 1998; Lund 2004; Mosges 2011; Parikh 2001;
Vlckova 2009). However, “headache” was reported as an “adverse effect” in certain studies. Only six of the included studies attempted
to assess all of the four symptoms used to define CRS in EPOS 2012 (nasal blockage/obstruction/congestion, nasal discharge
(anterior/posterior nasal drip), loss of sense of smell and facial pain/pressure (adults)/cough (children)) (Aukema 2005; Lund 1998;
Lund 2004; Mosges 2011; Parikh 2001; Vlckova 2009). Facial pain/pressure was not measured by most studies.
• Timing of measures:
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◦ Whether scores were filled every day:Johansen 1993 only required diaries to be filled once a week. Holopainen 1982 only
required patients to fill their “daily diary” for two weeks before each visit. Aukema 2005 seemed to only require patients to fill the
VAS at every visit. Parikh 2001 only required patients to fill in a 10 cm VAS “symptom score” at the beginning and end of the study
and a diary card “once every week”.
◦ Morning versus morning and evening: Some studies clearly stated that they required patients to fill in diary cards twice a day
(morning and evening) (Keith 2000; Hansen 2010; Penttilla 2000; Stjarne 2006a; Vlckova 2009), whereas others only required scores
in the morning (Small 2005; Stjarne 2006; Zhou 2015). This information was not reported in some studies (Lund 1998), and
seemed to require a mixture of different timings depending on the type of symptoms in Holmberg 1997. Keith 2000, Penttilla 2000
and Vlckova 2009 presented the data for the morning and evening scores separately. Stjarne 2006a did not report the scores apart
from stating that these were statistically significant different compared placebo, whereas Hansen 2010 only provided an overall score.
Where studies presented both morning and evening scores, we only used the morning score values in this review, to allow for
standardisation across studies.
◦ Period of time taken into account:Lund 1998, Small 2005; Vlckova 2009 and Zhou 2015 clearly stated that it was a four-
week or monthly period. Mosges 2011 used the area under the curve for a 16-week period, while Holopainen 1982 seemed to average
the daily diary scores, which patients had to fill in “daily for a fortnight before every check up”. It can only be assumed that Stjarne
2006 and Stjarne 2006a also used four-week averages. There was no information for Chur 2013, Hansen 2010 and Lund 1998.
• Scoring/analysis method:
◦ Overall score versus individual symptom score: Some studies used the overall score for all the symptoms measured. Others
seemed to combine several types of symptoms (e.g. “rhinitis symptoms” can be established by a combination of several individual
questions (anterior rhinorrhoea, postnasal drip, nasal blockage), or by a single question). The rationale for weighting types of
symptoms in their scoring and reporting was not discussed or provided at all.
◦ Weighting of symptoms in scores: Apart from Aukema 2005, which clearly stated that facial pain was “counted twice because
this symptom was considered most bothering”, none of the studies provided any information on how scores were weighted/calculated
and the rationale for their analysis.
◦ Method of reporting:Most studies used the mean scores (or median for smaller studies) for individual symptom scores with
or without the total symptom scores. However, other studies reported this as proportions of people above a certain threshold of
change from baseline, or above/below a certain threshold at the “endpoint”. Penttilla 2000 reported the proportion of patients who
had symptoms scores < 2 points (0- to 3-point scale). Stjarne 2006a used the proportion of patients who had an improvement of >= 1
point compared to baseline. Three studies used different cut-offs to present these as the percentage of patients with scores above a
certain value (Holmberg 1997; Keith 2000; Lund 1998): either different trial periods (Keith 2000; Lund 1998), or as percentage of
“blocks of treatment period” with certain thresholds (Holmberg 1997). These choices of cut-offs or treatment period were not
specified in the methods sections of the study report.
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In the protocol, the example given for local irritation was “including sore throat, oral thrush”. This has been expanded to include “and
other local nasal irritation such as dryness, itchiness etc.”
Although we had planned to present data for chronic rhinosinusitis without nasal polyps and chronic rhinosinusitis with nasal polyps
in subgroups as a visual comparison, this was not carried out except for the nasal polyps and adverse events outcomes. For all the other
outcomes there was no more than one study of patients with chronic rhinosinusitis without nasal polyps available for analysis. We had
footnoted this in the forest plots and highlighted it in the write up whenever this occurred.
As part of the discussions about the use of a total symptom score we noted that many papers within the suite of reviews did not present
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individual symptoms were recorded, they should be presented within the outcome of disease severity symptom score within the paper
as this information would be useful for the reader.
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